Imidazo[2,1-F][1,2,4]triazin-4-amine derivatives as TLR8 agonists

Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives address the limitations of current TLR agonists by providing enhanced TLR8 agonist activity and improved safety for cancer treatment through targeted immune stimulation.

JP7595643B2Active Publication Date: 2024-12-06BEIGENE SWITZERLAND GMBH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022504657
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-01-22
Filing Date
2020-07-31
Publication Date
2024-12-06
Estimated Expiration
2040-07-31

AI Technical Summary

Technical Problem

Current TLR agonists, such as imiquimod and motolimod, have limitations in cancer treatment, including restricted efficacy and potential side effects like cytokine storms, highlighting the need for more effective TLR8 agonists with improved safety and broader therapeutic benefits.

Method used

Development of imidazo[2,1-f][1,2,4]triazin-4-amine derivatives that act as TLR8 agonists, specifically designed to enhance anti-cancer immunity by activating dendritic cells and promoting cytokine secretion, with a focus on non-aromatic ring structures for enhanced activity.

Benefits of technology

The imidazo[2,1-f][1,2,4]triazin-4-amine derivatives exhibit potent TLR8 agonist activity, effectively stimulating immune responses and enhancing cancer treatment efficacy with reduced toxicity, offering a promising alternative to existing TLR agonists.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595643000001
    Figure 0007595643000001
  • Figure 0007595643000002
    Figure 0007595643000002
  • Figure 0007595643000003
    Figure 0007595643000003
Patent Text Reader

Abstract

The present invention discloses an imidazo[2,1-f][1,2,4]triazin-4-amine derivative, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for use as a TLR8 agonist, and a pharmaceutical composition containing the same. The present invention also discloses a method for treating cancer using the imidazo[2,1-f][1,2,4]triazin-4-amine derivative, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as a TLR8 agonist.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention discloses an imidazo[2,1-f][1,2,4]triazin-4-amine derivative, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for use as a TLR8 agonist, and a pharmaceutical composition containing the same. The present invention also discloses a method for treating cancer using the imidazo[2,1-f][1,2,4]triazin-4-amine derivative, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as a TLR8 agonist. [Background technology]

[0002] Toll-like receptors (TLRs) belong to the family of pattern recognition receptors (PRRs), which play an important role in the early innate immune response by detecting highly conserved molecular patterns (PAMPs) of different pathogens and endogenous risk-associated molecular patterns (DAMPs) (Barton, GM and R. Medzhitov (2002). "Toll-like receptors and their ligands." Curr Top Microbiol Immunol 270: 81-92.).

[0003] Ten distinct TLRs have been identified in humans. Among them, TLR7, TLR8, and TLR9 belong to the same subfamily of TLRs based on their genomic structure, sequence similarity, and endosomal localization. They have restricted expression patterns and are restricted to specific types of immune cells. TLR7 is expressed on B cells and plasmacytoid dendritic cells (pDCs), while TLR8 is expressed on monocytes and myeloid dendritic cells (mDCs) (Iwasaki, A. and R. Medzhitov (2004). "Toll-like receptor control of the adaptive immune responses." Nat Immunol 5(10): 987-995.).

[0004] In addition to the natural ligand single-stranded RNA, imidazoquinolones (or "imiquimod-like" ligands) and guanosine analogs have also been shown to activate TLR7 and / or TLR8 with different specificities. Activation of TLR7 and / or TLR8 induces dendritic cell (DC) maturation and secretion of proinflammatory cytokines (van Duin, D., et al. (2006). "Triggering TLR signaling in vaccination." Trends Immunol 27(1): 49-55.). CTL and NK cells are further activated and expanded by DCs stimulated by cytokines and antigen presentation. Therefore, the properties of TLR agonists constitute an effective strategy for enhancing anti-cancer immunity (Adams, S. (2009). "Toll-like receptor agonists in cancer therapy." Immunotherapy 1(6): 949-964.).

[0005] Imiquimod (a TLR7 agonist) has been successfully applied as a single antitumor agent with immunostimulatory properties to the treatment of many primary skin tumors and skin metastases (Stary, G., et al. (2007). "Tumoricidal activity of TLR7 / 8-activated inflammatory dendritic cells." J Exp Med 204(6): 1441-1451., Aranda, F., et al. (2014). "Trial Watch: Toll-like receptor agonists in oncological indications." Oncoimmunology 3: e29179.).

[0006] WO2016023511 discloses that pyrrolopyrimidine compounds are used as TLR7 agonists for the preparation of antiviral drugs.

[0007] Motolimod (VTX-2337) is a TLR8-specific small molecule agonist currently in clinical development as an immunotherapy for multiple cancer types. Motolimod has a favorable safety profile when used as an immunotherapy in cancer patients, exhibiting limited toxicity but no evidence of cytokine storm (Ann Oncol. 2017;28:996-1004). However, benefit is typically limited to subjects with injection site reactions (Clin Cancer Res. 2018 Jan 1;24(1):62-72. Ann Oncol. 2017 May 1;28(5):996-1004).

[0008] Currently, significant efforts have been expended in the preclinical and clinical development of TLR agonists for cancer therapy. Therefore, there is a need to develop more effective TLR agonists for cancer therapy. Summary of the Invention

[0009] Unexpectedly and surprisingly, the present inventors have found that the imidazo[2,1-f][1,2,4]triazin-4-amine derivatives disclosed in the present invention exhibit more effective TLR8 agonist activity, especially when ring A in formula (I) is a non-aromatic ring.

[0010] In a first embodiment, the present invention provides a compound of formula (I): [ka] or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

[0011] In formula (I), X is N or CR 7 and where R 7 is hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group; L 1 Ha-(CR a R b )m -, -O-, -S-, -S(O)-, -SO2-, -C(O)-, -C(O)O-, -OC(O)-, -NR a -, -C(O)NR a -, -NR a C(O)-, -NR a C(O)O-, -NR a C(O)NR b -,-SO2NR a -, -NR a SO2-, -NR a S(O)NR b -, -NR a S(O)NR b -, -C(O)NR a SO2-, -C(O)NR a SO- or -C(=NR a )NR b - and where m is a number from 0 to 8, and -(CR a R b ) m -One or two CRs a R b The moiety is unsubstituted or O, S, SO, SO2, C(O) and NR a and is substituted with one or more moieties selected from R a and R b are independently hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl, heteroaryl, or -OR c and where R c is hydrogen, an alkyl group, an alkoxy-alkyl-group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group, a heterocyclic group or a heteroaryl group, R 1 -OR 1a , -SR 1a , -NR 1a R 1b , -COR 1a , -SO2R 1a , -C(=O)OR 1a , -C(=O)NR 1a R1b , -C(=NR 1a )NR 1b R 1c , -N(R 1a )C(=O)R 1b , -N(R 1a )C(=O)OR 1b , -N(R 1a )C(O)NR 1b R 1c , -N(R 1a )S(O)NR 1b R 1c , -N(R 1a )S(O)NR 1b R 1c , -NR 1a SO2R 1b , an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group, or the heteroaryl group each independently and optionally has one, two, or three substituents R 1d is replaced by R 1a , R 1b and R 1c are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl or heteroaryl groups, and each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl or heteroaryl groups is optionally selected from the group consisting of halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e heteroaryl groups optionally substituted with CH3-(OCH2CH2) n - (where n is a number from 3 to 10) OR 1fand is substituted with one, two or three substituents selected from where R 1e is a halogen, nitro group, cyano group, hydroxyl group, amino group (-NH2), alkylamino group, dialkylamino group, -C optionally substituted with halogen 1-6 an alkyl group, a carboxyl group, an alkoxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group, or a dialkylaminocarbonyl group; where R 1f is an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group, each of which is optionally selected from the group consisting of -C 1-4 substituted with alkyl groups or halogens; R 1d are independently hydrogen, oxo, -CN, -NO2, hydroxyl, amino (-NH2), alkylamino, dialkylamino, halogen, haloalkyl, alkyl, haloalkoxy, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl, or heteroaryl; R 2 and R 3 are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group, or heteroaryl group is optionally substituted with 1 to 3 substituents selected from oxo, -CN, -NO2, an amino group (-NH2), an alkylamino group, a dialkylamino group, a halogen, a hydroxyl group, a haloalkyl group, an alkyl group, a haloalkoxy group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group; R 4 is hydrogen, halogen, cyano group, -NO2, -OR 4a , -SR 4a , -NR 4aR 4b , -COR 4a , -SO2R 4a , -C(=O)OR 4a , -C(=O)NR 4a R 4b , -C(=NR 4a )NR 4b R 4c , -N(R 4a )C(=O)R 4b , -N(R 4a )C(=O)OR 4b , -N(R 4a )C(O)NR 4b R 4c , -N(R 4a )S(O)NR 4b R 4c , -N(R 4a )S(O)NR 4b R 4c , -NR 4a SO2R 4b , an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group, or the heteroaryl group each independently and optionally has one, two, or three substituents R 4d is replaced by R 4a , R 4b and R 4c are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group, or heteroaryl group is each optionally substituted with a halogen, a hydroxyl group, NH-, an alkylamino group, a dialkylamino group, or an alkoxy group; R 4dare independently hydrogen, oxo, -CN, -NO2, halogen, hydroxyl, NH2-, alkylamino, dialkylamino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl, or heteroaryl, and each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl, or heteroaryl groups is optionally substituted with halogen, hydroxyl, NH2-, alkylamino, dialkylamino, or alkoxy; Ring A is a cycloalkyl group or a heterocyclic ring; R 5 is a halogen, oxo, hydroxyl group, alkyl group, haloalkyl group, alkoxy group, haloalkoxy group or -C(=O)OR 5a where R 5a is hydrogen, an alkyl group, or a haloalkyl group; p is a number 0, 1, 2 or 3; L 2 is a direct bond, -(CR f R g ) t -, -O-, -S-, -S(O)-, -SO2-, -C(O)-, -C(O)O-, -OC(O)-, or -NR d -, where R d Ha-C 1-6 alkyl group, where t is a number from 1 to 8, and -(CR f R g ) t -One or two CRs f R g The moiety is unsubstituted or O, S, SO, SO2, C(O) and NR f and is substituted with one or more moieties selected from R f and R g are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl, or heteroaryl groups; R 6is hydrogen, -NR 6a R 6b , alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group or heteroaryl group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group or heteroaryl group each independently and optionally has one, two or three substituents R 6c is replaced by R 6a and R 6b are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group, or heteroaryl group is each optionally substituted with a halogen, a hydroxyl group, NH-, an alkylamino group, a dialkylamino group, or an alkoxy group; R 6c are independently hydrogen, halogen, cyano group, -NO2, -OR 6d , -SR 6d , -NR 6d R 6e , -COR 6d , -SO2R 6d , -C(=O)OR 6d , -C(=O)NR 6d R 6e , -C(=NR 6d )NR 6e R 6f , -N(R 6d )C(=O)R 6e , -N(R 6d )C(=O)OR 6e , -N(R 6d )C(O)NR 6e R 6f , -N(R 6d )S(O)NR 6e R 6f , -N(R 6d )S(O)NR 6e R 6f , -NR6d SO2R 6e , alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group or heteroaryl group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group or heteroaryl group each independently and optionally has one, two or three substituents R 6g is replaced by R 6d , R 6e and R 6f are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group, or the heteroaryl group each optionally has one, two, or three substituents R 6g is replaced by R 6g If present, they are independently hydrogen, halogen, cyano group, -NO2, -OR 6h , -SR 6h , -NR 6h R 6i , -COR 6h , -SO2R 6h , -C(=O)OR 6h , -C(=O)NR 6h R 6i , -C(=NR 6h )NR 6i R 6j , -N(R 6h )C(=O)R 6i , -N(R 6h )C(=O)OR 6i , -N(R 6h )C(O)NR 6i R 6j , -N(R 6h )S(O)NR 6i R 6j , -N(R 6h )S(O)NR 6i R 6h , -NR6h SO2R 6i , an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group; R 6h , R 6i and R 6j are independently hydrogen, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group, or heteroaryl group are each independently and optionally selected from halogen, -C 1-4 Alkyl group, -C 1-4 It is substituted with one, two or three substituents selected from an alkoxy group, a hydroxyl group, a nitro group, -NH2, an alkylamino group, a dialkylamino group or a cyano group.

[0012] Definition of X In some embodiments, X is N. In some embodiments, X is CR 7 where R 7 is defined as in formula (I). In some embodiments, X is CH.

[0013] L 1 Definition of In some embodiments, m is a number from 0 to 5, or a number from 1 to 3, or a number of 1.

[0014] In some embodiments, L 1 Ha-CR a R b -, -O-, -S-, -S(O)-, -SO2- or -C(O)-, where R a and R b If present, they are independently hydrogen, halogen, and -C 1-8 Alkyl group or -OR c where R cis hydrogen or -C 1-4 In other embodiments, L 1 Ha-CR a R b -, where R a and R b If present, they are independently hydrogen, halogen, and -C 1-8 Alkyl group (preferably -C 1-4 In some embodiments, L is an alkyl group, more preferably a methyl group, or —OH. 1 is —CH—, —CH(OH)—, or —CH(CH)—. In some embodiments, L 1 is -CH2-.

[0015] R 1 Definition of In some embodiments, R 1 HA-OR 1a or -NR 1a R 1b where R 1a and R 1b is defined as in formula (I).

[0016] In some embodiments, R 1 HA-OR 1a or -NR 1a R 1b where R 1a , R 1b are independently hydrogen, -C 1-8 Alkyl group or -C 2-8 alkenyl group, 1-8 Alkyl group or -C 2-8 Each alkenyl group may optionally be R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with CH3-(OCH2CH2) n - (where n is a number from 3 to 10, preferably 4-8, more preferably 5-7) or -OR 1f and is substituted with one, two or three substituents selected from where R 1eis halogen, -C optionally substituted with halogen 1-6 an alkyl group, a carboxyl group, an alkoxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group, or a dialkylaminocarbonyl group; where R 1f Ha-C 1-8 an alkyl group, an aryl group, or a heteroaryl group, each of which is optionally —C 1-4 It is substituted with an alkyl group or a halogen.

[0017] In some embodiments, R 1 HA-OR 1a where R 1a is hydrogen.

[0018] In some embodiments, R 1 HA-OR 1a where R 1a is optionally a halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e heteroaryl groups optionally substituted with CH3-(OCH2CH2) n - (where n is a number from 3 to 10) OR 1f -C substituted with one, two or three substituents selected from 1-8 is an alkyl group, where R 1e and R 1f is defined as in formula (I).

[0019] In some embodiments, R 1 HA-OR 1a where R 1a is the substituted C 1-8 In some embodiments, R 1 HA-OR 1a where R 1ais linear. In some embodiments, R 1 HA-OR 1a where R 1a is a branched alkyl group. In some embodiments, R 1 HA-OR 1a where R 1a is a branched alkyl group, preferably -C 4-8 alkyl groups, where the branched chain substituent is alpha to the oxygen atom, including, but not limited to, but-2-yl, pent-2-yl, pent-3-yl, hept-2-yl, hept-3-yl, hept-4-yl, oct-2-yl, oct-3-yl, oct-4-yl, or oct-5-yl. 1 is a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a hexoxy group, a heptoxy group, or an octoxy group. 1 is preferably a propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a but-2-yloxy group (an s-butoxy group), a pent-2-yloxy group, a pent-3-yloxy group, a 2-methylbutoxy group, a hept-2-yloxy group, a hept-3-yloxy group, a hept-4-yloxy group, an oct-2-yloxy group, an oct-3-yloxy group, an oct-4-yloxy group, or an oct-5-yloxy group. 1 is an n-butoxy group, a but-2-yloxy group (an s-butoxy group), a pent-2-yloxy group, a pent-3-yloxy group, a hept-2-yloxy group, a hept-3-yloxy group, a hept-4-yloxy group, an oct-2-yloxy group, an oct-3-yloxy group, an oct-4-yloxy group, or an oct-5-yloxy group.

[0020] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 4-5It is an alkyl group, and the alkyl group is substituted with one to three halogens such as fluorine.

[0021] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 an alkyl group, the alkyl group being R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e substituted with a heteroaryl group optionally substituted with R 1e is defined as in formula (I).

[0022] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 alkyl group, which is substituted with a 5-6 membered heteroaryl group containing one, two or three heteroatoms as ring members selected from, for example, oxygen, nitrogen or optionally oxidized sulfur, and the heteroaryl group is -C 1-6 Optionally substituted with an alkyl group, preferably -C 1-4 In some embodiments, the heteroaryl group is a pyridyl group, an imidazolyl group, or an isoxazolyl group. 1 is a pyridin-3-ylmethoxy group, a 2-(1H-imidazol-1-yl)ethoxy group, or a (5-methylisoxazol-3-yl)methoxy group.

[0023] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C1-3 In some embodiments, R is an alkyl group, and the alkyl group is substituted with an aryl group, such as, for example, phenyl. 1 is a 2-phenylethoxy group or a 3-phenylpropoxy group.

[0024] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 an alkyl group, wherein the alkyl group is —OR 1f where R 1f Ha-C 1-8 is an alkyl group or an aryl group (e.g., a phenyl group). 1 is a 2-methoxyethoxy group or a 2-phenoxyethoxy group.

[0025] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 an alkyl group, the alkyl group being CH3-(OCH2CH2) n -, where n is a number from 3 to 10, preferably 3, 4, or 5. In some embodiments, R 1 is a 2,5,8,11-tetraoxatridecan-13-yloxy group.

[0026] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 2-8 alkenyl group, preferably -C 2-6 alkenyl groups, most preferably -C 4-6 In one embodiment, R is an alkenyl group. 1 is a but-3-eneoxy group.

[0027] In some embodiments, R 1 Ha-NR 1a R 1b where R 1a and R 1b Each of 1-8 is an alkyl group, preferably -C 1-6 alkyl group, said alkyl group optionally containing halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e and wherein R is substituted with one, two, or three substituents selected from a heteroaryl group optionally substituted with 1e is, for example, -C such as a methyl group. 1-6 It is an alkyl group.

[0028] In some embodiments, R 1 Ha-NR 1a R 1b where R 1a is hydrogen and R 1b is a straight or branched chain -C 1-8 In some embodiments, R 1 Ha-NR 1a R 1b where R 1a is hydrogen, R 1b is a branched alkyl group, preferably -C 4-8 Alkyl groups in which the branched chain substituent is alpha to the oxygen atom, including, but not limited to, but-2-yl, pent-2-yl, pent-3-yl, hept-2-yl, hept-3-yl, hept-4-yl, oct-2-yl, oct-3-yl, oct-4-yl, or oct-5-yl.

[0029] In some embodiments, R 1 is a butylamino group, an N-butyl-N-methylamino group, or an isopentylamino group.

[0030] In some embodiments, R 1 is optionally partially or fully deuterated, i.e., R 1 In the definition of , one or more hydrogens attached to the carbons are replaced with one or more deuteriums.

[0031] R 2 and R 3 Definition of In some embodiments, R 2 and R 3 If present, independently hydrogen or C 1-8 alkyl group, preferably C 1-6 In some embodiments, R 2 and R 3 Both are hydrogen.

[0032] R 4 Definition of In some embodiments, R 4 is hydrogen.

[0033] R 5 Definition of In some embodiments, R 5 is a halogen, oxo, hydroxyl group, C 1-8 Alkyl groups, halogenated C 1-8 Alkyl group, C 1-8 Alkoxy group, halogenated C 1-8 Alkoxy group, or -C(=O)OR 5a where R 5a is hydrogen, C 1-8 Alkyl group or halogenated C 1-8 is an alkyl group, and p is a number 0, 1, or 2.

[0034] In some embodiments, R 5 is halogen, oxo, C 1-3 Alkyl groups, halogenated C 1-3 Alkyl group, C 1-3 Alkoxy group or halogenated C 1-8 In some embodiments, R5 is a methyl group, an ethyl group, a propyl group, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a trifluoromethoxy group, or a trifluoromethyl group. 5 is a methyl group.

[0035] In some embodiments, p is the number one.

[0036] In some embodiments, R 5 and L 2 -R 6 is in the ortho position on ring A.

[0037] Definition of Ring A In some embodiments, ring A is a heterocyclic group.

[0038] In some embodiments, ring A is a 4-, 5-, 6-, 7-, 8-, or 9-membered monocyclic heterocyclic group containing one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members, preferably a 5- to 6-membered heteroaryl group containing one or two nitrogen atoms as ring members, more preferably a 5- to 6-membered heteroaryl group containing one nitrogen atom as a ring member. In some embodiments, ring A is an azetidinyl group (e.g., azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, azetidin-4-yl), a pyrrolidinyl group (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), a piperidinyl group (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl), or an azepanyl group (e.g., azepan-1-yl, azepan-2-yl, azacycloheptan-3-yl, azacycloheptan-4-yl), preferably a piperidinyl group (e.g., piperidin-1-yl, piperidin-4-yl). In some embodiments, ring A is a piperazinyl group (e.g., piperazin-1-yl or piperazin-2-yl).

[0039] In some embodiments, the heterocyclic ring may contain one or more double bonds (C=C or C=N) but is not aromatic. However, the heterocyclic ring is preferably saturated.

[0040] In some embodiments, ring A is a spiroheterocyclic group or a bridged heterocyclic group, e.g., 5 to 20 membered, preferably 6 to 14 membered, more preferably 7 to 12 membered. In some embodiments, the heterocyclic group is 7-azaspiro[3.5]nosyl, 3-azaspiro[3.1.0]hexyl, 2-azaspiro[3.3]heptyl, 7-azaspiro[3.5]nosyl, 2-azaspiro[3.5]nosyl, 2-azabicyclo[2.2.1]heptyl, 8-azabicyclo[3.2.1]octyl, or 2-azabicyclo[4.1.0]heptyl. More particularly, the spiroheterocyclic group is 7-azaspiro[3.5]non-2-yl, 3-azabicyclo[3.1.0]hex-6-yl, 2-azaspiro[3.3]hept-6-yl, 7-azaspiro[3.5]non-2-yl, 2-azaspiro[3.5]non-7-yl, 2-azabicyclo[2.2.1]hept-5-yl, 8-azabicyclo[3.2.1]oct-3-yl or 2-azabicyclo[4.1.0]hept-5-yl.

[0041] In some embodiments, Ring A is a cycloalkyl group, e.g., a spirocycloalkyl group, a fused cycloalkyl group, or a bridged cycloalkyl group, selected from a 3- to 8-membered monocyclic cycloalkyl group or a 6- to 12-membered bicyclic cycloalkyl group, e.g., a bicyclo[1.1.1]pentyl group (e.g., bicyclo[1.1.1]pentyl-1-yl). In some embodiments, Ring A is a cycloalkenyl group or a cycloalkynyl group.

[0042] L 2 -R 6 Definition of In some embodiments, L 2 is a direct bond, -(CH2) t-, -O-, -S-, -S(O)-, -SO2-, -C(O)-, -C(O)O-, -OC(O)-, or -NR d -, where R d Ha-C 1-6 alkyl group, where t is a number from 1 to 8, preferably 1 to 5, more preferably 1, 2, or 3, and R d Ha-C 1-6 It is an alkyl group.

[0043] In some embodiments, L 2 is a bond, -CH2-, -CH2CH2-, -CH2CH2CH2-, -O-, or -NR d -, where R d Ha-C 1-6 is an alkyl group, preferably -C 1-4 It is an alkyl group, more preferably a methyl group.

[0044] In some embodiments, R 6 is hydrogen, -NR 6a R 6b , -C 1-8 Alkyl group, -C 2-8 Alkenyl group, -C 2-8 an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group, 1-8 Alkyl group, -C 2-8 Alkenyl group, -C 2-8 The alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl groups each independently and optionally contain one, two or three substituents R 6c is replaced by R 6a and R 6b are independently hydrogen or -C 1-8 is an alkyl group, R 6c are independently hydrogen, halogen, -OR 6d , -SR 6d , -NR 6d R 6e , -COR 6d , -SO2R 6d , -C(=O)NR6d R 6e or -C 1-8 is an alkyl group, 1-8 The alkyl group may independently and optionally be one or two or three substituents R 6g is replaced by R 6d and R 6e are independently hydrogen, -C 1-8 Alkyl group, -C 2-8 is an alkenyl group, a heterocyclic group, or an aryl group, and 1-8 Alkyl group, -C 2-8 The alkenyl, heterocyclic or aryl group may each optionally contain one, two or three substituents R 6g is replaced by R 6g If present, they are independently hydrogen, halogen, -OR 6h , -SR 6h , -NR 6h R 6i , -N(R 6h )C(=O)OR 6i , -C 1-8 alkyl, heterocyclic, aryl, or heteroaryl group, where R 6h and R 6i are independently hydrogen or -C 1-8 It is an alkyl group.

[0045] L 2 -(CR f R g ) t - and R 6 L is a heterocyclic group 2 -R 6 Definition of In some embodiments, L 2 Ha-(CR f R g ) t -(where t, R f and R g is defined as in formula (I), preferably -CH- or -CHCH-, and R 6 is one or two substituents R 6c is a heterocyclic group optionally substituted with6c is defined as in formula (I).

[0046] In some embodiments, R 6 The heterocyclic group represented by the formula (I) is a monocyclic ring. In some embodiments, the heterocyclic group is bicyclic. In some embodiments, the heterocyclic group is saturated. In some embodiments, the heterocyclic group is a 5- to 8-membered saturated monocyclic ring containing one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members. In some embodiments, the heterocyclic group is a 5-, 6-, 7-, or 8-membered saturated monocyclic ring containing one, two, or three nitrogen heteroatoms as ring members.

[0047] In some embodiments, R 6 The heterocyclic group represented by is a pyrrolidinyl group (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), a piperidinyl group (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl), a triazolyl group (e.g., 1H-1,2,4-triazol-1-yl), an azepanyl group (e.g., azepan-2-yl, azepan-3-yl, azepan-4-yl, azepan-5-yl), a piperazinyl group (e.g., piperazin-1-yl, piperazin-2-yl, piperazin-3-yl) or a morpholino group. In some embodiments, the heterocyclic group is bicyclic and contains one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members. In some instances, the heterocyclic group is (1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl. In the above embodiment, R 6 The heterocyclic group as defined above may further contain one or two substituents R 6c In some embodiments, R 6c Ha-NR 6d R 6e , -COR 6d , -OR 6d or -C optionally substituted with a hydroxyl group 1-8is an alkyl group, where R 6d and R 6e are independently hydrogen or -C 1-8 Alkyl group (preferably -C 1-3 alkyl group) or a phenyl group, wherein the alkyl group is optionally substituted with NH-, an alkylamino group, or a dialkylamino group. In some embodiments, R 6c is an amino group, a dimethylamino group, a 2-(dimethylamino)acetyl group, a methyl group, a 3-hydroxypropyl group, or a phenoxy group. 2 is -CH- or -CHCH-. In some embodiments, R 6 is pyrrolidin-1-yl, morpholino, piperidin-1-yl, 4-methylpiperazin-1-yl, piperazin-1-yl, piperidin-4-yl, 4-(2-(dimethylamino)acetyl)piperazin-1-yl, (1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl, 4-aminopiperidin-1-yl, 3-(dimethylamino)pyrrolidin-1-yl, 4-phenoxypiperidin-1-yl, 1H-1,2,4-triazol-1-yl, 4-(3-hydroxypropyl)piperazin-1-yl or piperidin-3-yl.

[0048] L 2 -(CR f R g ) t - and R 6 Ga-NR 6a R 6b L 2 -R 6 Definition of In some embodiments, L 2 Ha-(CR f R g ) t -(where t, R f and R g is defined as in formula (I), preferably -CH- or -CHCH-, and R 6 Ha-NR 6a R 6b where R 6aand R 6b is defined as in formula (I). In some embodiments, L 2 Ha-(CH2) t - (wherein t is a number from 1 to 8, preferably 1 to 5, more preferably 1, 2 or 3), preferably -CH2- or -CH2CH2-, and R 6 Ha-NR 6a R 6b where R 6a and R 6b are independently hydrogen or C 1-8 alkyl group, preferably C 1-6 In some embodiments, L 2 -R 6 is an amino group and a methyl group.

[0049] L 2 is a bond and R 6 is an alkyl group, an alkenyl group, or an alkynyl group; 2 -R 6 Definition of In some embodiments, L 2 is a bond and R 6 Ha-C 1-8 Alkyl group, -C 2-8 Alkenyl group, or -C 2-8 It is an alkynyl group.

[0050] L 2 is -O- or -NR d - and R 6 L is an alkyl group, an alkenyl group, an alkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group. 2 -R 6 Definition of In some embodiments, L 2 is -O- and R 6 Ha-C 1-8 is an alkyl group or a heterocyclic group, 1-8 The alkyl and heterocyclic groups may optionally be joined by one or two R 6c In some embodiments, R 6c Ha-C1-8 Alkyl group, -NR 6d R 6e W-COR 6d where R 6d and R 6e are independently -C optionally substituted with NH-, an alkylamino group, or a dialkylamino group. 1-8 Alkyl group (preferably -C 1-3 alkyl group).

[0051] In some embodiments, L 2 Ha-NR d -, where R d Ha-C 1-6 is an alkyl group, and R 6 Ha-C 1-8 Alkyl group, -C 2-8 Alkenyl group or -C 2-8 alkynyl groups, each of which is optionally one or two R 6c In some embodiments, R 6c Ha-C 1-8 Alkyl group or -NR 6d R 6e where R 6d and R 6e independently, -C 1-8 Alkyl group (preferably -C 1-3 In some embodiments, L 2 -R 6 is the (2-(dimethylamino)ethyl)(methyl)amino group.

[0052] L 2 is a direct bond and R 6 L is a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group. 2 -R 6 Definition of In some embodiments, L 2 is a direct bond and R 6 is a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group, each of which is independently and optionally followed by one, two, or three substituents R6c is replaced by .

[0053] In some embodiments, L 2 is a direct bond and R 6 is a heterocyclic group, optionally containing one, two or three substituents R 6c is replaced by .

[0054] R 6 In some embodiments, the heterocyclic group is a monocyclic ring; in some embodiments, the heterocyclic group is a fused bicyclic heterocyclic group; and in some embodiments, the heterocyclic group is a spiro bicyclic heterocyclic group.

[0055] In some embodiments, the heterocyclic group is saturated. In some embodiments, the heterocyclic group is a 4-, 5-, 6-, 7-, or 8-membered saturated monocyclic ring containing one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members. In some embodiments, the heterocyclic group is a 5-, 6-, 7-, or 8-membered saturated monocyclic ring containing one, two, or three nitrogen heteroatoms as ring members. In some embodiments, the heterocyclic group is a 5- or 6-membered saturated monocyclic ring containing one or two nitrogen heteroatoms as ring members. In some embodiments, the heterocyclic group is a pyrrolidinyl group (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), a piperidinyl group (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl), a triazolyl group (e.g., 1H-1,2,4-triazol-1-yl), azepanyl, or the like. groups (e.g., azepan-2-yl, azepan-3-yl, azepan-4-yl, azepan-5-yl), diazepinyl groups (e.g., 1,4-diazepin-1-yl, 1,4-diazepin-2-yl, 1,4-diazepin-3-yl, 1,4-diazepin-4-yl), piperazinyl groups (e.g., piperazin-1-yl, piperazin-2-yl, piperazin-3-yl) or morpholino groups.

[0056] In some embodiments, the heterocyclic group is bicyclic and contains one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members. In some instances, the heterocyclic group is 2,5-diazabicyclo[2.2.1]hept-2-yl.

[0057] In some embodiments, the heterocyclic group is a 6- to 14-membered, more preferably a 7- to 10-membered spiro bicyclic heterocyclic group. In some embodiments, the heterocyclic group is a spiroheptyl group, a spirodecyl group, or a spironosyl group containing one or two nitrogen atoms as ring members. In some embodiments, the heterocyclic group is 8-azaspiro[4.5]dec-8-yl, 2,7-diazaspiro[3.5]non-7-yl, 2,8-diazaspiro[4.5]dec-2-yl, 2,7-diazaspiro[3.5]non-2-yl, or 2,8-diazaspiro[4.5]dec-8-yl.

[0058] In the above embodiment, R 6 The heterocyclic group as defined above may further contain one or two substituents R 6c is optionally replaced by

[0059] In some embodiments, R 6c HA-COR 6d where R 6d is one or two substituents R 6g -C optionally substituted with 1-8 is an alkyl group, where R 6g Ha-NR 6h R 6i , -N(R 6h )C(=O)R 6i , -C 1-8 an alkyl group, an aryl group, or a heteroaryl group, where R 6h and R 6i is defined as in formula (I). In some embodiments, R 6c HA-COR 6d where R 6d is one or two substituents R 6g -C optionally substituted with1-8 Alkyl group (preferably C 1-6 alkyl group, more preferably C 1-4 is an alkyl group, where R 6g Ha-NR 6h R 6i , -N(R 6h )C(=O)R 6i , -C 1-8 an alkyl group, an aryl group, or a heteroaryl group, where R 6h and R 6i are each independently hydrogen or -C 1-8 Alkyl group (preferably C 1-6 alkyl group, more preferably C 1-4 alkyl group).

[0060] In some embodiments, R 6c HA-COR 6d where R 6d Ha-C 2-8 It is an alkenyl group.

[0061] In some embodiments, R 6c HA-COR 6d where R 6d is a heterocyclic group.

[0062] In some embodiments, R 6c is an acetyl group, a 2-(dimethylamino)acetyl group, a 2-(dimethylamino)acetyl group, an aminoacetyl group, a 2-(methylamino)acetyl group, a 3-(dimethylamino)propionyl group, a 4-(dimethylamino)butyryl group, a 5-(dimethylamino)pentanoyl group, a (2S,3S)-2-amino-3-methylpentanoyl group, a 2-(methylamino)acetyl group, a 2-amino-4-methylpentanoyl group, a 2-amino-3-methylbutyryl group, a 2-(dimethylamino)acetyl group, a phenylpropionyl group, a 2-(piperazin-1-yl)acetyl group, an acryloyl group, a piperazine-2-carbonyl group, a piperidine-4-carbonyl group, a pyrrolidine-2-carbonyl group, or a 2-(N-methylacetylamino)acetyl group.

[0063] In some embodiments, R 6c Ha-C 1-8 an alkoxy group, preferably -C such as a methoxy group 1-6 It is an alkoxy group.

[0064] In some embodiments, R 6c Ha-C 1-8 is an alkyl group, preferably -C 1-6 is an alkyl group, which may contain one or two substituents R 6g where R 6g HA-OR 6h , -NR 6h R 6i , heterocyclic group, aryl group, where R 6h and R 6i is defined as in formula (I). In some aspects, R 6c Ha-C 1-8 is an alkyl group, preferably -C 1-6 is an alkyl group, which optionally has one substituent R 6g where R 6g HA-OR 6h , -NR 6h R 6i , a heterocyclic group (e.g., a morpholino group), an aryl group (e.g., a phenyl group), where R 6h and R 6i Ha-C 1-4 is an alkyl group, preferably a methyl group. In some embodiments, R 6c is a methyl group, an ethyl group, an isobutyl group, a methoxymethyl group, a 2-methoxyethyl group, a (methylamino)methyl group, a 2-(dimethylamino)ethyl group, a (dimethylamino)methyl group, a 2-aminoethyl group, a 2-(methylamino)ethyl group, a 2-(dimethylamino)ethyl group, a morpholinomethyl group, or a phenethyl group.

[0065] In some embodiments, R 6c is a heterocyclic group, optionally containing one substituent R 6g In some embodiments, R6c is a heterocyclic group, optionally containing one heterocyclic group substituent R 6g In some embodiments, R 6c is 4-morpholinopiperidin-1-yl.

[0066] In some embodiments, R 6c is -C(=O)NR 6d R 6e where R 6d and R 6e are independently hydrogen, -C 1-8 Alkyl group (preferably -C 1-3 alkyl group) or aryl group, 1-8 The alkyl or aryl groups may independently and optionally be halogen or -C 1-4 In some embodiments, R 6c is -C(=O)NR 6d R 6e where R 6d and R 6e are independently hydrogen and -C 1-4 In some embodiments, R 6c is -C(=O)NR 6d R 6e where R 6d and R 6e are independently hydrogen and an aryl group optionally substituted with halogen. In some embodiments, R 6c is a dimethylcarbamoyl group, an isopropylcarbamoyl group, or a 2,4,5-trifluorophenylcarbamoyl group.

[0067] In some embodiments, R 6c Ha-NR 6d R 6e where R 6d and R 6e are independently hydrogen or -C 1-8 Alkyl group (preferably -C 1-6 alkyl group, more preferably -C 1-3In some embodiments, R 6c is a dimethylamino group or an amino group.

[0068] In some embodiments, R 6c Ha-SO2R 6d where R 6d Ha-C 1-8 Alkyl group, -C 2-8 Alkenyl group, -C 2-8 In some embodiments, R is an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group. 6c Ha-SO2R 6d where R 6d Ha-C 1-8 In some embodiments, R 6c is a propylsulfonyl group.

[0069] In some embodiments, L 2 is a direct bond, and R 6 is a pyrrolidinyl group, optionally substituted with one, two or three substituents selected from a methyl group, a (dimethylamino)methyl group or a dimethylamino group.

[0070] In some embodiments, L 2 is a direct bond, and R 6is a piperazinyl group, and optionally is an acryloyl group, a 2-(dimethylamino)acetyl group, an aminoacetyl group, a 2-(methylamino)acetyl group, a 3-(dimethylamino)propionyl group, a 2-(piperazin-1-yl)acetyl group, a piperazine-2-carbonyl group, a 4-(dimethylamino)butyryl group, a 5-(dimethylamino)pentanoyl group, a methyl group, a piperidine-4-carbonyl group, an acetyl group, a 2-(N-methylacetylamino)acetyl group, an isopropylcarbamoyl group, a 2,4,5-trifluorophenyl ... and is substituted by one, two or three substituents selected from a 2-amino-3-methylpentanoyl group, a 2-methoxyethyl group, a 2-(methylamino)acetyl group, an ethyl group, an isobutyl group, a pyrrolidine-2-carbonyl group, a 2-amino-4-methylpentanoyl group, a 2-amino-3-methylbutyryl group, a 2-(dimethylamino)acetyl group, a 2-(methylamino)ethyl group, a 2-(dimethylamino)ethyl group, an amino group, a phenylpropionyl group, a propylsulfonyl group or a 2-aminoethyl group.

[0071] In some embodiments, L 2 is a direct bond, and R 6 is a piperidinyl group, optionally substituted with one, two or three substituents selected from a 2-(dimethylamino)acetyl group, a methoxy group, a methoxymethyl group, a (methylamino)methyl group, a 4-morpholinopiperidin-1-yl, a morpholinomethyl group, a 2-(dimethylamino)ethyl group, a phenethyl group, a (dimethylamino)methyl group, an amino group, a dimethylamino group or a dimethylcarbamoyl group.

[0072] Ring A, R 5 and L 2 -R 6 Definition of In some embodiments, Ring A is azetidin-3-yl, azepan-4-yl; piperidin-2-yl, piperidin-3-yl, piperidin-4-yl; pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl; piperazin-1-yl; 7-azaspiro[3.5]non-2-yl, 2-azaspiro[3.3]hept-6-yl, 7-azaspiro[3.5]non-2-yl, 2-azaspiro[ 3.5]non-7-yl; 3-azabicyclo[3.1.0]hex-6-yl, 2-azabicyclo[2.2.1]hept-5-yl, 8-azabicyclo[3.2.1]oct-3-yl, 2-azabicyclo[4.1.0]hept-5-yl; cyclobutyl group, bicyclo[1.1.1]pent-1-yl; bicyclo[1.1.1]pent-1-yl; or 1,2,3,6-tetrahydropyridin-4-yl. In some embodiments, ring A is a piperidinyl group, preferably piperidin-1-yl or piperidin-4-yl.

[0073] p is 0 or 1.

[0074] In some embodiments, R 5 and L 2 -R 6 are each independently a methyl group, an ethyl group, an isopropyl group; a 2-(methylamino)ethyl group; a benzyl group; a piperidin-4-ylmethyl group; a (methylamino)methyl group; a 2-(methylamino)ethyl group; a methylol group; a trifluoromethyl group; a pyrrolidin-3-yl, a pyrrolidin-2-yl, a piperidin-4-yl group; a hydroxyl group; an oxo group; a fluorine group; an ethoxycarbonyl group; a phenyl group; a methylamino group, or an amino group.

[0075] In some embodiments, the moiety [ka] are piperidin-4-yl, 1-methylpiperidin-4-yl, 1-(2-(methylamino)ethyl)piperidin-4-yl, 1-(pyrrolidin-3-yl)piperidin-4-yl, 1-(pyrrolidin-2-yl)piperidin-4-yl, 1-(piperidin-4-yl)piperidin-4-yl, 4-methylpiperidin-4-yl, 3-hydroxypiperidin-4-yl, 3-oxopiperidin-4-yl, 3-fluoropiperidin-4-yl, 3,3-difluoropiperidin-4-yl, 3-benzylpiperidin-4-yl, 1-( Piperidin-4-ylmethyl)piperidin-4-yl, 4-((methylamino)methyl)piperidin-1-yl, 2-ethylpiperidin-4-yl, 2-ethoxycarbonyl piperidin-4-yl, 2-methylolpiperidin-4-yl, 1-methyl-2-((methylamino)methyl)piperidin-4-yl, 1-isopropyl-2-((methylamino)methyl)piperidin-4-yl, 2,6-dimethylpiperidin-4-yl, 2,2-dimethylpiperidin-4-yl, 2-(trifluoromethyl)piperidin-4-yl, 2- Phenylpiperidin-4-yl, 4-(methylamino)piperidin-1-yl; Piperidin-2-yl; Pyrrolidin-3-yl; Azetidin-3-yl; Azepan-4-yl; (R)-3-Methylpiperazin-1-yl; (S)-3-Methylpiperazin-1-yl; (S)-3-Methylpiperazin-1-yl; (R)-3-Methylpiperazin-1-yl; 2-Hydroxy-7-azaspiro[3.5]non-2-yl; 3-Azabicyclo[3.1.0]hex-6-yl; 2-Azaspiro[3.3]hept-6-yl; 7-Azaspiro [3.5]non-2-yl; 2-azaspiro[3.5]non-7-yl; 2-azabicyclo[2.2.1]hept-5-yl; 8-azabicyclo[3.2.1]oct-3-yl; 3-aminocyclobutyl; 1-(2-(methylamino)ethyl)-2-oxo-piperidin-4-yl; 2-azabicyclo[4.1.0]hept-5-yl; 1,2,3,6-tetrahydropyridin-4-yl; 3-aminobicyclo[1.1.1]pent-1-yl; 3-((methylamino)methyl)bicyclo[1.1.1]pent-1-yl.

[0076] In a second embodiment, the present invention provides a compound of formula (II): [ka] or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

[0077] In formula (II), R a and R b are independently hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl, heteroaryl, or -OR c and where R c is hydrogen, an alkyl group, an alkoxy group-alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group, a heterocyclic group or a heteroaryl group, R 1 -OR 1a , -SR 1a , -NR 1a R 1b , -COR 1a , -SO2R 1a , -C(=O)OR 1a , -C(=O)NR 1a R 1b , -C(=NR 1a )NR 1b R 1c , -N(R 1a )C(=O)R 1b , -N(R 1a )C(=O)OR 1b , -N(R 1a )C(O)NR 1b R 1c , -N(R 1a )S(O)NR 1b R 1c , -N(R 1a )S(O)NR 1b R 1c , -NR 1a SO2R 1b, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, wherein the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group, or the heteroaryl group each independently and optionally has one, two, or three substituents R 1d is replaced by R 1a , R 1b and R 1c are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl or heteroaryl groups, and each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl or heteroaryl groups is optionally selected from the group consisting of halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e heteroaryl groups optionally substituted with CH3-(OCH2CH2) n - (where n is a number from 3 to 10) OR 1f and is substituted with one, two or three substituents selected from where R 1e is a halogen, nitro group, cyano group, hydroxyl group, amino group (-NH2), alkylamino group, dialkylamino group, -C optionally substituted with halogen 1-6 an alkyl group, a carboxyl group, an alkoxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group, or a dialkylaminocarbonyl group; where R 1f is an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group, each of which is optionally selected from the group consisting of -C 1-4 substituted with alkyl groups or halogens; R 1d are independently hydrogen, oxo, -CN, -NO2, hydroxyl, amino (-NH2), alkylamino, dialkylamino, halogen, haloalkyl, alkyl, haloalkoxy, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, aryl, or heteroaryl; Ring A is a cycloalkyl group or a heterocyclic ring; Het is a heterocyclic group; R 5 is a halogen, a hydroxyl group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, or -C(=O)OR 5a where R 5a is hydrogen, an alkyl group, or a haloalkyl group; p is a number 0, 1, 2 or 3; R 6c are independently hydrogen, halogen, cyano group, -NO2, -OR 6d , -SR 6d , -NR 6d R 6e , -COR 6d , -SO2R 6d , -C(=O)OR 6d , -C(=O)NR 6d R 6e , -C(=NR 6d )NR 6e R 6f , -N(R 6d )C(=O)R 6e , -N(R 6d )C(=O)OR 6e , -N(R 6d )C(O)NR 6e R 6f , -N(R 6d )S(O)NR 6e R 6f , -N(R 6d )S(O)NR 6e R 6f , -NR 6d SO2R 6e, alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group or heteroaryl group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group or heteroaryl group each independently and optionally has one, two or three substituents R 6g is replaced by R 6d , R 6e and R 6f are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group, or the heteroaryl group each optionally has one, two, or three substituents R 6g is replaced by R 6g If present, they are independently hydrogen, halogen, cyano group, -NO2, -OR 6h , -SR 6h , -NR 6h R 6i , -COR 6h , -SO2R 6h , -C(=O)OR 6h , -C(=O)NR 6h R 6i , -C(=NR 6h )NR 6i R 6j , -N(R 6h )C(=O)R 6i , -N(R 6h )C(=O)OR 6i , -N(R 6h )C(O)NR 6i R 6j , -N(R 6h )S(O)NR 6i R 6j , -N(R 6h )S(O)NR 6i R 6h , -NR 6h SO2R 6i, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group; R 6h , R 6i and R 6j are independently hydrogen, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group, or heteroaryl group are each independently and optionally selected from halogen, -C 1-4 Alkyl group, -C 1-4 It is substituted with one, two or three substituents selected from an alkoxy group, a hydroxyl group, a nitro group, -NH2, an alkylamino group, a dialkylamino group or a cyano group.

[0078] R 1 Definition of In some embodiments, R 1 HA-OR 1a or -NR 1a R 1b where R 1a and R 1b is defined as in formula (II).

[0079] In some embodiments, R 1 HA-OR 1a or -NR 1a R 1b where R 1a , R 1b are independently hydrogen, -C 1-8 Alkyl group or -C 2-8 alkenyl group, 1-8 Alkyl group or -C 2-8 Each alkenyl group may optionally be R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with CH3-(OCH2CH2) n- (where n is a number from 3 to 10, preferably 4-8, more preferably 5-7) or -OR 1f and is substituted with one, two or three substituents selected from where R 1e is halogen, -C optionally substituted with halogen 1-6 an alkyl group, a carboxyl group, an alkoxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group, or a dialkylaminocarbonyl group, where R 1f Ha-C 1-8 an alkyl group, an aryl group, or a heteroaryl group, each of which is optionally —C 1-4 It is substituted with an alkyl group or a halogen.

[0080] In some embodiments, R 1 HA-OR 1a where R 1a is hydrogen.

[0081] In some embodiments, R 1 HA-OR 1a where R 1a is optionally a halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e heteroaryl groups optionally substituted with CH3-(OCH2CH2) n - (where n is a number from 3 to 10) OR 1f -C substituted with one, two or three substituents selected from 1-8 is an alkyl group, where R 1e and R 1f is defined as in formula (II).

[0082] In some embodiments, R 1 HA-OR 1awhere R 1a is the substituted C 1-8 In some embodiments, R 1 HA-OR 1a where R 1a is linear. In some embodiments, R 1 HA-OR 1a where R 1a is a branched alkyl group. In some embodiments, R 1 HA-OR 1a where R 1a is a branched alkyl group, preferably -C 4-8 alkyl groups, where the branched chain substituent is alpha to the oxygen atom, including, but not limited to, but-2-yl, pent-2-yl, pent-3-yl, hept-2-yl, hept-3-yl, hept-4-yl, oct-2-yl, oct-3-yl, oct-4-yl, or oct-5-yl. 1 is a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a hexoxy group, a heptoxy group, or an octoxy group. 1 is preferably a propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a but-2-yloxy group (an s-butoxy group), a pent-2-yloxy group, a pent-3-yloxy group, a 2-methylbutoxy group, a hept-2-yloxy group, a hept-3-yloxy group, a hept-4-yloxy group, an oct-2-yloxy group, an oct-3-yloxy group, an oct-4-yloxy group, or an oct-5-yloxy group. 1 is an n-butoxy group, a but-2-yloxy group (an s-butoxy group), a pent-2-yloxy group, a pent-3-yloxy group, a hept-2-yloxy group, a hept-3-yloxy group, a hept-4-yloxy group, an oct-2-yloxy group, an oct-3-yloxy group, an oct-4-yloxy group, or an oct-5-yloxy group.

[0083] In some embodiments, R1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 4-5 It is an alkyl group, and the alkyl group is substituted with one to three halogens such as fluorine.

[0084] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 an alkyl group, the alkyl group being R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e and a heteroaryl group optionally substituted with R 1e is defined as in formula (II).

[0085] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 alkyl group, which is substituted with a 5-6 membered heteroaryl group containing one, two or three heteroatoms as ring members selected from, for example, oxygen, nitrogen or optionally oxidized sulfur, and the heteroaryl group is -C 1-6 Optionally substituted with an alkyl group, preferably -C 1-4 In some embodiments, the heteroaryl group is a pyridyl group, an imidazolyl group, or an isoxazolyl group. 1 is a pyridin-3-ylmethoxy group, a 2-(1H-imidazol-1-yl)ethoxy group, or a (5-methylisoxazol-3-yl)methoxy group.

[0086] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 In some embodiments, R is an alkyl group, and the alkyl group is substituted with an aryl group, such as, for example, phenyl. 1 is a 2-phenylethoxy group or a 3-phenylpropoxy group.

[0087] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 an alkyl group, wherein the alkyl group is —OR 1f where R 1f Ha-C 1-8 is an alkyl group or an aryl group (e.g., a phenyl group). 1 is a 2-methoxyethoxy group or a 2-phenoxyethoxy group.

[0088] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 1-8 is an alkyl group, preferably -C 1-3 an alkyl group, the alkyl group being CH3-(OCH2CH2) n -, where n is a number from 3 to 10, preferably 3, 4, or 5. In some embodiments, R 1 is a 2,5,8,11-tetraoxatridecan-13-yloxy group.

[0089] In some embodiments, R 1 HA-OR 1a where R 1a Ha-C 2-8 alkenyl group, preferably -C 2-6 alkenyl groups, most preferably -C4-6 In one embodiment, R is an alkenyl group. 1 is a but-3-eneoxy group.

[0090] In some embodiments, R 1 Ha-NR 1a R 1b where R 1a and R 1b Each of 1-8 is an alkyl group, preferably -C 1-6 alkyl group, said alkyl group optionally containing halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with R 1e an aryl group optionally substituted with R 1e and wherein R is substituted with one, two, or three substituents selected from a heteroaryl group optionally substituted with 1e is, for example, -C such as a methyl group. 1-6 It is an alkyl group.

[0091] In some embodiments, R 1 Ha-NR 1a R 1b where R 1a is hydrogen and R 1b is a straight or branched chain -C 1-8 In some embodiments, R 1 Ha-NR 1a R 1b where R 1a is hydrogen and R 1b is a branched alkyl group, preferably -C 4-8 Alkyl groups in which the branched chain substituent is alpha to the oxygen atom, including, but not limited to, but-2-yl, pent-2-yl, pent-3-yl, hept-2-yl, hept-3-yl, hept-4-yl, oct-2-yl, oct-3-yl, oct-4-yl, or oct-5-yl.

[0092] In some embodiments, R 1 is a butylamino group, an N-butyl-N-methylamino group, or an isopentylamino group.

[0093] In some embodiments, R 1 is optionally partially or fully deuterated, i.e., R 1 In the definition of , one or more hydrogens attached to the carbons are replaced with one or more deuteriums.

[0094] R 5 Definition of In some embodiments, R 5 is a halogen, oxo, hydroxyl group, C 1-8 Alkyl groups, halogenated C 1-8 Alkyl group, C 1-8 Alkoxy group, halogenated C 1-8 Alkoxy group, or -C(=O)OR 5a where R 5a is hydrogen, C 1-8 Alkyl group or halogenated C 1-8 is an alkyl group, and p is a number 0, 1, or 2.

[0095] In some embodiments, R 5 is halogen, oxo, C 1-3 Alkyl groups, halogenated C 1-3 Alkyl group, C 1-3 Alkoxy group or halogenated C 1-8 In some embodiments, R 5 is a methyl group, an ethyl group, a propyl group, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a trifluoromethoxy group, or a trifluoromethyl group. 5 is a methyl group.

[0096] In some embodiments, p is the number one.

[0097] In some embodiments, R5 and Het-R 6c is in the ortho position on ring A.

[0098] Definition of Ring A In some embodiments, ring A is a heterocyclic group.

[0099] In some embodiments, ring A is a 4-, 5-, 6-, 7-, 8-, or 9-membered monocyclic heterocyclic group containing one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members, preferably a 5- to 6-membered heteroaryl group containing one or two nitrogen atoms as ring members, more preferably a 5- to 6-membered heteroaryl group containing one nitrogen atom as a ring member. In some embodiments, ring A is an azetidinyl group (e.g., azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, azetidin-4-yl), a pyrrolidinyl group (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), a piperidinyl group (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl), or an azepanyl group (e.g., azepan-1-yl, azepan-2-yl, azacycloheptan-3-yl, azacycloheptan-4-yl), preferably a piperidinyl group (e.g., piperidin-1-yl, piperidin-4-yl). In some embodiments, ring A is a piperazinyl group (e.g., piperazin-1-yl or piperazin-2-yl).

[0100] In some embodiments, the heterocyclic ring may contain one or more double bonds (C=C or C=N) but is not aromatic. However, the heterocyclic ring is preferably saturated.

[0101] In some embodiments, ring A is a spiroheterocyclic group or a bridged heterocyclic group, e.g., 5 to 20 membered, preferably 6 to 14 membered, more preferably 7 to 12 membered. In some embodiments, the heterocyclic group is 7-azaspiro[3.5]nosyl, 3-azaspiro[3.1.0]hexyl, 2-azaspiro[3.3]heptyl, 7-azaspiro[3.5]nosyl, 2-azaspiro[3.5]nosyl, 2-azabicyclo[2.2.1]heptyl, 8-azabicyclo[3.2.1]octyl, or 2-azabicyclo[4.1.0]heptyl. More particularly, the spiroheterocyclic group is 7-azaspiro[3.5]non-2-yl, 3-azabicyclo[3.1.0]hex-6-yl, 2-azaspiro[3.3]hept-6-yl, 7-azaspiro[3.5]non-2-yl, 2-azaspiro[3.5]non-7-yl, 2-azabicyclo[2.2.1]hept-5-yl, 8-azabicyclo[3.2.1]oct-3-yl or 2-azabicyclo[4.1.0]hept-5-yl.

[0102] In some embodiments, Ring A is a cycloalkyl ring, e.g., a spirocycloalkyl group, a fused cycloalkyl group, or a bridged cycloalkyl group, selected from a 3- to 8-membered monocyclic cycloalkyl group or a 6- to 12-membered bicyclic cycloalkyl group, e.g., a bicyclo[1.1.1]pentyl group (e.g., bicyclo[1.1.1]pentyl-1-yl). In some embodiments, Ring A is a cycloalkenyl group or a cycloalkynyl group.

[0103] Definition of Het In some embodiments, Het is a monocyclic heterocyclic group. In some embodiments, Het is a fused bicyclic heterocyclic group. In some embodiments, Het is a spiro bicyclic heterocyclic group.

[0104] In some embodiments, Het is a saturated heterocyclic group. In some embodiments, Het is a 4-, 5-, 6-, 7-, or 8-membered saturated monocyclic heterocyclic ring containing one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members. In some embodiments, Het is a 5-, 6-, 7-, or 8-membered saturated monocyclic heterocyclic ring containing one, two, or three nitrogen heteroatoms as ring members. In some embodiments, Het is a 5- or 6-membered saturated monocyclic heterocyclic ring containing one or two nitrogen heteroatoms as ring members. In some embodiments, Het is a pyrrolidinyl group (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), a piperidinyl group (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl), a triazolyl group (e.g., 1H-1,2,4-triazol-1-yl), an azepanyl group (e.g., 1H-1,2,4-triazol-1-yl), an aryl ... For example, azepan-2-yl, azepan-3-yl, azepan-4-yl, azepan-5-yl), a diazepinyl group (e.g., 1,4-diazepin-1-yl, 1,4-diazepin-2-yl, 1,4-diazepin-3-yl, 1,4-diazepin-4-yl), a piperazinyl group (e.g., piperazin-1-yl, piperazin-2-yl, piperazin-3-yl) or a morpholino group.

[0105] In some embodiments, Het is a bicyclic heterocyclic ring containing one, two, or three heteroatoms selected from oxygen, nitrogen, or optionally oxidized sulfur as ring members. In some instances, Het is 2,5-diazabicyclo[2.2.1]hept-2-yl.

[0106] In some embodiments, Het is a 6- to 14-membered, more preferably 7- to 10-membered spiro bicyclic heterocyclic group. In some embodiments, the heterocyclic group is a spiroheptyl group, a spirodecyl group, or a spironosyl group containing one or two nitrogen atoms as ring members. In some embodiments, the heterocyclic group is 8-azaspiro[4.5]dec-8-yl, 2,7-diazaspiro[3.5]non-7-yl, 2,8-diazaspiro[4.5]dec-2-yl, 2,7-diazaspiro[3.5]non-2-yl, or 2,8-diazaspiro[4.5]dec-8-yl.

[0107] R 6c Definition of In some embodiments, Het is optionally one or two or three substituents R 6c In some embodiments, Het is optionally substituted with one R 6c is replaced by .

[0108] In some embodiments, R 6c are independently hydrogen, halogen, -OR 6d , -SR 6d , -NR 6d R 6e , -COR 6d , -SO2R 6d , -C(=O)NR 6d R 6e or -C 1-8 is an alkyl group, 1-8 The alkyl group may independently and optionally be one or two or three substituents R 6g is replaced by .

[0109] R 6d and R 6e are independently hydrogen, -C 1-8 Alkyl group, -C 2-8 is an alkenyl group, a heterocyclic group, or an aryl group, and 1-8 Alkyl group, -C 2-8 The alkenyl, heterocyclic or aryl group may each optionally contain one, two or three substituents R 6g is replaced by .

[0110] R 6g If present, they are independently hydrogen, halogen, -OR 6h , -SR 6h , -NR 6h R 6i , -N(R 6h )C(=O)OR 6i , -C 1-8 is an alkyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and R 6h and R 6i are independently hydrogen or -C 1-8 It is an alkyl group.

[0111] In some embodiments, R 6c HA-COR 6d where R 6d is one or two substituents R 6g -C optionally substituted with 1-8 is an alkyl group, where R 6g Ha-NR 6h R 6i , -N(R 6h )C(=O)R 6i , -C 1-8 an alkyl group, an aryl group, or a heteroaryl group, where R 6h and R 6i is defined as in formula (II). 6c HA-COR 6d where R 6d is one or two substituents R 6g -C optionally substituted with 1-8 Alkyl group (preferably C 1-6 alkyl group, more preferably C 1-4 alkyl), where R 6g Ha-NR 6h R 6i , -N(R 6h )C(=O)R 6i , -C 1-8 an alkyl group, an aryl group, or a heteroaryl group, where R 6h and R 6i are each independently hydrogen or -C1-8 Alkyl group (preferably C 1-6 alkyl group, more preferably C 1-4 alkyl).

[0112] In some embodiments, R 6c HA-COR 6d where R 6d Ha-C 2-8 It is an alkenyl group.

[0113] In some embodiments, R 6c HA-COR 6d where R 6d is a heterocyclic group.

[0114] In some embodiments, R 6c is an acetyl group, a 2-(dimethylamino)acetyl group, a 2-(dimethylamino)acetyl group, an aminoacetyl group, a 2-(methylamino)acetyl group, a 3-(dimethylamino)propionyl group, a 4-(dimethylamino)butyryl group, a 5-(dimethylamino)pentanoyl group, a (2S,3S)-2-amino-3-methylpentanoyl group, a 2-(methylamino)acetyl group, a 2-amino-4-methylpentanoyl group, a 2-amino-3-methylbutyryl group, a 2-(dimethylamino)acetyl group, a phenylpropionyl group, a 2-(piperazin-1-yl)acetyl group, an acryloyl group, a piperazine-2-carbonyl group, a piperidine-4-carbonyl group, a pyrrolidine-2-carbonyl group, or a 2-(N-methylacetylamino)acetyl group.

[0115] In some embodiments, R 6c Ha-C 1-8 an alkoxy group, preferably -C 1-6 Alkoxy groups, for example methoxy groups.

[0116] In some embodiments, R 6c Ha-C 1-8 is an alkyl group, preferably -C 1-6 is an alkyl group, which may contain one or two substituents R 6gwhere R 6g HA-OR 6h , -NR 6h R 6i , heterocyclic group, aryl group, where R 6h and R 6i is defined as in formula (II). In some aspects, R 6c Ha-C 1-8 is an alkyl group, preferably -C 1-6 is an alkyl group, which optionally has one substituent R 6g where R 6g HA-OR 6h , -NR 6h R 6i , a heterocyclic group (e.g., a morpholino group), an aryl group (e.g., a phenyl group), where R 6h and R 6i Ha-C 1-4 is an alkyl group, preferably a methyl group. In some embodiments, R 6c is a methyl group, an ethyl group, an isobutyl group, a methoxymethyl group, a 2-methoxyethyl group, a (methylamino)methyl group, a 2-(dimethylamino)ethyl group, a (dimethylamino)methyl group, a 2-aminoethyl group, a 2-(methylamino)ethyl group, a 2-(dimethylamino)ethyl group, a morpholinomethyl group, or a phenethyl group.

[0117] In some embodiments, R 6c is a heterocyclic group, optionally containing one substituent R 6g In some embodiments, R 6c is a heterocyclic group, optionally containing one heterocyclic group substituent R 6g In some embodiments, R 6c is 4-morpholinopiperidin-1-yl.

[0118] In some embodiments, R 6c is -C(=O)NR 6d R 6e where R 6d and R 6e are independently hydrogen, -C1-8 Alkyl group (preferably -C 1-3 alkyl) or aryl group, 1-8 The alkyl or aryl groups may independently and optionally be halogen or -C 1-4 In some embodiments, R 6c is -C(=O)NR 6d R 6e where R 6d and R 6e are independently hydrogen and -C 1-4 In some embodiments, R 6c is -C(=O)NR 6d R 6e where R 6d and R 6e are independently hydrogen and an aryl group optionally substituted with halogen. In some embodiments, R 6c is a dimethylcarbamoyl group, an isopropylcarbamoyl group, or a 2,4,5-trifluorophenylcarbamoyl group.

[0119] In some embodiments, R 6c Ha-NR 6d R 6e where R 6d and R 6e are independently hydrogen or -C 1-8 Alkyl group (preferably -C 1-6 alkyl group, more preferably -C 1-3 In some embodiments, R 6c is a dimethylamino group or an amino group.

[0120] In some embodiments, R 6c Ha-SO2R 6d where R 6d Ha-C 1-8 Alkyl group, -C 2-8 Alkenyl group, -C 2-8In some embodiments, R is an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group. 6c Ha-SO2R 6d where R 6d Ha-C 1-8 Alkyl group (preferably -C 1-6 In some embodiments, R 6c is a propylsulfonyl group.

[0121] In some embodiments, Het is a pyrrolidinyl group, optionally substituted with one, two, or three substituents selected from a methyl group, a (dimethylamino)methyl group, or a dimethylamino group. In some embodiments, Het is 1-methylpyrrolidin-3-yl, pyrrolidin-1-yl, 3-((dimethylamino)methyl)pyrrolidin-1-yl, or 3-(dimethylamino)pyrrolidin-1-yl.

[0122] In some embodiments, Het is a piperazinyl group, and optionally, an acryloyl group, a 2-(dimethylamino)acetyl group, an aminoacetyl group, a 2-(methylamino)acetyl group, a 3-(dimethylamino)propionyl group, a 2-(piperazin-1-yl)acetyl group, a piperazine-2-carbonyl group, a 4-(dimethylamino)butyryl group, a 5-(dimethylamino)pentanoyl group, a methyl group, a piperidine-4-carbonyl group, an acetyl group, a 2-(N-methylacetylamino)acetyl group, an isopropylcarbamoyl group, a 2,4,5-trifluoromethyl group, a 2-(N-methylacetylamino)acetyl ... and each of the 2-amino-4-methylpentanoyl, 2-amino-3-methylbutyryl, 2-(dimethylamino)acetyl, 2-(methylamino)ethyl, 2-(dimethylamino)ethyl, amino, phenylpropionyl, propylsulfonyl, and 2-aminoethyl is substituted by one, two, or three substituents selected from the group consisting of 2-amino-4-methylpentanoyl, 2-amino-3-methylbutyryl, 2-(dimethylamino)acetyl, 2-(methylamino)ethyl, 2-(dimethylamino)ethyl, amino, phenylpropionyl, propylsulfonyl, and 2-aminoethyl.In some embodiments, Het is piperazin-1-yl, 4-acryloylpiperazin-1-yl, 4-(2-(dimethylamino)acetyl)piperazin-1-yl, (4-aminoacetyl)piperazin-1-yl, piperazin-1-yl, 4-(2-(methylamino)acetylpiperazin-1-yl), 4-(3-(dimethylamino)propionyl)piperazin-1-yl, 4-(2-(piperazin-1-yl)acetyl)piperazin-1-yl, 4-(piperazine-2-carbonyl)piperazin-1-yl, 4- Acryloylpiperazin-1-yl, 4-(4-(dimethylamino)butyryl)piperazin-1-yl, 4-(5-(dimethylamino)pentanoyl)piperazin-1-yl, 3,5-dimethylpiperazin-1-yl, 4-(piperidine-4-carbonyl)piperazin-1-yl, 4-acetylpiperazin-1-yl, 4-(2-(N-methylacetylamino)acetyl)piperazin-1-yl, 4-(isopropylcarbamoyl)piperazin-1-yl, 4-(2,4,5-trifluorophenylcarbamoyl)piperazine -1-yl, 4-(3,5-dimethylpiperazin-1-yl, 4-((2S,3S)-2-amino-3-methylpentanoyl)piperazin-1-yl, 4-(2-methoxyethyl)piperazin-1-yl, 4-(2-(methylamino)acetyl)piperazin-1-yl, 4-ethylpiperazin-1-yl, 4-isobutylpiperazin-1-yl, 4-(pyrrolidine-2-carbonyl)piperazin-1-yl, 4-(2-amino-4-methylpentanoyl)piperazin-1-yl, 4-(2-amino-3-methylbutyryl)piperazin-1-yl 4-(2-(dimethylamino)ethyl)piperazin-1-yl, 4-(2-amino-3-phenylpropionyl)piperazin-1-yl, 4-(propylsulfonyl)piperazin-1-yl, 4-(2-aminoethyl)piperazin-1-yl, or 3-methylpiperazin-1-yl.

[0123] In some embodiments, Het is a piperidinyl group, optionally substituted with one, two, or three substituents selected from a 2-(dimethylamino)acetyl group, a methoxy group, a methoxymethyl group, a (methylamino)methyl group, a 4-morpholinopiperidin-1-yl, a morpholinomethyl group, a 2-(dimethylamino)ethyl group, a phenethyl group, a (dimethylamino)methyl group, an amino group, a dimethylamino group, or a dimethylcarbamoyl group. In some embodiments, Het is piperidin-4-yl, 4-(2-(dimethylamino)acetyl)piperidin-1-yl, piperidin-3-yl, piperidin-4-yl, piperidin-1-yl, piperidin-4-yl, 4-methoxypiperidin-1-yl, 4-(methoxymethyl)piperidin-1-yl, 4-((methylamino)methyl)piperidin-1-yl, (4-morpholinopiperidin-1-yl)pyridin-3-yl, 4-(morpholinomethyl)piperidin-1-yl, 4-(2-(dimethylamino)ethyl)piperidin-1-yl, 1-phenethylpiperidin-4-yl, 4-((dimethylamino)methyl)piperidin-1-yl, 4-aminopiperidin-1-yl, 4-(dimethylamino)piperidin-1-yl, or 4-(dimethylcarbamoyl)piperidin-1-yl.

[0124] In some embodiments, Het is azepan-1-yl or 1,4-diazepan-1-yl.

[0125] In some embodiments, Het is octahydro-2H-isoindol-2-yl.

[0126] In some embodiments, Het is a morpholino group.

[0127] In some embodiments, Het is 8-azaspiro[4.5]dec-8-yl, 2,7-diazaspiro[3.5]non-7-yl, 2,8-diazaspiro[4.5]dec-2-yl, 2,7-diazaspiro[3.5]non-2-yl, 2,8-diazaspiro[4.5]dec-8-yl, (1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl.

[0128] In some embodiments, ring A is a piperidinyl group, preferably piperidin-1-yl or piperidin-4-yl.

[0129] In some embodiments, the present invention provides a compound of formula (IIIA) or (IIIB): [ka] or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

[0130] where the variable R a , R b , L 2 , R 5 , R 6 and p is as defined above.

[0131] In some embodiments, the present invention discloses a compound selected from the specific compounds exemplified herein, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. [ka] [ka] [ka] [ka] [ka]

[0132] In a third embodiment, the present invention discloses a pharmaceutical composition comprising a compound disclosed herein, the pharmaceutical composition comprising a compound of formula (I) or (II) or a specific compound exemplified herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

[0133] In a fourth embodiment, the present invention discloses a method of modulating TLR8 comprising administering to an individual a compound of formula (I) or (II) or any compound disclosed herein, including the specific compounds exemplified herein, or a pharmaceutically acceptable salt thereof.

[0134] In a fifth embodiment, this invention discloses a method for treating a disease or condition in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or (II) or a compound disclosed herein, including specific compounds exemplified herein, or a pharmaceutically acceptable salt thereof, as a TLR8 agonist. In some embodiments, the disease or condition is associated with modulation of a TLR, e.g., TLR-8 (e.g., agonizing TLR-8). In some embodiments, the disease or condition includes a viral infection caused by a virus, wherein the virus is selected from dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus, and hepatitis C. In some embodiments, the disease or condition includes melanoma, non-small cell lung cancer, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, liver fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza. Preferably, the disease or condition is cancer. DETAILED DESCRIPTION OF THE INVENTION

[0135] The following terms have the meanings given in the manual throughout the specification.

[0136] As used in this specification (including the appended claims), singular words such as "one," "a kind," and "the" include the corresponding plural indicator unless the context clearly indicates otherwise.

[0137] Unless the context clearly indicates otherwise, the term "or" is used to mean and is used interchangeably with the term "and / or."

[0138] The term "alkyl group" herein refers to a hydrocarbon group selected from a straight-chain saturated hydrocarbon group and a branched-chain saturated hydrocarbon group, which contains 1 to 18 (e.g., 1 to 12, or even 1 to 10, or even 1 to 8 or 1 to 6 or 1 to 4) carbon atoms. Examples of alkyl groups containing 1 to 6 carbon atoms (i.e., C alkyl groups) include methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), 1,1-dimethylethyl or t-butyl ("t-Bu"), 1-pentyl ... groups, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.

[0139] The term "alkoxy group" or "alkyloxy group" refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom.

[0140] The term "amino group" refers to -NH2. The term "alkylamino group" refers to -NH(alkyl group). The term "dialkylamino group" refers to -N(alkyl group). As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

[0141] The term "haloalkyl group," as used herein, refers to an alkyl group in which one or more hydrogens have been replaced with one or more halogen atoms (e.g., fluorine, chlorine, bromine, and iodine). Examples of haloalkyl groups include halogenated C 1-8 Alkyl groups, halogenated C 1-6 Alkyl or halogenated C 1-4 Alkyl groups include, but are not limited to, -CF3, -CH2Cl, -CH2CF3, -CCl2, CF3, and the like.

[0142] The term "alkenyl group," as used herein, refers to a hydrocarbon group selected from straight-chain and branched-chain hydrocarbon groups, which contains at least one C=C double bond and 2 to 18 (e.g., 2 to 8, or even 2 to 6) carbon atoms. Examples of alkenyl groups, such as C2-6 alkenyl groups, include, but are not limited to, ethylene (ethenyl or vinyl), prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, but-1,3-dienyl, 2-methylbut-1,3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hex-1,3-dienyl groups.

[0143] The term "alkynyl group," as used herein, refers to a hydrocarbon group selected from straight-chain and branched-chain hydrocarbon groups, which contains at least one C≡C triple bond and 2 to 18 (e.g., 2 to 8, or even 2 to 6) carbon atoms. Examples of alkynyl groups, e.g., C2-6 alkynyl groups, include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups.

[0144] The term "alkyloxy group" or "alkoxy group," as used herein, refers to an alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. Examples of alkoxy groups, such as C1-6 alkoxy groups or C1-4 alkoxy groups, include, but are not limited to, methoxy, ethoxy, isopropoxy, propoxy, n-butoxy, t-butoxy, pentoxy, and hexoxy.

[0145] The term "alkoxy-alkyl-" refers to an alkyl group as defined above substituted with an alkoxy group as defined above. Examples of alkoxy-alkyl-, such as C alkoxy-C alkyl- or C alkoxy-C alkyl-, include, but are not limited to, methoxymethyl, ethoxymethyl, ethoxyethyl, isopropoxymethyl, or propoxymethyl.

[0146] The term "cycloalkyl group" refers to a hydrocarbon group selected from saturated cyclic hydrocarbon groups, including monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups, including fused, bridged, or spirocycloalkyls.

[0147] For example, the cycloalkyl group can contain 3 to 12 (e.g., 3 to 10, further 3 to 8, further 3 to 6, 3 to 5, or 3 to 4) carbon atoms. Further, for example, the cycloalkyl group can be selected from monocyclic groups containing 3 to 12 (e.g., 3 to 10, further 3 to 8, 3 to 6) carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. In particular, examples of saturated monocyclic cycloalkyl groups include, for example, C 3-8 Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In preferred embodiments, cycloalkyl groups are monocyclic rings containing 3 to 6 carbon atoms (abbreviated as C 3-6

[0023] Bicyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of bicyclic cycloalkyl groups include those having 7 to 12 ring atoms arranged in a fused bicyclic ring selected from a [4,4], [4,5], [5,5], [5,6], or [6,6] ring system, or arranged in a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. Other examples of bicyclic cycloalkyl groups include those arranged as a bicyclo selected from a [5,6] and [6,6] ring system.

[0148] The term "spirocycloalkyl group" includes cyclic structures containing carbon atoms and formed by at least two rings that share one atom. The term "7- to 12-membered spirocycloalkyl group" includes cyclic structures containing 7 to 12 carbon atoms and formed by at least two rings that share one atom.

[0149] The term "fused cycloalkyl group" includes bicyclic cycloalkyl groups, as defined herein, that are saturated and are formed by two or more rings that share two adjacent atoms.

[0150] The term "bridged cycloalkyl group" includes a cyclic structure containing carbon atoms and formed by two rings that share two non-adjacent atoms. The term "7- to 10-membered bridged cycloalkyl group" includes a cyclic structure containing 7 to 12 carbon atoms and formed by two rings that share two non-adjacent atoms.

[0151] The term "cycloalkenyl group" refers to a non-aromatic cyclic alkyl group having from 3 to 10 carbon atoms, having single or multiple rings and at least one double bond, preferably one to two double bonds. In one embodiment, a cycloalkenyl group is cyclopentenyl or cyclohexenyl, preferably cyclohexenyl.

[0152] The term "cycloalkynyl group" refers to a non-aromatic cyclic alkyl group having from 5 to 10 carbon atoms with single or multiple rings and at least one triple bond.

[0153] The term "deuterated" is used herein to modify a chemical structure or organic group in which one or more carbon-bonded hydrogen atoms have been replaced with one or more deuterium atoms, such as "deuterated-alkyl group," "deuterated-cycloalkyl group," "deuterated-heterocycloalkyl group," "deuterated-aryl group," "deuterated-morpholinyl," and the like. For example, the term "deuterated-alkyl group," as defined above, refers to an alkyl group, as defined herein, in which at least one carbon-bonded hydrogen atom has been replaced with deuterium. In a deuterated alkyl group, at least one carbon atom is bonded to deuterium, and a carbon atom may be bonded to one or more deuterium atoms, and one or more carbon atoms in an alkyl group may be bonded to deuterium.

[0154] The term "aryl group", used alone or in combination with other terms, refers to a group selected from: 5- and 6-membered carbocyclic aromatic rings, such as phenyl; Bicyclic ring systems, such as 7- to 12-membered bicyclic ring systems, in which at least one ring is carbocyclic and aromatic, such as naphthyl and indanyl groups; and Tricyclic systems, such as 10 to 15 membered tricyclic systems, in which at least one ring is carbocyclic and aromatic, such as fluorenyl.

[0155] The terms "aromatic hydrocarbon ring" and "aryl group" are used interchangeably in this disclosure. In some embodiments, the monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C 5-10 aryl group). Examples of monocyclic or bicyclic aromatic hydrocarbon rings include, but are not limited to, phenyl, naphth-1-yl, naphth-2-yl, anthracene, phenanthrenyl, and the like. In some embodiments, the aromatic hydrocarbon ring is a naphthalene ring (naphth-1-yl or naphth-2-yl) or a benzene ring. In some embodiments, the aromatic hydrocarbon ring is a benzene ring.

[0156] As used herein, the term "heteroaryl group" refers to a group selected from: The 5-, 6-, or 7-membered aromatic monocyclic ring contains at least one heteroatom, such as from 1 to 4 heteroatoms, or in some embodiments, from 1 to 3 heteroatoms, and in some embodiments, from 1 to 2 heteroatoms, selected from nitrogen (N), sulfur (S), and oxygen (O), with the remaining ring atoms being carbon.

[0157] The 7- to 12-membered bicycle contains at least one heteroatom, such as 1 to 4 heteroatoms, or in some embodiments 1 to 3 heteroatoms, or in other embodiments 1 or 2 heteroatoms, selected from nitrogen, oxygen, or optionally oxidized sulfur (as one or more ring members), with the remaining ring atoms being carbon, and at least one ring therein being aromatic, with at least one heteroatom being in the aromatic ring; The 11- to 14-membered tricyclic ring contains at least one heteroatom, e.g., 1 to 4 heteroatoms, or in some embodiments 1 to 3 heteroatoms, or in other embodiments 1 or 2 heteroatoms, selected from nitrogen, oxygen, or optionally oxidized sulfur (as one or more ring members), with the remaining ring atoms being carbon, and at least one ring therein being aromatic, with at least one heteroatom being in the aromatic ring.

[0158] When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is 2 or less. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is 1 or less. When a heteroaryl group contains multiple heteroatom ring members, the heteroatoms can be the same or different. Nitrogen atoms in one or more rings of a heteroaryl group can be oxidized to form an N-oxide.

[0159] As used herein, the term "optionally oxidized sulfur" refers to S, SO, or SO.

[0160] The terms "heteroaromatic ring" and "heteroaryl group" are used interchangeably in the present disclosure. In some embodiments, a monocyclic or bicyclic heteroaromatic ring has 5, 6, 7, 8, 9, or 10 ring members, of which 1, 2, 3, or 4 heteroatom ring members are independently selected from nitrogen (N), sulfur (S), and oxygen (O), and the remaining ring members are carbon. In some embodiments, a monocyclic or bicyclic heteroaromatic ring is monocyclic or bicyclic, containing one or two heteroatom ring members independently selected from nitrogen (N), sulfur (S), and oxygen (O). In some embodiments, a monocyclic or bicyclic heteroaromatic ring is a 5- to 6-membered heteroaryl ring, which is monocyclic and has one or two heteroatom ring members independently selected from nitrogen (N), sulfur (S), and oxygen (O). In some embodiments, the monocyclic or bicyclic heteroaromatic ring is an 8- to 10-membered heteroaryl ring that is bicyclic and has 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur, and oxygen.

[0161] Examples of heteroaryl groups or monocyclic or bicyclic aromatic heterocycles include (numbering starts from the attachment position designated as priority 1) pyridyl groups (e.g., 2-pyridyl groups, 3-pyridyl groups, or 4-pyridine groups), cinnolinyl groups, pyrazinyl groups, 2,4-pyrimidinyl groups, 3,5-pyrimidinyl groups, 2,4-imidazolyl groups, imidazopyridyl groups, isoxazolyl groups, xazolyl groups, thiazolyl groups, isothiazolyl groups, thiadiazolyl groups (e.g., 1,2,3-thiadiazolyl groups, 1,2,4-thiadiazolyl groups, or 1,3,4-thiadiazolyl groups), Tetrazolyl group, thienyl group (e.g., thiophen-2-yl, thiophen-3-yl), triazinyl group, benzothienyl group, furanyl group (furyl or furanyl), benzofuranyl group, benzimidazolyl group, indolyl group, isoindolyl group, indolinyl group, oxadiazolyl group (e.g., 1,2,3-oxadiazolyl group, 1,2,4-oxadiazolyl group, or 1,3,4-oxadiazolyl group), phthalazinyl group, pyrazinyl group, pyridazinyl group, pyrrolyl group, triazolyl group (e.g., 1,2,3-triazolyl group, 1,2,4-triazolyl group), azolyl or 1,3,4-triazolyl group), quinolinyl group, isoquinolinyl group, pyrazolyl group, pyrrolopyridyl group (e.g., 1H-pyrrolo[2,3-b]pyridin-5-yl), pyrazolopyridyl group (e.g., 1H-pyrazolo[3,4-b]pyridin-5-yl), benzoxazolyl group (e.g., benzo[d]oxazol-6-yl), pteridyl group, purinyl group, 1-oxa-2,3-diazolyl group, 1-oxa-2,4-diazolyl group, 1-oxa-2,5-diazolyl group, 1-oxa-3,4-diazolyl group, 1-thia-2,3-diazolyl group, These include, but are not limited to, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, furazan (e.g., furazan-2-yl, furazan-3-yl), benzofurazan, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridyl, benzothiazolyl (e.g., benzo[d]thiazol-6-yl), indazole (e.g., 1H-indazol-5-yl), and 5,6,7,8-tetrahydroisoquinoline.

[0162] The terms "heterocyclic group," "heterocycle," or "heterocyclic" are interchangeable and refer to a non-aromatic heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen, or optionally oxidized sulfur as ring members (the remaining ring members are carbon), and include monocyclic, fused, bridged, and spiro rings, i.e., monocyclic heterocyclic groups, bridged heterocyclic groups, spiro heterocyclic groups, and fused heterocyclic groups.

[0163] The term "monocyclic heterocyclic group" refers to a monocyclic group in which at least one ring member is a heteroatom selected from nitrogen, oxygen, or optionally oxidized sulfur. The heterocyclic ring may be saturated or partially saturated.

[0164] Exemplary monocyclic 4- to 9-membered heterocyclic groups are (numbering starting from the attachment position designated as priority 1) pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrazolidin-2-yl, pyrazolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 2,5-piperazinyl group, pyranyl group, morpholinyl group, morpholino group, morpholin-2-yl, morpholin-3-yl, oxiranyl group, methyl ... aryl group, aziridin-1-yl, aziridin-2-yl, azacyclooctan-1-yl, azacyclooctan-2-yl, azacyclooctan-3-yl, azacyclooctan-4-yl, azacyclooctan-5-yl, thiiranyl group, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, oxatanyl group, thiacyclobutyl group, 1,2-dithiacyclobutyl group, 1,3-dithiacyclobutyl group, dihydropyridyl group, tetrahydropyridyl group, thiomorpholinyl group, thioxanyl group nyl), piperazinyl, homopiperazinyl, homopiperidinyl, azepan-1-yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, oxepanyl, thiepanyl, 1,4-oxathianyl, 1,4-dioxepanyl, 1,4-oxathiepanyl, 1,4-oxazepanyl, 1,4-dithiepanyl, 1,4-thiazepanyl and 1,4-diazepanyl, 1,4-dithianyl, 1, 4-Azathianyl, oxazepinyl, diazepinyl, thiazepinyl, dihydrothienyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, 1,4-dioxanyl, 1,Examples of the alkyl group include, but are not limited to, 3-dioxolane, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrazolidinyl, imidazolinyl, pyrimidinone, or 1,1-dioxo-thiomorpholinyl.

[0165] The term "spiroheterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group, whose rings are connected by shared carbon atoms (called spiroatoms) and contain one or more heteroatoms selected from nitrogen, oxygen, or optionally oxidized sulfur as ring members, with the remaining ring members being carbon. One or more rings of a spiroheterocyclic group may contain one or more double bonds, but none of the rings have a completely conjugated π-electron system. Preferably, spiroheterocyclic groups have 6 to 14 members, more preferably 7 to 12 members. Depending on the number of shared spiro atoms, spiroheterocyclic groups are divided into monospiroheterocyclic groups, dispiroheterocyclic groups, and polyspiroheterocyclic groups, preferably monospiroheterocyclic groups or dispiroheterocyclic groups, more preferably 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospiroheterocyclic groups. For example, spiroheterocyclic groups are 7-azaspiro[3.5]nosyl, 2-azaspiro[3.3]heptyl, 7-azaspiro[3.5]nosyl, or 2-azaspiro[3.5]nosyl. More particularly, the spiroheterocyclic group is 7-azaspiro[3.5]non-2-yl, 2-azaspiro[3.3]hept-6-yl, 7-azaspiro[3.5]non-2-yl or 2-azaspiro[3.5]non-7-yl.

[0166] The term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent atom pair (carbon-carbon or carbon-nitrogen) with another ring, and contains one or more heteroatoms selected from nitrogen, oxygen, or optionally oxidized sulfur as ring members, with the remaining ring members being carbon. One or more rings in the fused heterocyclic group may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. Preferably, the fused heterocyclic group has 6 to 14 members, more preferably 7 to 10 members. Depending on the number of membered rings, the fused heterocyclic group can be divided into bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic fused heterocyclic groups, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic groups. Representative examples of fused heterocycles include, but are not limited to, octahydrocyclopenta[c]pyrrole (e.g., octahydrocyclopenta[c]pyrrol-2-yl), octahydropyrrolo[3,4-c]pyrrolyl, octahydroisoindolyl, isoindolinyl (e.g., isoindolin-2-yl), and octahydro-benz[b][1,4]dioxin.

[0167] The term "bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocycloalkyl group, in which every two rings in the system share two non-bonding atoms and contain one or more heteroatoms selected from nitrogen, oxygen, or optionally oxidized sulfur as ring members, with the remaining ring members being carbon. One or more rings in the bridged heterocyclic group may contain one or more double bonds, but none of these rings has a completely conjugated π-electron system. Preferably, the bridged heterocyclic group has 6 to 14 members, more preferably 7 to 10 members. Depending on the number of membered rings, bridged heterocyclic groups are divided into bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic, or tetracyclic bridged heterocyclic groups, more preferably bicyclic or tricyclic bridged heterocyclic groups. Representative examples of bridged heterocyclic groups include, but are not limited to, 2-azabicyclo[2.2.1]heptyl, azabicyclo[3.1.0]hexyl, 2-azabicyclo[2.2.2]octyl and 2-azabicyclo[3.3.2]decyl, 3-azabicyclo[3.1.0]hexyl, 2-azabicyclo[2.2.1]heptyl, 8-azabicyclo[3.2.1]octyl or 2-azabicyclo[4.1.0]heptyl groups, such as 3-azabicyclo[3.1.0]hex-6-yl, 2-azabicyclo[2.2.1]hept-5-yl, 8-azabicyclo[3.2.1]oct-3-yl or 2-azabicyclo[4.1.0]hept-5-yl.

[0168] The compounds disclosed herein may contain asymmetric centers and therefore may exist as enantiomers. "Enantiomer" refers to two stereoisomers of a compound, which are non-superimposable mirror images of one another. When compounds disclosed herein have two or more asymmetric centers, they may exist as separate diastereomers. Enantiomers and diastereomers are within the broader category of stereoisomers. All possible stereoisomers are intended to be included, including substantially pure resolved enantiomers, their racemic mixtures, and mixtures of diastereomers. All stereoisomers of the compounds disclosed herein and / or their pharmaceutically acceptable salts are intended to be included. Unless otherwise specified, reference to an isomer applies to all possible isomers. Whenever an isomeric composition is not specified, all possible isomers are included.

[0169] As used herein, the term "substantially pure" means that the desired stereoisomer contains 35% or less by weight (e.g., 30% or less, even 25% or less, even 20% or less, etc.) of any other stereoisomer. In some embodiments, the term "substantially pure" means that the desired stereoisomer contains 10% or less by weight (e.g., 5% or less, even 1% or less) of any other stereoisomer.

[0170] When compounds disclosed herein contain ethylenic double bonds, unless otherwise specified, such double bond is intended to include both E and Z geometric isomers.

[0171] When the compounds disclosed herein contain a disubstituted cyclohexyl or cyclobutyl group, the substituents found on the cyclohexyl or cyclobutyl ring can be in cis and trans configurations, where cis configuration means that the two substituents are above the two substituent positions on the carbon, and trans configuration means that they are opposite.

[0172] It may be advantageous to separate reaction products from one another and / or from starting materials. By techniques commonly used in the art, the desired products of each step or series of steps are separated and / or purified (hereinafter, "separated") to the desired degree of homogeneity. Typically, such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography encompasses many methods, including, but not limited to: reversed-phase, normal-phase, size exclusion, ion exchange, high-, medium-, and low-pressure liquid chromatography methods and devices, small-scale analytical, simulated moving bed (SMB) and preparative thin- or thick-layer chromatography, as well as small-scale thin-layer and flash chromatography techniques. Those skilled in the art will apply the technique most likely to achieve the desired separation.

[0173] "Diastereomers" refer to stereoisomers of a compound containing two or more chiral centers, but which are not mirror images of one another. Diastereomeric mixtures can be separated into their individual diastereomers based on their physical chemical differences by methods well known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting each diastereomer into its corresponding pure enantiomer (e.g., by hydrolysis). Chiral HPLC columns can also be used to separate enantiomers.

[0174] Single stereoisomers (e.g., substantially pure enantiomers) can be obtained by resolving racemic mixtures using methods such as forming diastereomers with optically active resolving agents (Eliel, E. and Wilen, S. Stereochemistry of Organic Compounds. New York: John Wiley & Sons, Inc., 1994; Lochmuller, C.H. et al., "Chromatographic resolution of enantiomers: Selective review." J. Chromatogr., 113(3) (1975): pp. 283-302). Racemic mixtures of chiral compounds of the present invention can be separated and resolved by any suitable method, including (1) forming ionic diastereomeric salts with chiral compounds and separating them by fractional crystallization or other methods, (2) forming diastereomeric compounds with chiral derivatizing agents, separating the diastereomers, and converting them to pure stereoisomers, and (3) directly isolating substantially pure or enriched stereoisomers under chiral conditions. See Wainer, Irving W., Ed. Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993.

[0175] "Pharmaceutically acceptable salts" refers to salts as described below which, within the scope of sound medical judgment, are suitable for contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and possess a reasonable benefit / risk ratio. Pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds disclosed herein, or prepared separately by reacting a free base function with a suitable organic acid, or an acidic group with a suitable base.

[0176] And, when a compound disclosed herein is obtained as an acid addition salt, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, following conventional procedures for preparing acid addition salts from basic compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts without undue experimentation.

[0177] As defined herein, "a pharmaceutically acceptable salt thereof" includes salts of at least one compound of formula (I) and salts of stereoisomers of compounds of formula (I), such as enantiomeric and / or diastereomeric salts.

[0178] The terms "administration," "administering," "treating," and "treatment," when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, refer to the contact of an exogenous agent, therapeutic agent, diagnostic agent, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid. Treating a cell includes contacting a reagent with the cell and contacting a reagent with a fluid when the fluid is in contact with the cell. The terms "administration" and "treatment" also refer to in vitro and ex vivo treatment, e.g., of a cell, with a reagent, diagnostic agent, binding compound, or with another type of cell. As used herein, the term "subject" includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, rabbit), and most preferably a human.

[0179] The term "effective amount" or "therapeutically effective amount" refers to an amount of an active ingredient (e.g., a compound) that, when administered to a subject to treat a disease or at least one clinical symptom of a disease or condition, is sufficient to affect such treatment of the disease, condition, or condition. A "therapeutically effective amount" may vary depending on the compound, the disease, condition, and / or symptoms of the disease or condition, the severity of the disease, condition, and / or symptoms of the disease or condition, the age and / or weight of the subject being treated. In any limited example, an appropriate amount will be apparent to one of ordinary skill in the art or can be determined by routine experimentation. In some embodiments, a "therapeutically effective amount" is an amount of at least one compound disclosed herein and / or at least one stereoisomer thereof and / or at least one pharmaceutically acceptable salt thereof that is effective to "treat" (e.g., as defined above) a disease or condition in a subject. In the case of combination therapy, a "therapeutically effective amount" refers to the total amount of the combined compounds used to effectively treat a disease, condition, or condition.

[0180] Pharmaceutical compositions containing the compounds disclosed herein can be administered to subjects in need thereof via oral, inhalation, rectal, parenteral, or topical administration. For oral administration, the pharmaceutical composition can be a conventional solid formulation such as a tablet, powder, granule, or capsule, a liquid formulation such as a water or oil suspension, or other liquid formulations such as a syrup, solution, or suspension. For parenteral administration, the pharmaceutical composition can be a solution, an aqueous solution, an oil suspension concentrate, a lyophilized powder, or the like. Preferably, the pharmaceutical composition is selected from tablets, coated tablets, capsules, suppositories, nasal sprays, or injections, more preferably tablets or capsules. The pharmaceutical composition can be administered as a single unit at a precise dosage. In addition, the pharmaceutical composition can also contain additional active ingredients.

[0181] All formulations of the pharmaceutical compositions disclosed herein can be prepared by conventional methods in the pharmaceutical field. For example, the active ingredient can be mixed with one or more excipients to prepare the desired formulation. "Pharmaceutically acceptable excipients" refer to conventional pharmaceutical carriers appropriate for the required pharmaceutical formulation, such as diluents, vehicles (e.g., water, various organic solvents, etc.), fillers (e.g., starch, sucrose, etc.), binders (e.g., cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone (PVP)), humectants such as glycerin, disintegrating agents such as agar, calcium carbonate and sodium bicarbonate, absorption enhancers such as quaternary ammonium compounds, surfactants such as cetyl alcohol, absorption carriers such as kaolin and bentonite, and lubricants such as talc, calcium stearate, magnesium stearate, and polyethylene glycol. The pharmaceutical composition may also contain other pharmaceutically acceptable excipients, such as dispersants, stabilizers, thickeners, complexing agents, buffers, penetration enhancers, polymers, flavors, sweeteners, and dyes.

[0182] The term "disease" refers to any disease, ailment, illness, symptom or indication and is interchangeable with the terms "symptom" or "condition."

[0183] Throughout the specification and the claims that follow, unless the context dictates otherwise, the terms "comprises" and "comprising" are intended to describe the presence of the subsequent element but do not preclude the presence or addition of one or more other features. As used herein, the term "comprises" can be substituted for "contains," "including," or in some cases, "having."

[0184] Throughout the specification and claims that follow, the term "C" refers to an inclusive range, where n and m are integers and represent the number of carbons. Examples include C, C, etc.

[0185] Unless expressly defined elsewhere herein, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.

[0186] General Synthesis The compounds disclosed herein (including salts thereof) can be prepared using known organic synthesis techniques, or can be synthesized according to any of a number of possible synthetic routes.

[0187] The reaction for preparing the compounds disclosed herein can be carried out in a suitable solvent, and the solvent can be easily selected by those skilled in the art of organic synthesis.A suitable solvent can be substantially inert to the starting material, intermediate, or product at the temperature at which the reaction is carried out, and for example, the temperature can range from room temperature to the boiling temperature of the solvent.A given reaction can be carried out in one solvent or a mixture of solvents.

[0188] The selection of an appropriate protecting group can be readily determined by one of skill in the art.

[0189] Reactions can be monitored according to any suitable method known in the art, such as NMR, UV, HPLC, LC-MS, and TLC. Compounds can be purified by a variety of methods, such as HPLC or normal phase silica gel chromatography.

[0190] Chiral analytical HPLC is used to analyze the retention time of different chiral samples, and the conditions are divided into the following methods depending on the column, mobile phase, and solvent ratio used:

[0191] Scheme I [ka] where: R 1a , R 5 , L 2 and R 6is defined as in formula (I), m' is 0, 1, 2 or 3, and n' is 1, 2 or 3.

[0192] In Scheme I, commercially available 1H-imidazolyl-2-ethyl formate was reacted with 2-O-(4-nitrobenzoyl)hydroxylamine to form compound 2, which was then reacted with ethyl chloroformate followed by ring closure in the presence of ammonium hydroxide to give imidazo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione 4. After introducing one Br atom using a brominating reagent, compound 5 was obtained, and the diketone was then chlorinated to form compound 6. One chlorine atom was replaced with a protected amine, and the other chlorine atom was replaced with R 1 The reaction with ONa gave key intermediate 8, which was then reacted with different aldehydes under alkaline conditions to give formula 9A. Removal of the amine protecting group and hydroxyl group gave formula 10A. After coupling with different aldehydes under alkaline conditions with different acids or reducing agents, compounds of formula IA were obtained.

[0193] Scheme II [ka] where R 1a , R 5 is defined as in formula (I), m' is 0, 1, 2 or 3, and n' is 1, 2 or 3.

[0194] In Scheme II, this method can also be used to prepare compound 9A. Imidazo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione 4 was chlorinated to form compound 11. One chlorine atom was replaced with a protected amine, and the other chlorine atom was replaced with R. 1 ONa to form key intermediate 13, which was then reacted with different aldehydes under alkaline conditions to form formula 9A.

[0195] Scheme III [ka] where R 1a , R 5 , R 6 is defined as in formula (I), m' is 0, 1, 2 or 3, and n' is 1, 2 or 3.

[0196] In Scheme III, key intermediate 8 was reacted with different borates under metal-free or metal-free coupling conditions, followed by removal of the amine protecting group to give compounds of formula 10A. After coupling with different aldehydes under alkaline conditions under different acids or reducing agents, compounds of formula IA were obtained.

[0197] Scheme IV [ka] where R 1a , R 5 , L 2 , R 6 is defined as in formula (I), m' is 0, 1, 2 or 3, and n' is 1, 2 or 3.

[0198] In Scheme IV, key intermediate 8 was reacted with different alkylamines and alkylalcohols under metal-free or metal-free coupling conditions. Removal of the amine protecting group gave formula 14. After deprotection and coupling with different acids under alkaline conditions or with different aldehydes under reducing agents, compounds of formula II were obtained.

[0199] Scheme V [ka] where R 1a , R 5 , L 2 , R 6 is defined as in formula (I), m' is 0, 1, 2 or 3, and n' is 1, 2 or 3.

[0200] In Scheme V, key intermediates 8 or 13 were reacted with DMF or morpholine-4-carbaldehyde under alkaline conditions to form aldehydes 15, which were reacted with different amines under a reducing agent to form compounds of formula 10B. After deprotection and coupling with different acids under alkaline conditions or with different aldehydes under a reducing agent, compounds of formula IB were obtained.

[0201] Example The following examples are for illustrative purposes only and should not be construed as limiting in any way. Unless otherwise noted, the experimental methods in the following examples are conventional. Unless otherwise specified, all reagents and materials are commercially available. All solvents and chemicals used are analytical grade or chemically pure. Solvents must be redistilled before use. All anhydrous solvents are prepared according to standard or reference methods. Silica gel (100-200 mesh) for column chromatography and silica gel (GF254) for thin-layer chromatography (TLC) are available from Tsingdao Haiyang Chemical Co., Ltd. or Yantai Chemical Co., Ltd. Unless otherwise specified, all elutions were performed with petroleum ether (60-90°C) / ethyl acetate (v / v) and developed with a solution of iodine or phosphomolybdic acid in ethanol. Unless otherwise specified, all extraction solvents were dried over anhydrous Na2SO4. 1 H NMR spectra were recorded on a Bruck-400 nuclear magnetic resonance spectrometer with TMS (tetramethylsilane) as the internal standard. LC / MS data were recorded using an Agilent 1100 high-performance liquid chromatography-ion trap mass spectrometer (LC-MSD trap) equipped with a diode array detector (DAD) detecting at 214 nm and 254 nm, and an ion trap (ESI source). All compound names, except for reagents, were generated by ChemDraw.

[0202] In the examples below, the following abbreviations are used: AcOH: acetic acid Aq.: Aqueous BINAP: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl Brine: saturated aqueous sodium chloride solution Bn: Benzyl BnBr: benzyl bromide BPO: Benzoyl peroxide BSA: N,O-bis(trimethylsilyl)acetamide CH2Cl2 or DCM: methylene chloride DIAD: Diisopropyl azodiformate DMF: N,N-dimethylformamide Dppf: 1,1'-bis(diphenylphosphino)ferrocene DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene DIEA or DIPEA: N,N-diisopropylethylamine DMAP: 4-N,N-dimethylaminopyridine DMF: N,N-dimethylformamide DMSO: dimethyl sulfoxide EtOAc or EA: Ethyl acetate EtOH: ethanol Et2O or ether: diethyl ether G: Gram h or hr: hours HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate Hex: Hexane HCl: Hydrochloric acid HMDS: hexamethyldisilazane HPLC IBX: High-performance liquid chromatography 2-Iodoxybenzoic acid IPA: Isopropyl alcohol i-PrOH: Isopropyl alcohol LCMS: Liquid Chromatography-Mass Spectrometry mg: milligram mL: milliliter mmol: millimolar MeCN: acetonitrile MeOH: Methanol Min: minutes ms or MS: mass spectrometry MTBE: Methyl t-butyl ether Na2SO4: Sodium sulfate NBS: N-bromosuccinimide NMP: N-methylpyrrolidone PE: Petroleum ether PMB: (4-methoxyphenyl)methylamine prep: preparation Rt or rt: room temperature sat.: saturated TBAF: Tetrabutylammonium fluoride TBSCl: tert-butyldimethylsilyl chloride t-BuOK: Potassium t-butoxide TFA: Trifluoroacetic acid THF: tetrahydrofuran TLC: Thin-layer chromatography μL: microliter Synthesis of intermediate I: 7-Bromo-2-butoxy-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: 1-amino-1H-imidazolyl-2-ethyl formate hydrochloride [ka] To a stirred solution of 1H-imidazolyl-2-ethyl formate (56 g, 0.4 mol) in NMP (1.2 L) was added t-BuOK (1 M in THF, 440 ml, 0.44 mol) at 20-30°C. The mixture was stirred for 0.5 h. A solution of O-(4-nitrobenzoyl)hydroxylamine (80.08 g, 0.44 mol) in NMP (0.4 L) was added dropwise below 30°C. The solution was stirred at room temperature for 2 h. The solution was diluted with MTBE (500 ml). The reaction was quenched by adding HCl (4 M in EA, 100 ml). Diatomaceous earth (20 g) was added to the above mixture, which was then stirred for 0.5 h. The mixture was filtered. The filtrate was diluted with MTBE (2 L), and HCl (4 M in EA, 200 ml) was added dropwise. The suspension was stirred for 0.5 h and filtered. The cake was rinsed with MTBE and dried in an oven to give the product (70 g, 91%). MS: M / e 156 (M+1) + .

[0203] Step B: A mixture of 1-((ethoxycarbonyl)amino)-1H-imidazolyl-2-ethyl formate and 1-(bis(ethoxycarbonyl)amino)-1H-imidazolyl-2-ethyl formate (1:1) [ka] To a stirred solution of 1-amino-1H-imidazolyl-2-ethyl formate hydrochloride (80 g, 0.42 mol) in THF (900 ml) and H2O (900 ml) was added NaHCO3 (178.9 g, 2.1 mol) in a batch. Ethyl chloroformate (98.55 g, 0.9 mol) was added dropwise below 30 °C. The mixture was stirred at room temperature for 4 h. The mixture was diluted with EA (1 L) and then separated. The aqueous layer was extracted with EA (800 ml). The collected organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to give the crude product (113 g) as a yellow oil, which could be used directly in the next step without further purification. MS: M / e 228 (M+1) + & M / e 300 (M+1) + .

[0204] Step C: Imidazo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione [ka] A sealed tube was charged with a mixture of 1-((ethoxycarbonyl)amino)-1H-imidazolyl-2-ethyl formate and 1-(bis(ethoxycarbonyl)amino)-1H-imidazolyl-2-ethyl formate (110 g) in ammonium hydroxide (400 ml, 3.6 V) and IPA (200 ml, 1.8 V). The mixture was stirred at 120° C. overnight. After cooling, the mixture was filtered. The cake was rinsed with MeOH. The filtrate was concentrated under reduced pressure. The resulting residue was slurried with MeOH, filtered, and rinsed with MeOH. The resulting cake and the previous cake were combined and dried in an oven to give the product (56 g) as a white solid. MS: M / e 153 (M+1) + .

[0205] Step D: 7-Bromoimidazo[2,1-f][1,2,4]triazine-2,4-(1H,3H)-dione [ka] NBS (24.6 g, 0.14 mol) was added in batches to a solution of imidazo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione (30 g, 0.20 mol) in HO (1.2 L) below 25 °C. The mixture was stirred at room temperature for 1 h. The mixture was filtered. The filtrate was concentrated to remove the solvent. The resulting residue and the previous cake were mixed and slurried with MeOH (20 V) followed by MeOH:HO (1:1, 20 V) to give the product (30.4 g, 94%) as a white solid. MS: M / e 231 (M+1) + .

[0206] Step E: 7-Bromo-2,4-dichloroimidazo[2,1-f][1,2,4]triazine [ka] A 350 ml sealed tube was charged with 7-bromoimidazo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione (10 g, 43 mmol), triethylamine hydrochloride (12 g, 88 mmol), and POCl3 (100 ml). The mixture was stirred at 120 °C overnight. The mixture was concentrated to remove POCl3. The residue was diluted with EA (200 ml), and saturated NaHCO3 (aq) was added dropwise at below 20 °C until the pH value was higher than 7. The solution was separated. The organic layer was washed with HO, dried over Na2SO4, filtered, and concentrated. The resulting residue was purified by column chromatography eluting with 0-20% EA in PE to give the product (8.5 g, 73%) as a white solid. MS: M / e 267 (M+1). + .

[0207] Step F: 7-Bromo-2-chloro-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a stirred solution of 7-bromo-2,4-dichloroimidazo[2,1-f][1,2,4]triazine (30 g, 0.11 mol) in THF (500 ml) was added dropwise TEA (22.6 g, 0.22 mol). The mixture was stirred at room temperature for 10 minutes. A solution of bis(4-methoxybenzyl)amine (31.6 g, 0.12 mol) in THF (80 ml) was added dropwise to the above solution. The mixture was stirred at room temperature for 2 hours. The solution was quenched with H2O (300 ml) and extracted with EA (200 ml x 2). The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The resulting residue was slurried with PE (300 ml) and filtered to give the product (41.4 g, 76%) as a white solid. MS: M / e 488 (M+1) + .

[0208] Step G: 7-Bromo-2-butoxy-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of 7-bromo-2-chloro-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (35 g, 71.6 mmol) and n-BuONa / n-BuOH (20%, 200 ml) was stirred at 80 °C under N for 1 h. The solution was quenched with H2O (200 ml). The aqueous solution was extracted with EA (150 ml × 2). The collected organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The resulting residue was purified by column chromatography eluting with 0-20% EA in PE to give the product (33 g, 88%) as a colorless oil, which hardened after several hours. MS: M / e 526 (M+1). + .

[0209] Synthesis of Intermediate II 2-Chloro-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0210] [ka] DIPEA (25.5 g, 0.20 mmol) was added to a mixture of imidazo[2,1-f][1,2,4]triazine-2,4(1H,3H)-dione (10 g, 65.8 mmol), POCl3 (50 g, 0.33 mol), and toluene (60 mL) at 60 °C within 30 min. An exotherm was observed, and the temperature rose to 90 °C (the solid gradually dissolved). After the addition was complete, the reaction was warmed to 100 °C (internal temperature approximately 95 °C) and stirred overnight. The reaction was then cooled to room temperature. The mixture was concentrated under reduced pressure. The residue was dissolved in THF (100 mL), and DIPEA (25.5 g, 0.20 mmol) was added dropwise to the mixture. Within 1 h, this mixture was added to a solution of bis(2,4-dimethoxybenzyl)amine (31.3 g, 0.10 mol), K2CO3 (18 g, 1.32 mol), THF (260 mL), and water (260 mL) at 0 °C. After the addition was complete, the mixture was extracted with EA (300 mL × 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was dissolved in EA (400 mL), and the mixture was stirred under reflux for 1 h and filtered at this temperature. The filtrate was concentrated under reduced pressure. EA was converted to MeOH, and the mixture was stirred at room temperature overnight. The mixture was filtered, and the solid (off-white) was collected. The product was directly used in the next step (20 g, HPLC: 98.87%, yield: 54.4%).

[0211] Compound B1: 2-butoxy-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 7-bromo-2-butoxy-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.38 mmol) in THF (8 mL) was added a solution of n-BuLi (0.4 mL, 0.6 mmol) dropwise, while maintaining the temperature between -75 and -65 °C. After 1 h, a solution of tert-butyl 4-formylpiperidine-1-formate (120 mg, 0.57 mmol) in THF (1 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 1 h and then allowed to warm to room temperature over 3 h. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (60 mL), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (210 mg, crude). MS: M / e 661 (M+1) + .

[0212] Step B: 2-Butoxy-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step B (210 mg, crude) in TFA (6 mL) was added EtSiH (2 mL). The reaction was heated at 85° C. for 72 h. The mixture was concentrated to dryness, and the residue was purified by preparative HPLC to give the product (20 mg, 17%, over two steps). 1 HNMR (400 MHz, DMSO-d6) δ 8.49 (s, 1H), 8.16 (s, 1H), 8.10 (s, 1H), 7.37 (d, J = 2.0 Hz, 1H), 4.22 (t, J = 6.8 Hz, 2H), 3.24 (d, J = 12.0 MS: M / e 305 (M+1) + .

[0213] Compound B2: 2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: N,N-Bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a solution of pento-2-ol (2.8 g, 31.82 mmol) in THF (50 mL) was added NaH (1.27 g, 31.75 mmol, 60%) at 0 °C under N2. After stirring at 25 °C for 0.5 h, 2-chloro-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (5 g, 10.64 mmol) was added. The reaction mixture was stirred at 70 °C for 16 h. Upon completion, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (25%) in petroleum ether to give the title compound (4.8 g, 87%). 1 H NMR (400 MHz, DMSO-d6) δ 7.93 (s, 1H), 7.50 (s, 1H), 7.04 - 6.96 (m, 2H), 6.60 - 6.52 (m, 2H), 6.45 (m, 2H), 5.64 (m, 2H), 4.94 - 4.84 (m, 1H), 4.72 (m, 2H), 3.73 (t, J = 9.2 Hz, 12H), 1.68 - 1.41 (m, 2H), 1.37-1.25 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H), 0.84 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 458 (M+1) + .

[0214] Step B: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a stirred solution of N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (1.17 g, 2.3 mmol) in THF (10 mL) was added n-BuLi (1.6 M, 2.85 mL, 4.6 mmol) at −78°C under a N2 atmosphere. The mixture was stirred at −78°C for 1 hour. Then, a solution of tert-butyl 4-formylpiperidine-1-formate (0.97 g, 4.6 mmol) in THF (10 mL) was added at −78°C. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated aqueous NH4Cl at room temperature. The mixture was extracted with EA (20 mL × 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by combiflash to give the title compound (1.2 g, yield: 71.0%). MS: M / e 735 (M+1) + .

[0215] Step C: (4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(piperidin-4-yl)methanol [ka] A mixture of the product of Step B (1.2 g, 1.6 mmol) in TFA / HO (9:1, 12 mL) was stirred at 30 °C overnight. The reaction was cooled to room temperature and concentrated under reduced pressure. The mixture was concentrated, and 20 mL of HO was added. The mixture was stirred at room temperature for 30 minutes and then filtered. The filtrate was extracted with DCM (20 mL x 3) to remove impurities. The aqueous layer was basified to pH = 12 with aqueous NaOH (2 M) and extracted with DCM / IPA (8:2, 20 mL x 3). The combined extracts were washed with brine (20 mL), dried over NaSO, and concentrated to give the title product (350 mg, yield: 64.1%). MS: M / e 335 (M+1) + .

[0216] Step D: 2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of the product of Step C (350 mg, 1.05 mmol), TFA (2.5 mL), and EtSiH (4 mL) was stirred at 60 °C overnight. LC_MS showed no remaining starting material. TFA (1 mL) was added to the mixture, and the mixture was stirred at 60 °C overnight. The reaction was concentrated under reduced pressure. The residue was dissolved in water (15 mL) and extracted with DCM (25 mL x 3). The organic phase was discarded. The inorganic phase was basified to pH = 12 with aqueous NaOH (2 M). A white solid precipitated from the system. The mixture was extracted with DCM / iPrOH (8:2, 20 mL x 2). The combined organic phase was washed with 20% aqueous NaCl, dried over NaSO, and concentrated. The residue was purified by combiflash to give the title compound (90 mg, yield: 27.0%). 1H NMR (400 MHz, DMSO-d6) δ 8.21 - 7.80 (m, 2H), 7.27 (s, 1H), 5.06 - 4.89 (m, 1H), 2.98 - 2.80 (m, 2H), 2.69 (d, J = 6.6 Hz, 2H), 2.38 (t, J = 12 Hz, 2H), 1.86 - 1.61 (m, 2H), 1.58 - 1.47 (m, 3H), 1.43 - 1.33 (m, 2H), 1.26 (t, J = 6.0 Hz, 3H), 1.08 (dd, J = 20.8, 12 Hz, 2H), 0.90 (t, J = 7.2 Hz, 3H)ppm. MS: M / e 319 (M+1) + MS: M / e 319 (M+1) + .

[0217] Compound B3: 2-butoxy-7-(2-(piperidin-4-yl)ethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-(2-(4-(bis(4-methoxybenzyl)amino)-2-butoxyimidazo[2,1-f][1,2,4]triazin-7-yl)-2-hydroxyethyl)piperidine-1-formate [ka] To a stirred solution of 7-bromo-2-butoxy-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (150 mg, 0.29 mmol) in THF (10 mL) was added n-BuLi (1.6 M, 0.57 mL) at -78 °C under a N atmosphere. The mixture was stirred at -78 °C for 1 hour. Then, a solution of tert-butyl 4-(2-oxoethyl)piperidine-1-formate (92 mg, 0.41 mmol) in THF (0.5 mL) was added at -78 °C. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated aqueous NH4Cl at room temperature. The mixture was extracted with EA (20 mL x 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by combiflash to give the title compound (150 mg, yield: 76.7%). MS: M / e 675 (M+1) + .

[0218] Step B: 2-Butoxy-7-(2-(piperidin-4-yl)ethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a stirred solution of the product of Step A (150 mg, 0.22 mmol) in EtSiH (4 mL) at room temperature was added CFCOOH (2 mL). The mixture was stirred at 80°C for 1 hour. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in CFCOOH (4 mL). The mixture was stirred at 80°C overnight. The reaction was cooled to room temperature. The mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title compound (15 mg, yield: 21.4%). 1H NMR (400 MHz, DMSO-d6) δ 8.15 - 7.90 (m, 2H), 7.29 (s, 1H), 4.20 (t, J = 6.4 Hz, 2H), 2.94 (d, J = 12.0 Hz, 2H), 2.78 (t, J = 7.6 Hz, 2H), 2.44 (t, J = 11.6 Hz, 2H), 1.77 - 1.52 (m, 6H), 1.50 - 1.35 (m, 2H), 1.35 - 1.24 (m, 1H), 1.13 - 0.99 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 319 (M+1) + .

[0219] Compound B4: N2-butyl-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine [ka] Step A: 7-Bromo-N2-butyl-N4,N4-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine [ka] A mixture of 7-bromo-2-chloro-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (244 mg, 0.5 mmol), but-1-amine (365 mg, 5 mmol), and DIPEA (645 mg, 5 mmol) in NMP (3 mL) was stirred at 220 °C for 6 h in a sealed tube. The mixture was added to HO (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine, dried over NaSO, concentrated, and purified by column chromatography (petroleum ether / EtOAc = 20:1 to 5:1) to give the target compound (220 mg, 83.8%). MS: M / e 525 / 527 (M+1). + .

[0220] Step B: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(butylamino)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] At -78 °C under N2 atmosphere, 7-bromo-N 2 -Butyl-N 4 ,N 4 To a stirred solution of 150 mg (0.29 mmol) of bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine in 5 mL of THF was added n-BuLi (1.6 M, 0.54 mL, 0.86 mmol). The mixture was stirred at −78° C. for 1 hour. Then, at −78° C., a solution of tert-butyl 4-formylpiperidine-1-formate (91 mg, 0.39 mmol) in 0.5 mL of THF was added. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated aqueous NH4Cl at room temperature. The mixture was extracted with EA (20 mL × 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by combiflash to give the title compound as a yellow oil (110 mg, yield: 58.3%). MS: M / e 660 (M+1) + .

[0221] Step C:N 2 -butyl-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine [ka] To a stirred solution of the product of Step B (110 mg, 0.17 mmol) in EtSiH (4 mL) at room temperature was added CFCOOH (2 mL). The mixture was stirred at 80°C for 1 hour. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in CFCOOH (4 mL). The mixture was stirred at 80°C overnight. The reaction was cooled to room temperature. The mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title compound (15 mg, yield: 50.7%). 1 H NMR (400 MHz, DMSO-d6) δ 7.46 (br.s, 2H), 7.11 (s, 1H), 6.36 - 5.96 (m, 1H), 3.22 - 3.08 (m, 2H), 3.00 - 2.86 (m, 2H), 2.74 - 2.59 (m, 2H), 2.48 - 2.38 (m, 2H), 1.80 (br.s, 1H), 1.60 - 1.45 (m, 4H), 1.41 - 1.29 (m, 2H), 1.18 - 1.00 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 304 (M+1) + .

[0222] Compound B5: N 2 -(pent-2-yl)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine [ka] Step A: 7-Bromo-N 4 ,N 4 -Bis(4-methoxybenzyl)-N2-(pent-2-yl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine [ka] To a stirred solution of 7-bromo-2-chloro-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (1 g, 2.05 mmol) in NMP (10 mL) was added pent-2-amine (1 g, 11.5 mmol) and DIEA (400 mg, 3.1 mmol). The reaction mixture was sealed and stirred at 220 °C for 6 h. The mixture was cooled to room temperature, HO (20 mL) was added, and extracted with EtOAc (10 mL x 3). The combined organic phase was washed with brine, dried over NaSO, and concentrated in vacuo. The crude product was purified by column chromatography to give the product (250 mg, 22.7%) as a white solid. MS: M / e 539 (M+1). + .

[0223] Step B: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(pent-2-ylamino)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a stirred solution of 7-bromo-2-butoxy-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (161 mg, 0.29 mmol) in THF (2 mL) was added n-BuLi (1.6 M, 0.56 mL, 0.9 mmol) at −78°C under a N2 atmosphere. The mixture was stirred at −78°C for 1 hour. Then, a solution of tert-butyl 4-(2-oxoethyl)piperidine-1-formate (76.5 mg, 0.36 mmol) in THF (0.3 mL) was added at −78°C. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated aqueous NH4Cl at room temperature. The mixture was extracted with EA (20 mL × 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by combiflash to give the title compound as a yellow oil (80 mg, yield: 39.8%). MS: M / e 674 (M+1) + .

[0224] Step C:N 2 -(pent-2-yl)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazine-2,4-diamine [ka] To a stirred solution of the product of Step B (80 mg, 0.12 mmol) in EtSiH (4 mL) at room temperature was added CFCOOH (2 mL). The mixture was stirred at 80 °C for 1 h. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in CFCOOH (4 mL). The mixture was stirred at 80 °C overnight. The reaction was cooled to room temperature. The mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title compound (9 mg, yield: 23.9%). 1 H NMR (400 MHz, DMSO-d6) δ 7.43 (br.s, 2H), 7.10 (s, 1H), 5.94 (d, J = 8.0 Hz, 1H), 3.91 - 3.61 (m, 1H), 3.03 - 2.82 (m, 2H), 2.74 - 2.58 (m, 2H), 2.46 - 2.31 (m, 2H), 1.92 - 1.73 (m, 1H), 1.65 - 1.48 (m, 3H), 1.42 - 1.28 (m, 3H), 1.14 - 1.01 (m, 5H), 0.99 - 0.81 (m, 3H) ppm. MS: M / e 318 (M+1) + .

[0225] Compound B6: (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0226] [ka] Step A: (S)-N,N-Bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0227] [ka] To a solution of (S)-pent-2-ol (2.35 g, 26.7 mmol) in THF (50 mL) was slowly added NaH (60% in mineral oil, 1.07 g, 26.7 mmol) at room temperature. The mixture was stirred at room temperature for 1 h. 2-Chloro-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (5 g, 10.7 mmol) was added, and the resulting mixture was stirred at 60 °C overnight. The reaction was cooled to room temperature. The mixture was quenched with 80 mL of water and extracted with EA (60 mL x 2). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated. The residue was purified by combiflash to give the title product (4.5 g, yield: 81.1%) as a gel. MS: M / e 522 (M+1) + .

[0228] Step B: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a stirred solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (1.56 g, 3 mmol) in THF (10 mL) was added n-BuLi (1.6 M, 3.8 mL, 6 mmol) at -78 °C under a N atmosphere. The mixture was stirred at -78 °C for 1 hour. Then, a solution of tert-butyl 4-formylpiperidine-1-formate (1.3 g, 6 mmol) in THF (1 mL) was added at -78 °C. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated aqueous NH4Cl at room temperature. The mixture was extracted with EA (20 mL x 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by combiflash to give the title compound (1.6 g, yield: 72.7%). MS: M / e 735 (M+1) + .

[0229] Step C: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(piperidin-4-yl)methanol.

[0230] [ka] tert-Butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate (1.4 g, 1.9 mmol) in TFA / HO (9:1, 20 mL) was stirred at room temperature for 65 h. The reaction was concentrated under reduced pressure. 20 mL HO was added. The mixture was stirred at room temperature for 30 min and then filtered. The filtrate was extracted with DCM (20 mL x 3) to remove impurities. The aqueous layer was basified to pH > 10 with aqueous NaOH (4 M) and extracted with DCM / IPA (5:1, 20 mL x 5). The combined extracts were washed with brine (50 mL x 3), dried over Na2SO4, and concentrated to give the title product (460 mg, yield: 72%). MS: M / e 335 (M+1). + .

[0231] Step D: (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0232] [ka] A mixture of (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(piperidin-4-yl)methanol (460 mg, 1.37 mmol), TFA (10 mL), and EtSiH (10 mL) was stirred at 60 °C overnight. LC_MS showed that the starting material had disappeared. EtSiH (5 mL) was added to the mixture, and the mixture was stirred at 60 °C overnight. The reaction was concentrated under reduced pressure. The residue was dissolved in HCl (4 M, 2 mL) and extracted with DCM (5 mL × 3). The organic phase was discarded. The inorganic phase was basified to pH = 12 with aqueous NaOH (4 M). A white solid precipitated from the system. The mixture was extracted with DCM / iPrOH (5:1, 10 mL × 5). The combined organic phase was washed with brine (20 mL x 2), dried over Na2SO4, and concentrated. The residue was purified by column chromatography to give the title compound (320 mg, yield: 72%). 1 H NMR (400 MHz, DMSO-d6) δ 8.04 (br.s, 1H), 7.94 (br.s, 1H), 7.27 (s, 1H), 5.03 - 4.89 (m, 1H), 2.87 (d, J = 12.0 Hz, 2H), 2.68 (d, J = 6.8 Hz, 2H), 2.36 (t, J = 12.0 Hz, 2H), 1.84 - 1.61 (m, 2H), 1.59 - 1.44 (m, 3H), 1.44 - 1.32 (m, 2H), 1.28 (d, J = 6.2 Hz, 3H), 1.14 - 0.99 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 319 (M+1) + .

[0233] Compound B7: (R)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Compound B7 can be obtained as follows: Chiral resolution of compound B2 gave two chiral compounds, compound B6 and compound B7.

[0234] Preparative HPLC conditions [Table 1] Compound B7: (R)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] 1 H NMR (400 MHz, DMSO-d6) δ 8.14 - 7.86 (m, 2H), 7.27 (s, 1H), 5.06 - 4.88 (m, 1H), 2.98 - 2.81 (m, 2H), 2.69 (d, J = 6.6 Hz, 2H), 2.38 (t, J = 11.6 Hz, 2H), 1.85 - 1.61 (m, 2H), 1.58 - 1.45 (m, 3H), 1.44 - 1.32 (m, 2H), 1.28 (d, J = 6.0 Hz, 3H), 1.08 (dd, J = 21.6, 11.6 Hz, 2H), 0.90 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 319 (M+1) + .

[0235] Compound B8: 7-((4-methylpiperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: Benzyl 4-formyl-4-methylpiperidine-1-formate [ka] To a stirred mixture of 4-formylpiperidine-1-benzyl formate (2 g, 8.09 mmol) in DCM (20 ml) was added t-BuOK (1.2 g, 10.7 mmol) and CHCl (1.55 ml, 24.9 mmol). After the addition, the reaction mixture was stirred at room temperature overnight. The reaction mixture was added to H2O and extracted with EtOAc (15 mL x 3). The combined organic phases were washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by column chromatography to give the title product (800 mg, 38%). 1 H NMR (400 MHz, CDCl3-d6) δ 9.45 (t, J = 5.4 Hz, 1H), 7.40 - 7.28 (m, 5H), 5.13 (dd, J = 5.8, 1.0 Hz, 2H), 3.84 - 3.68 (m, 2H), 3.26 - 3.09 (m, 2H), 1.93 (d, J = 13.2 Hz, 2H), 1.42 (s, 2H), 1.08 (d, J = 2.3 Hz, 3H) ppm. MS: M / e 262(M+1) + .

[0236] Step B: Benzyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-4-methylpiperidine-1-formate [ka] To a stirred solution of N,N-bis(4-methoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.43 mmol) in THF (8 mL) cooled to -78 °C and under a nitrogen atmosphere, n-BuLi (1.6 M in hexanes, 0.86 mmol, 0.54 mL) was added dropwise. After stirring for 30 min, a solution of benzyl 4-formyl-4-methylpiperidine-1-formate (226 mg, 0.86 mmol) in THF (2 mL) was slowly added. The reaction mixture was slowly warmed to room temperature and stirred overnight. The reaction mixture was added to saturated ammonium chloride solution and extracted with EtOAc (15 mL x 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by column chromatography to give the title product (120 mg, 38.7%). MS: M / e 723 (M+1) + .

[0237] Step C: 7-((4-methylpiperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a stirred mixture of benzyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-4-methylpiperidine-1-formate (120 mg, 0.166 mmol) in TFA (5 ml) was added EtSiH (5 ml). After the addition, the reaction mixture was stirred at 80 °C for 2 h. The mixture was cooled to room temperature and concentrated in vacuo. To the residue was added TFA (10 ml) and stirred at 80 °C overnight. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by preparative HPLC to give the desired compound (10 mg, 22.4%). 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.30 (s, 1H), 8.13 (s, 1H), 8.04 (s, 1H), 7.36 (s, 1H), 4.99 (s, 1H), 3.17 (s, 2H), 3.03 MS: M / e 333 (M+1) + .

[0238] Compound B9: 2-(pent-2-yloxy)-7-(piperazin-1-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: N,N-Bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a solution of pento-2-ol (2.8 g, 31.82 mmol) in THF (50 mL) was added NaH (1.27 g, 31.75 mmol, 60%) at 0 °C under N2. After stirring at 25 °C for 0.5 h, 2-chloro-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (5 g, 10.64 mmol) was added. The reaction mixture was stirred at 70 °C for 16 h. Upon completion, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (25%) in petroleum ether to give the title compound (4.8 g, 87%). 1H NMR (400 MHz, DMSO-d6) δ 7.93 (s, 1H), 7.50 (s, 1H), 7.04 - 6.96 (m, 2H), 6.60 - 6.52 (m, 2H), 6.45 (m, 2H), 5.64 (m, 2H), 4.94 - 4.84 (m, 1H), 4.72 (m, 2H), 3.73 (t, J = 9.2 Hz, 12H), 1.68 - 1.41 (m, 2H), 1.37-1.25 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H), 0.84 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 458 (M+1) + .

[0239] Step B: 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1 f][1,2,4]triazine-7-carbaldehyde [ka] To a solution of N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (3 g, 5.76 mmol) in THF (100 mL) was added n-BuLi (7.2 mL, 11.52 mmol) at -78 °C under N2. After stirring at -78 °C for 1 h, DMF (1.7 g, 23.29 mmol) was added. The reaction mixture was warmed to 25 °C and stirred for 3 h. Upon completion, the reaction mixture was quenched with aqueous NH4Cl (80 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (25%) in petroleum ether to give the title compound (1.8 g, 57%). 1H NMR (300 MHz, DMSO-d6) δ 10.17 (s, 1H), 8.14 (s, 1H), 7.04 (d, J = 8.0 Hz, 2H), 6.56 (d, J = 2.4 Hz, 2H), 6.50-6.39 (m, 2H), 5.60 (m, MS: M / e 550 (M+1) + .

[0240] Step C: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperazine-1-formate [ka] To a solution of 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1 f][1,2,4]triazine-7-carbaldehyde (200 mg, 0.384 mmol) and tert-butyl piperazine-1-formate (143 mg, 0.768 mmol) in THF (5 mL) was added AcOH (46 mg, 0.768 mmol) and NaBH(AcO) (244 mg, 1.152 mmol). The reaction mixture was stirred at 25 °C for 4 h. Upon completion, the reaction mixture was quenched with water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give the residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (40%) in petroleum ether to give the title compound (230 mg, 83%) as a white solid. MS: M / e 719.9 (M+1)+.

[0241] Step D: 2-(pent-2-yloxy)-7-(piperazin-1-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] 2-(pent-2-yloxy)-7-(piperazin-1-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine Under N2, tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperazine-1-formate (230 mg, 0.319 mmol) was dissolved in TFA (8 mL) and HO (0.8 mL). The reaction mixture was stirred at 70 °C for 3 h. Upon completion, the reaction mixture was quenched with aqueous NaHCO3 (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (DCM / MeOH = 5 / 2) to give the title compound (23 mg, 23%). 1 H NMR (300 MHz, DMSO-d6) δ 8.12 (m, 2H), 7.44 (s, 1H), 4.98 (dd, J = 12.4, 6.4 Hz, 1H), 3.82 (s, 2H), 3.04-2.92 (m, 4H), 2.58 (s, 4H), 1.72-1.47 (m, 2H), 1.37 (m, 2H), 1.28 (d, J = 6.4 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 320.40 (M+1)+.

[0242] Compound B10: 2-(((S)-pent-2-yl)oxy)-7-(piperidin-3-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 3-((4-(bis(3,4-dimethylbenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a cooled solution of N-protected (S)-N,N-bis(3,4-dimethylbenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazine-4 (200 mg, 0.38 mmol) in THF (8 mL) was added n-BuLi (1.6 M, 0.4 mL) dropwise at -78 °C. After stirring at -78 °C for 30 min, a solution of tert-butyl 3-formylpiperidine-1-formate (98 mg, 0.46 mmol) in THF (2 mL) was added. The resulting mixture was stirred at this temperature for 30 min and then gradually warmed to room temperature overnight. The solution was quenched with NH4Cl solution (5 mL) and extracted with ethyl acetate (10 mL). The organic layer was dried over Na2SO4, filtered and concentrated to give the crude product, which was further purified by CombiFlash (PE:EA=40%) to give the pure product (110 mg, 39%). MS: M / e 671 (M+1). + Step B: 2-(((S)-pent-2-yl)oxy)-7-(piperidin-3-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A solution of the product of Step A (110 mg, 0.15 mmol) in trifluoroacetic acid and water (9:1, v / v, 2 mL) was heated at 40 °C overnight. The solvent was evaporated under an oil pump to give a residue. Water (5 mL) was added to the residue, which was then slurried and filtered. The filtrate was extracted with DCM (5 mL). The aqueous phase was basified to pH = 13 with 1 M NaOH solution and then extracted with DCM / MeOH (10 mL, 20%). The organic layer was dried and concentrated to give the intermediate. The intermediate was dissolved in triethylsilane / trifluoroacetic acid (1:1, v / v, 2 mL) and heated at 80 °C overnight. After evaporation, water was added to the residue, which was basified to pH = 13 with 1 M NaOH solution and extracted with DCM / MeOH (10 mL, 20%). The organic layer was dried, concentrated and purified by preparative TLC (DCM:NH3.MeOH=9:1, 4M NH3.MeOH) to give the product (6 mg, 13%). 1 H NMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H), 8.01 (s, 1H), 7.32 (s, 1H), 7.14 (s, 1H), 5.01 - 4.97 (m, 1H), 3.61 (t, J=4.0 Hz, 2H), 3.10 (t, J=12.0 Hz, 2H), 2.76 (d, J=8.0 Hz, 2H), 2.68 (t, J=8.0 Hz, 1H), 1.97 (br.s, 1H), 1.78 - 1.65 (m, 4H), 1.58-1.49 (m, 2H), 1.43-1.33 (m, 2H), 1.28 (d, J=4.0 Hz, 3H), 1.23-1.17 (m, 2H), 0.91 (t, J=8.0 Hz, 3H) ppm. MS: M / e 319 (M+1) + Compound B11: 2-pentyl-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (E)-N,N-bis(4-methoxybenzyl)-2-(pent-1-en-1-yl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of 2-chloro-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (0.5 g, 1.2 mmol), (E)-pent-1-en-1-ylboronic acid (0.21 g, 1.8 mmol), Pd(dppf)Cl (45 mg, 0.06 mmol), and NaCO (0.26 g, 2.4 mmol) in dioxane (10 ml) and HO (3 ml) was stirred overnight at 80 °C under a N atmosphere. After completion, the mixture was concentrated, diluted with EA (20 ml), and washed with brine (10 ml). The organic layer was dried and evaporated under reduced pressure. The resulting residue was purified by flash column chromatography eluting with 0–25% EA in PE to give the product (0.5 g, 92%) as a colorless oil. MS: M / e 444 (M+1) + .

[0243] Step B: (E)-tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(pent-1-en-1-yl)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of (E)-N,N-bis(4-methoxybenzyl)-2-(pent-1-en-1-yl)imidazo[2,1-f][1,2,4]triazin-4-amine (0.5 g, 1.1 mmol) in THF (15 ml) was added dropwise n-BuLi (1.6 M, 1.4 ml, 2.2 mmol) at -70 °C under N2. The solution was stirred at -70 °C for 0.5 h. A solution of tert-butyl 4-formylpiperidine-1-formate (0.47 g, 2.2 mmol) in THF (2 ml) was added to the above solution at -70 °C over 0.5 h and then allowed to warm to room temperature for 1 h. After completion, the solution was quenched with HO (15 ml) and extracted with EA (15 ml × 2). The organic layer was washed with brine (10 ml), dried, and concentrated. The resulting residue was purified by combi-flash eluting with 10%-70% EA in PE to give the product as a white semi-solid (0.65 g, 88%). MS: M / e 657 (M+1). + .

[0244] Step C: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-pentylimidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] A mixture of (E)-tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(pent-1-en-1-yl)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate (0.65 g, 0.99 mmol) and Pd / C (0.1 g) in MeOH (15 ml) was stirred at room temperature under an atmosphere of H2 overnight. Upon completion, the mixture was filtered through diatomaceous earth and evaporated under reduced pressure to give the product (0.6 g, 92%) as a white oil. MS: M / e 659 (M+1). + .

[0245] Step D: 2-Pentyl-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-pentylimidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate (0.6 g, 0.91 mmol) in TFA (8 ml) and triethylsilane (2 ml) was stirred at 80°C for 2 days, then at 100°C for 2 days. The mixture was concentrated under reduced pressure. The residue was diluted with aqueous NaHCO3 (20 ml) and then extracted with EA (20 ml × 3). The organic layer was dried and concentrated. The resulting residue was purified by preparative TLC and then by preparative HPLC to give the product (28 mg). 1 H NMR (400 MHz, DMSO-d6) δ 8.59 (s, 1H), 8.35 - 7.98 (m, 3H), 7.50 - 7.38 (m, 1H), 3.24 (d, J = 12.7 Hz, 2H), 2.90 - 2.75 (m, 4H), 2.57 (t, J = 7.5 Hz, 2H), 2.06 - 1.92 (m, 1H), 1.81 - 1.65 (m, 4H), 1.44 - 1.25 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H) ppm. MS: M / e 303 (M+1) + .

[0246] Compound B12: (S)-7-((1-(2-(methylamino)ethyl)piperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0247] [ka] Step A: (S)-(2-(4-((4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)ethyl)(methyl) tert-butylcarbamate.

[0248] [ka] To a solution of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (20 mg, 0.063 mmol) and (2-oxoethyl) tert-butylcarbamate (20 mg, 0.116 mmol) in THF (1 mL) was added AcOH (20 mg, 0.33 mmol), followed by NaBH(OAc) (40 mg, 0.189 mmol), and the mixture was stirred for 16 h at room temperature. 2 mL of brine was added, and the mixture was extracted with EA (2 mL x 3). The combined extracts were washed with brine (5 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CHCl / MeOH (in NH) = 15:1) to give the title product (15 mg, 50%). MS: M / e 476 (M+1) + .

[0249] Step B: (S)-7-((1-(2-(methylamino)ethyl)piperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0250] [ka] The product of Step A (15 mg, 0.032 mmol) in HCl / EA solution (4 M, 5 mL) was stirred at room temperature for 5 h. The mixture was concentrated, basified with NaOH (4 M, aq.), and extracted with CHCl (2 mL x 3). The combined extracts were washed with brine (5 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CHCl / MeOH (in NH) = 15:1) to give the title product (4.5 mg, 38%). 1 H NMR (400 MHz, CD3OD) δ 7.38 (s, 1H), 5.19 - 5.04 (m, 1H), 3.69 - 3.54 (m, 2H), 3.54 - 3.35 (m, 4H), 3.09 - 2.85 (m, 4H), 2.78 (s, 3H), 2.20 - 2.06 (m, 1H), 2.00 - 1.89 (m, 2H), 1.84 - 1.66 (m, 3H), 1.67 - 1.41 (m, 3H), 1.36 (d, J = 6.4 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 376 (M+1) + .

[0251] Compound B13: 2-(((S)-pent-2-yl)oxy)-7-((1-(pyrrolidin-3-yl)piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 3-(4-((4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)pyrrolidine-1-formate [ka] To a stirred solution of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (20 mg, 0.063 mmol) and tert-butyl 3-oxopyrrolidine-1-formate (23 mg, 0.126 mmol) in THF (5 mL) was added AcOH (2 drops). The mixture was then stirred at room temperature for 30 minutes, after which NaBH(OAc) (27 mg, 0.126 mmol) was added. After the addition, the reaction mixture was stirred for 2 days. The reaction mixture was concentrated to give a residue, which was purified by preparative TLC (CHCl / MeOH=10:1) to give the desired compound (22 mg, 71.7%). MS: M / e 488 (M+1). + .

[0252] Step B: 2-(((S)-pent-2-yl)oxy)-7-((1-(pyrrolidin-3-yl)piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of the product of Step A (22 mg, 0.045 mmol) in EtOAc / HCl (4.0 M, 5 mL) was stirred overnight. The reaction mixture was concentrated to give a residue, which was purified by preparative HPLC to give the desired compound (5 mg). 1H NMR (400 MHz, DMSO-d6) δ 9.83 (s, 1H), 9.22 (s, 1H), 9.06 (s, 1H), 8.12 (s, 1H) 8.05 (s, 1H), 7.36 (s, 1H), 5.02 - 4.93 (m, 1H), 3.94 - 3.89 (m, 1H), 3.65 - 3.58 (m, 1H), 3.55 - 3.28 (m, 4H), 3.27 - 2.86 (m, 4H), 2.79 (d, J = 6.4 Hz, 2H), 2.38 - 2.31 (m, 1H), 2.16 - 1.92 (m, 2H), 1.86 - 1.77 (m, 2H), 1.73 - 1.49 (m, 2H), 1.48 - 1.35 (m, 4H), 1.28 (d, J = 6.0 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 388 (M+1) + .

[0253] Compound B14: (S)-2-(pent-2-yloxy)-7-((1-(piperidin-4-ylmethyl)piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (S)-tert-butyl 4-((4-((4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)methyl)piperidine-1-formate [ka] A mixture of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (20 mg, 0.06 mmol), tert-butyl 4-formylpiperidine-1-formate (27 mg, 0.12 mmol), and sodium triacetoxyborohydride (27 mg, 0.12 mmol) in THF (5 mL) was stirred at room temperature for 3 hours. The mixture was extracted with DCM (20 mL), washed with water (5 mL), concentrated, and purified by column chromatography (DCM / MeOH = 20:1 to 3:1) to give the title product (30 mg, 92.62%). MS: M / e 516 (M+1). + .

[0254] Step B: (S)-2-(pent-2-yloxy)-7-((1-(piperidin-4-ylmethyl)piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of (S)-tert-butyl 4-((4-((4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)methyl)piperidine-1-formate (30 mg, 0.06 mmol) and TFA (0.5 mL) in DCM (3 mL) was stirred at room temperature for 2 hours. The mixture was concentrated and purified by preparative HPLC to give the product (18 mg, 74.46%). 1H NMR (400 MHz, DMSO-d6) δ 8.93 (s, 1H), 8.55 (s, 1H), 8.31 (s, 1H), 8.14 (s,1H), 8.06 (s,1H), 7.37 (s, 1H), 5.01 - 4.97 (m, 1H), 3.48 (d, J = 11.8 Hz, 2H), 3.38 - 3.18 (m, 3H), 2.96 (t, J = 5.9 Hz, 2H), 2.92 - 2.81 (m, 4H), 2.79 (d, J = 6.3 Hz, 2H), 2.07 (s, 1H), 1.95 (s, 1H), 1.83 (t, J = 14.5 MS: M / e 416 (M+1) + .

[0255] Compound B15: 7-(((R)-3-methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0256] [ka] Step A: (2R)-4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-2-methylpiperazine-1-tert-butyl formate.

[0257] [ka] To a mixture of 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazine-7-carbaldehyde (100 mg, 0.18 mmol) and (R)-2-methylpiperazine-1-tert-butylformate (72 mg, 0.36 mmol) in THF (2 mL) was added AcOH (25 mg, 0.42 mmol), followed by NaBH(OAc) (115 mg, 0.54 mmol), and the mixture was stirred for 16 h at room temperature. 2 mL of brine was added, and the mixture was extracted with EA (2 mL x 3). The combined extracts were washed with brine (2 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (PE / EA = 1:1) to give the title product (85 mg, 64%). MS: M / e 734 (M+1) + .

[0258] Step B: 7-(((R)-3-Methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0259] [ka] The product of Step A (85 mg, 0.12 mmol) in HCl / EA solution (4 M, 5 mL) was stirred at room temperature for 16 h. The mixture was concentrated to dryness, 5 mL TFA was added, and the mixture was stirred at room temperature for 2 h and at 60 °C for 5 h. The mixture was concentrated to dryness under high vacuum. 2 mL of NaOH (aqueous, 4 M) was added, and the mixture was extracted with CHCl (5 mL x 5). The combined extracts were washed with brine (10 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CHCl / MeOH (in NH) = 10:1) to give the title product (25 mg, 65%). 1H NMR (400 MHz, CD3OD) δ 7.49 (s, 1H), 5.22 - 5.06 (m, 1H), 4.05 - 3.87 (m, 2H), 3.17 - 2.91 (m, 5H), 2.38 - 2.22 (m, 1H), 2.08 - 1.96 (m, 1H), 1.83 - 1.69 (m, 1H), 1.69 - 1.56 (m, 1H), 1.55 - 1.40 (m, 2H), 1.40 - 1.30 (m, 3H), 1.20 - 1.07 (m, 3H), 1.00 - 0.91 (m, 3H) ppm. MS: M / e 334 (M+1) + .

[0260] Compound B16: 7-(((S)-3-methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0261] [ka] Step A: (2S)-4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-2-methylpiperazine-1-formate tert-butyl.

[0262] [ka] To a mixture of 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazine-7-carbaldehyde (100 mg, 0.18 mmol) and (S)-2-methylpiperazine-1-tert-butylformate (72 mg, 0.36 mmol) in THF (2 mL) was added AcOH (25 mg, 0.42 mmol), followed by NaBH(OAc) (115 mg, 0.54 mmol), and the mixture was stirred for 16 h at room temperature. 2 mL of brine was added, and the mixture was extracted with EA (2 mL x 3). The combined extracts were washed with brine (2 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (PE / EA = 1:1) to give the title product (92 mg, 68%). MS: M / e 734 (M+1) + .

[0263] Step B: 7-(((S)-3-Methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0264] [ka] The product of Step A (92 mg, 0.12 mmol) in HCl / EA solution (4 M, 5 mL) was stirred at room temperature for 16 h. The mixture was concentrated to dryness, 5 mL of TFA was added, and the mixture was stirred at room temperature for 2 h and at 60 °C for 5 h. The mixture was concentrated to dryness under high vacuum. 2 mL of NaOH (aqueous, 4 M) was added, and the mixture was extracted with CHCl (5 mL x 5). The combined extracts were washed with brine (10 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CHCl / MeOH (in NH) = 10:1) to give the title product (21 mg, 50%). 1H NMR (400 MHz, CD3OD) δ 7.48 (s, 1H), 5.17 - 5.06 (m, 1H), 3.93 (s, 2H), 3.12 - 2.90 (m, 5H), 2.35 - 2.22 (m, 1H), 1.99 (t, J = 10.8 Hz, 1H), 1.85 - 1.69 (m, 1H), 1.69 - 1.55 (m, 1H), 1.53 - 1.39 (m, 2H), 1.36 (d, J = 6.0 Hz, 3H), 1.12 (d, J = 6.4 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 334 (M+1) + .

[0265] Compound B17: 7-(((S)-2-methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0266] [ka] Step A: tert-butyl (3S)-4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-3-methylpiperazine-1-formate.

[0267] [ka] To a mixture of 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazine-7-carbaldehyde (100 mg, 0.18 mmol) and (S)-tert-butyl 3-methylpiperazine-1-formate (72 mg, 0.36 mmol) in THF (2 mL) was added AcOH (25 mg, 0.42 mmol), followed by NaBH(OAc) (115 mg, 0.54 mmol), and the mixture was stirred for 16 h at room temperature. 2 mL of brine was added, and the mixture was extracted with EA (2 mL x 3). The combined extracts were washed with brine (2 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (PE / EA = 1:1) to give the title product (86 mg, 64%). MS: M / e 734 (M+1) + .

[0268] Step B: 7-(((S)-2-Methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0269] [ka] Tert-butyl (3S)-4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-3-methylpiperazine-1-formate (86 mg, 0.12 mmol) in HCl / EA (4 M, 5 mL) was stirred at room temperature for 16 h. The mixture was concentrated to dryness, and 5 mL of TFA was added. The mixture was stirred at room temperature for 2 h and then at 60 °C for 5 h. The mixture was concentrated to dryness under high vacuum. 2 mL of NaOH (aq, 4 M) was added and extracted with CHCl (5 mL x 5). The combined extracts were washed with brine (10 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CH2Cl2 / MeOH (in NH3) = 10:1) to give the title product (15 mg, 38%). 1H NMR (400 MHz, CD3OD) δ 7.49 (s, 1H), 5.17 - 5.02 (m, 1H), 4.26 (d, J = 14.8 Hz, 1H), 3.92 (dd, J = 14.8, 5.2 Hz, 1H), 3.11 - 3.04 (m, 2H), 3.03 - 2.97 (m, 1H), 2.96 -2.86 (m, 1H), 2.70 - 2.51 (m, 2H), 2.46 - 2.34 (m, 1H), 1.83 - 1.70 (m, 1H), 1.67 - 1.55 (m, 1H), 1.55 - 1.39 (m, 2H), 1.36 (dd, MS: M / e 334 (M+1) + .

[0270] Compound B18: 7-(((R)-2-methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0271] [ka] Step A: (3R)-4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-3-methylpiperazine-1-tert-butyl formate.

[0272] [ka] To a mixture of 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazine-7-carbaldehyde (100 mg, 0.18 mmol) and (R)-tert-butyl 3-methylpiperazine-1-formate (72 mg, 0.36 mmol) in THF (2 mL) was added AcOH (25 mg, 0.42 mmol), followed by NaBH(OAc) (115 mg, 0.54 mmol), and the mixture was stirred for 16 h at room temperature. 2 mL of brine was added, and the mixture was extracted with EA (2 mL x 3). The combined extracts were washed with brine (2 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (PE / EA = 1:1) to give the title product (82 mg, 62%). MS: M / e 734 (M+1) + .

[0273] Step B: 7-(((R)-2-Methylpiperazin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0274] [ka] Tert-butyl (3R)-4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-3-methylpiperazine-1-formate (82 mg, 0.11 mmol) in HCl / EA (4 M, 5 mL) was stirred at room temperature for 16 h. The mixture was concentrated to dryness, and 5 mL of TFA was added. The mixture was stirred at room temperature for 2 h and then at 60 °C for 5 h. The mixture was concentrated to dryness under high vacuum. 2 mL of NaOH (aq, 4 M) was added and extracted with CHCl (5 mL x 5). The combined extracts were washed with brine (10 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CH2Cl2 / MeOH (in NH3) = 10:1) to give the title product (13 mg, 35%). 1H NMR (400 MHz, CD3OD) δ 7.49 (s, 1H), 5.21 - 5.01 (m, 1H), 4.25 (d, J = 14.8 Hz, 1H), 3.92 (dd, J = 14.8, 5.6 Hz, 1H), 3.06 - 2.93 (m, 3H), 2.92 - 2.81 (m, 1H), 2.64 - 2.45 (m, 2H), 2.43 - 2.31 (m, 1H), 1.82 - 1.70 (m, 1H), 1.67 - 1.55 (m, 1H), 1.54 - 1.40 (m, 2H), 1.36 (d, J = 6.0 Hz, 3H), 1.30 (d, J = 5.6 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 334 (M+1) + .

[0275] Compound B19: (S)-7-((1-(3-(methylamino)propyl)piperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0276] [ka] Step A: (3-oxopropyl)methyl tert-butylcarbamate.

[0277] [ka] A solution of oxalyl chloride (510 mg, 4.0 mmol) in CHCl (5 mL) was added to a solution of DMSO (624 mg, 8.0 mmol) in CHCl (5 mL) at −78 °C under N. The mixture was stirred for 20 min. A solution of (3-hydroxypropyl)(methyl) tert-butylcarbamate (500 mg, 2.64 mmol) in CHCl (5 mL) was added below −55 °C. The resulting mixture was stirred at −78 °C for 30 min and then at −50 °C for 30 min. A solution of EtN (1.54 g, 15.2 mmol) in CHCl (5 mL) was added, and the mixture was stirred at room temperature for 16 h. The mixture was diluted with 20 mL of CHCl, washed with brine (5 mL × 3), dried over NaSO, and concentrated. The resulting residue was purified by column chromatography (PE / EA = 5:1) to give the title product (180 mg, crude). MS: M / e 188 (M+1) + .

[0278] Step B: t-Butyl (S)-(3-(4-((4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)propyl)(methyl) tert-butylcarbamate.

[0279] [ka] To a mixture of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (20 mg, 0.063 mmol) and (3-oxopropyl)tert-butylcarbamate (26 mg, crude) in THF (1 mL) was added AcOH (20 mg, 0.33 mmol), followed by NaBH(OAc) (40 mg, 0.189 mmol), and the mixture was stirred for 16 h at room temperature. 2 mL of brine was added, and the mixture was extracted with EA (2 mL x 3). The combined extracts were washed with brine (2 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CHCl / MeOH (in NH) = 15:1) to give the title product (17 mg, 55%). MS: M / e 490 (M+1) + .

[0280] Step C: (S)-7-((1-(3-(methylamino)propyl)piperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0281] [ka] The product of Step B (17 mg, 0.035 mmol) in HCl / EA solution (4 M, 5 mL) was stirred at room temperature for 5 h. The mixture was concentrated, basified with NaOH (4 M, aq.), and extracted with CHCl (2 mL x 5). The combined extracts were washed with brine (5 mL x 3), dried over NaSO, and concentrated. The resulting residue was purified by preparative TLC (CHCl / MeOH (in NH) = 10:1) to give the title product (3.5 mg, 26%). 1H NMR (400 MHz, CD3OD) δ 7.35 (d, J = 5.2 Hz, 1H), 5.18 - 5.05 (m, 1H), 3.46 - 3.34 (m, 2H), 3.11 - 3.04 (m, 2H), 3.03 - 2.85 (m, 4H), 2.72 (s, 3H), 2.14 - 1.99 (m, 3H), 1.97 - 1.84 (m, 2H), 1.82 - 1.68 (m, 1H), 1.67 - 1.41 (m, 5H), 1.36 (d, J = 6.0 Hz, 1H), 0.97 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 390 (M+1) + .

[0282] Compound B20: 2-(((S)-pent-2-yl)oxy)-7-((1-(pyrrolidin-2-ylmethyl)piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 2-((4-((4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)methyl)pyrrolidine-1-formate [ka] To a stirred solution of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (20 mg, 0.063 mmol) and tert-butyl 2-formylpyrrolidine-1-formate (25 mg, 0.126 mmol) in THF (5 mL) was added AcOH (2 drops). The mixture was then stirred at room temperature for 30 minutes, after which NaBH(OAc) (27 mg, 0.126 mmol) was added. After the addition, the reaction mixture was stirred overnight. The reaction mixture was concentrated to give a residue, which was purified by preparative TLC (CHCl / MeOH=10:1) to give the desired compound (23 mg, 72.8%). MS: M / e 502 (M+1). + .

[0283] Step B: 2-(((S)-pent-2-yl)oxy)-7-((1-(pyrrolidin-2-ylmethyl)piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of the product of Step A (22 mg, 0.045 mmol) in EtOAc / HCl (4.0 M, 5 mL) was stirred overnight. The reaction mixture was concentrated to give a residue, which was purified by preparative HPLC to give the desired compound (10 mg). 1H NMR (400 MHz, DMSO-d6) δ 9.33 (s,1H), 9.08 (s,1H), 8.84 (s,1H), 8.14 (s,1H), 8.06 (s,1H), 7.37 (s, 1H), 5.06 - 4.94 (m, 1H), 3.94 (s, 1H), 3.66 - 3.30 (m, 4H), 3.24 (s, 2H), 3.08 - 2.71 (m, 4H), 2.22 - 2.10 (m, 1H), 2.09 - 1.74 (m, 5H), 1.73 - 1.60 (m, 2H), 1.61 - 1.34 (m, 5H), 1.28 (d, J = 6.0 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 402 (M+1) + .

[0284] Compound B21: 7-((4-(methylamino)piperidin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (1-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-4-yl)(methyl) tert-butylcarbamate [ka] To a solution of 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1 f][1,2,4]triazine-7-carbaldehyde (200 mg, 0.364 mmol) and methyl (piperidin-4-yl) tert-butylcarbamate (136 mg, 0.732 mmol) in THF (5 mL) was added AcOH (44 mg, 0.733 mmol) and NaBH(AcO) (233 mg, 1.09 mmol). The reaction mixture was stirred at 25 °C for 3 h. Upon completion, the reaction mixture was quenched with water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (80%) to give the title compound (230 mg, 85%). MS: M / e 748 (M+1) + .

[0285] Step B: 7-((4-(methylamino)piperidin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] The product of Step A (230 mg, 0.307 mmol) was dissolved in TFA (5 mL) under N. The reaction mixture was stirred at 70 °C for 12 h. Upon completion, the reaction mixture was quenched with aqueous NaHCO (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC under the following conditions: Column: XBridge Prep C18 OBD column 19 x 150 mm 5 um; Mobile phase A: water (0.1% TFA), Mobile phase B: ACN; Flow rate: 17 mL / min; Gradient: 5% B to 30% B in 11 min; 214 / 254 nm to give the title compound (64 mg, 30%). 1H NMR (400 MHz, DMSO-d6) δ 8.93 (br.s, 2H), 8.39 (s, 1H), 8.29 (s, 1H), 7.66 (s, 1H), 5.05 (dd, J = 12.4, 6.4 Hz, 1H), 4.57 (s, 2H), 3.57 (s, 3H), 3.20 - 3.03 (m, 3H), 2.55 (s, 3H), 2.19 (d, J = 12.4 Hz, 2H), 1.88 - 1.60 (m, 3H), 1.59 -1.47 (m, 1H), 1.46 - 1.31 (m, 2H), 1.28 (d, J = 6.4 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 348 (M+1) + .

[0286] Compound B22: 7-((4-((methylamino)methyl)piperidin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: ((1-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-4-yl)methyl)(methyl) tert-butylcarbamate [ka] To a solution of 4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1 f][1,2,4]triazine-7-carbaldehyde (200 mg, 0.364 mmol) and methyl (piperidin-4-ylmethyl) tert-butylcarbamate (166 mg, 0.728 mmol) in THF (5 mL) was added AcOH (44 mg, 0.733 mmol) and NaBH(AcO) (233 mg, 1.09 mmol). The reaction mixture was stirred at 25 °C for 3 h. Upon completion, the reaction mixture was quenched with water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (80%) to give the title compound (210 mg, 76%). MS: M / e 762 (M+1) + .

[0287] Step B: 7-((4-((methylamino)methyl)piperidin-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Under N2, ((1-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-4-yl)methyl)(methyl) tert-butylcarbamate (210 mg, 0.276 mmol) was dissolved in TFA (5 mL). The reaction mixture was stirred at 70 °C for 12 h. Upon completion, the reaction mixture was quenched with aqueous NaHCO3 (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC under the following conditions: Column: XBridge Prep C18 OBD column 19 x 150 mm 5 um; Mobile phase A: water (0.1% TFA), Mobile phase B: ACN; Flow rate: 17 mL / min; Gradient: 5% B to 30% B in 11 min; 214 / 254 nm to give the title compound (15 mg, 15%). 1 H NMR (400 MHz, DMSO-d6) δ 10.05 (br.s, 1H), 8.56 (br.s, 2H), 8.40 - 8.25 (m, 2H), 7.67 (s, 1H), 5.06 (dd, J = 12.4, 6.4 Hz, 1H), 4.54 (s, 2H), 3.45 - 3.35 (m, 2H), 3.02 (s, 3H), 2.82 (d, J = 4.4 Hz, 2H), 2.55 (t, J = 5.2 Hz, 3H), 1.90 (d, J = 13.2 Hz, 3H), 1.73 - 1.49 (m, 2H), 1.49 - 1.31 (m, 4H), 1.28 (d, J = 6.4 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 362 (M+1) + .

[0288] Compound B23: (S)-7-([1,4'-bipiperidin]-4-ylmethyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (S)-tert-butyl 4-((4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)-t-butyl-[1,4'-bipiperidine]-1'-formate [ka] A mixture of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (20 mg, 0.06 mmol), tert-butyl 4-oxopiperidine-1-formate (19 mg, 0.09 mmol), and titanium tetraisopropoxide (54 mg, 0.19 mmol) in EtOH (5 mL) was stirred at room temperature for 3 hours. Sodium borohydride (27 mg, 0.12 mmol) was then added and stirred at room temperature for 1 hour. The mixture was quenched with water (0.5 mL), extracted with DCM (20 mL), washed with water (5 mL), concentrated, and purified by column chromatography (DCM / MeOH = 20:1 to 3:1) to give the product (29 mg, 92.04%). MS: M / e 502 (M+1). + .

[0289] Step B: (S)-7-([1,4'-bipiperidin]-4-ylmethyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of the product of Step A (29 mg, 0.06 mmol) and TFA (0.5 mL) in DCM (3 mL) was stirred at room temperature for 2 h. The mixture was concentrated and purified by preparative HPLC to give the product (18 mg, 74.5%). 1H NMR (400 MHz, DMSO-d6) δ 9.40 (br.s, 1H), 8.73 (d, J = 9.1 Hz, 1H), 8.43 (d, J = 10.1 Hz, 1H), 8.11 (s,1H), 8.03 (s, 1H), 7.35 (s, 1H), 5.01 - 4.99 (m, 1H), 3.48 - 3.35 (m, 5H), 2.98 - 2.86 (m, 4H), 2.79 (d, J = 6.5 Hz, 2H), 2.15 (d, J = 12.1 Hz, 2H), 1.98 (s, 1H), 1.86 (d, J = 13.5 Hz, 2H), 1.79 - 1.69 (m, 2H), 1.69 - 1.62 (m, 1H), 1.60 - 1.42 (m, 3H), 1.42 - 1.32 (m, 2H), 1.28 (d, J = 6.1 Hz, 3H), 0.91 (t, J = 7.3 Hz, 3H) ppm. MS: M / e 402 (M+1) + .

[0290] Compound B24: 2-(4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)-7-azaspiro[3.5]non-2-ol [ka] Step A: tert-butyl 2-(4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)-2-hydroxy-7-azaspiro[3.5]nonane-7-formate [ka] To a solution of N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.576 mmol) in THF (8 mL) was added n-BuLi (1.8 mL, 2.88 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-formate (165 mg, 0.691 mmol) was added. The reaction mixture was warmed to −78 °C and stirred for 2.5 h. Upon completion, the reaction mixture was quenched with aqueous NHCl (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (40%) to give the title compound (210 mg, 48%). MS: M / e 761 (M+1). + .

[0291] Step B: 2-(4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)-7-azaspiro[3.5]non-2-ol [ka] Under N2, tert-butyl 2-(4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)-2-hydroxy-7-azaspiro[3.5]nonane-7-formate (210 mg, 0.276 mmol) was dissolved in TFA (5 mL) and HO (0.5 mL). The reaction mixture was stirred at 35 °C for 12 h. Upon completion, the reaction mixture was quenched with aqueous NaHCO3 (30 mL) and extracted with EtOAc (3 x 80 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC under the following conditions: Column: XBridge Prep C18 OBD column 19 x 150 mm 5 um; Mobile phase A: water (0.1% TFA), Mobile phase B: ACN; Flow rate: 17 mL / min; Gradient: 5% B to 45% B in 11 min; 214 / 254 nm to give the title compound (51 mg, 51%). 1 H NMR (400 MHz, DMSO-d6) δ 8.27 (br.s, 2H), 8.20 -7.98 (m, 2H), 7.43 (s, 1H), 5.45 (s, 1H), 4.96 (dd, J = 12.4, 6.4 Hz, 1H), 3.15-2.80 (m, 5H), 2.74-2.64 (m, 2H), 2.18 (d, J = 12.6 Hz, 2H), 1.90 (s, 2H), 1.72-1.46 (m, 4H), 1.45-1.32 (m, 2H), 1.28 (t, J = 6.4 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 361 (M+1) + .

[0292] Compound B25: 7-(azepan-4-ylmethyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)azepane-1-formate [ka] To a stirred solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.383 mmol) in THF (8 mL) cooled to -78 °C and under a nitrogen atmosphere, n-BuLi (1.6 M in hexanes, 0.78 mmol, 0.48 mL) was added dropwise. After stirring for 30 min, a solution of tert-butyl 4-formylazepane-1-formate (150 mg, 0.66 mmol) in THF (2 mL) was slowly added. The reaction mixture was slowly warmed to room temperature and stirred overnight. The reaction mixture was added to saturated ammonium chloride solution and extracted with EtOAc (15 mL x 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by column chromatography to give the title product (120 mg, 41.3%). MS: M / e 748.9 (M+1) + .

[0293] Step B: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(azepan-4-yl)methanol [ka] To a stirred mixture of the product of Step A (120 mg, 0.16 mmol) in TFA (8 ml) was added HO (2 ml). After the addition, the reaction mixture was stirred at 30 °C overnight. The reaction mixture was cooled to room temperature and concentrated in vacuo. 1 M HCl solution (20 ml) was added to the residue and filtered. The filtrate was extracted with DCM (20 ml). The pH of the aqueous phase was adjusted to 12-13 with 2 M NaOH aqueous solution and extracted with DCM (20 mL x 3). The organic phase was washed with brine, dried over NaSO, and concentrated in vacuo to give the product (35 mg, 62.5%), which was used directly in the next step. MS: M / e 349 (M+1) + .

[0294] Step C: 7-(azepan-4-ylmethyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a stirred mixture of (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(azepan-4-yl)methanol (35 mg, 0.1 mmol) in TFA (5 mL) was added EtSiH (5 mL). After the addition, the reaction mixture was stirred at 80 °C for 2 days. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by preparative HPLC to give the desired compound (10 mg, 22.4%). 1H NMR (400 MHz, MeOH-d6) δ 7.59 (s, 1H), 5.18 - 5.13 (m, 1H), 3.44 - 3.36 (m, 2H), 3.28 (s, 1H), 3.14 (m, 2H), 2.96 (dd, J = 16.6, 7.0 Hz, 2H), 2.10 - 1.95 (m, 2H), 1.83 - 1.75 (m, 2H), 1.72 - 1.61 (m, 2H), 1.53 - 1.44 (m, 4H), 1.39 (d, J = 6.1 Hz, 3H), 1.09 - 1.04 (m, 1H), 0.99 (t, J = 7.3 Hz, 3H) ppm. MS: M / e 333 (M+1) + .

[0295] Compound B26: 2-(((S)-pent-2-yl)oxy)-7-(pyrrolidin-3-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 3-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)pyrrolidine-1-formate [ka] To a stirred solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.383 mmol) in THF (8 mL) cooled to -78 °C and under a nitrogen atmosphere, n-BuLi (1.6 M in hexanes, 0.78 mmol, 0.48 mL) was added dropwise. After stirring for 30 min, a solution of tert-butyl 3-formylpyrrolidine-1-formate (150 mg, 0.75 mmol) in THF (2 mL) was slowly added. The reaction mixture was slowly warmed to room temperature and stirred overnight. The reaction mixture was added to saturated ammonium chloride solution and extracted with EtOAc (15 mL x 3). The combined organic phase was washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by column chromatography to give the title product (110 mg, 40%). MS: M / e 721 (M+1) + .

[0296] Step B: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(pyrrolidin-3-yl)methanol [ka] To a stirred mixture of the product of Step A (110 mg, 0.152 mmol) in TFA (8 ml) was added HO (2 ml). After the addition, the reaction mixture was stirred at 30 °C overnight. The reaction mixture was cooled to room temperature and concentrated in vacuo. 1 M HCl solution (20 ml) was added to the residue and filtered. The filtrate was extracted with DCM (20 ml). The pH of the aqueous phase was adjusted to 12-13 with 2 M aqueous NaOH and extracted with DCM (20 mL x 3). The organic phase was washed with brine, dried over NaSO, and concentrated in vacuo to give the product (30 mg, 61.4%), which was used directly in the next step. MS: M / e 321 (M+1) + .

[0297] Step C: 2-(((S)-pent-2-yl)oxy)-7-(pyrrolidin-3-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a stirred mixture of the product of Step B (30 mg, 0.093 mmol) in TFA (5 mL) was added EtSiH (5 mL). After the addition, the reaction mixture was stirred at 80 °C for 3 days. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by preparative HPLC to give the desired compound (12 mg, 32%). 1 H NMR (400 MHz, MeOH-d6) δ 7.90 (s, 1H), 5.44 - 5.40 (m, 1H), 3.78 - 3.66 (m, 2H), 3.56 - 5.53 (m, 2H), 3.37 (d, J = 7.1 Hz, 2H), 3.34 - 3.25 (m, 1H), 3.16 - 3.13 (m, 1H), 2.50 - 2.47 (m, 1H), 2.11 - 2.03 (m, 2H), 1.89 - 1.85 (m, 1H), 1.82 - 1.68 (m, 2H), 1.64 (d, J = 6.0 Hz, 3H), 1.23 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 305 (M+1) + .

[0298] Compound B27: 7-((2-methylpiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-(methylol)-2-methylpiperidine-1-formate [ka] To a solution of 1-(t-butoxycarbonyl)-2-methylpiperidine-4-carboxylic acid (243 mg, 1 mmol) in THF (10 mL) was added BH3-THF (1 M, 3 mL, 3 mmol) at 0°C. The reaction mixture was stirred at room temperature overnight. Aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated to give the product (220 mg, 100%), which was used directly in the next step. MS: m / e 230 (M+1) + .

[0299] Step B: tert-butyl 4-formyl-2-methylpiperidine-1-formate [ka] Dess-Martin periodinane (636 mg, 1.5 mmol) was added to a solution of tert-butyl 4-(methylol)-2-methylpiperidine-1-formate (220 mg, 1 mmol) in DCM (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. Aqueous NaHCO3 was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (140 mg, 61.7%). 1 H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H), 4.28 (td, J = 6.6, 4.5 Hz, 1H), 3.85 (ddd, J = 13.9, 5.5, 2.5 Hz, 1H), 2.91 (ddd, J = 13.9, 12.7, 3.8 Hz, 1H), 2.50 (t, J = 4.7 Hz, 1H), 2.15 - 2.09 (m, 1H), 2.08 - 2.03 (m, 1H), 1.91 (ddd, J = 14.1, 6.4, 2.5 Hz, 1H), 1.71 (dt, J = 13.3, 6.4 Hz, 1H), 1.50 - 1.40 (m, 9H), 1.06 (d, J = 6.9 Hz, 3H). MS: m / e228 (M+1)+ .

[0300] Step C: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-2-methylpiperidine-1-formate [ka] To a solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.38 mmol) in THF (8 mL) was added a solution of n-BuLi (1.6 M, 0.48 mL, 0.76 mmol) dropwise, maintaining the temperature between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formyl-2-methylpiperidine-1-formate (140 mg, 0.63 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (110 mg, crude yellow oil). MS: M / e 749 (M+1) + .

[0301] Step D: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(2-methylpiperidin-4-yl)methanol [ka] To a mixture of the product of Step C (110 mg, crude) in TFA (8 mL) was added HO (4 mL), and the resulting mixture was stirred at room temperature for 2 days. The mixture was concentrated to dryness. HO was added to the residue and filtered. The filtrate was washed with DCM, and the pH was adjusted to 12-13 with 2M NaOH solution. The solution was extracted with DCM (20 mL x 3). The organic phase was washed with brine, dried over NaSO, filtered, and concentrated to give the target compound (35 mg), which was used directly in the next step. MS: M / e 349 (M+1) + .

[0302] Step E: 7-((2-methylpiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step D (35 mg, crude) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85 °C for 2 h. The mixture was cooled to room temperature and concentrated to dryness. The residue was purified by preparative HPLC to give the desired compound (17 mg, 34.8%, over three steps). 1 H NMR (400 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.13 (br.s, 3H), 7.46 (s, 1H), 5.00 (m, 1H), 3.27 (s, 2H), 3.09 (s, 1H), 2.87 (s, 2H), 2.77 (s, 1H), 2.00 (s, 1H), 1.78 (s, 2H), 1.66 (s, 1H), 1.57 (s, 1H), 1.38 (s, 3H), 1.28 (d, J = 6.0 Hz, 3H), 1.16 (d, J = 6.2 Hz, 3H), 1.11 (d, J = 10.9 Hz, 1H), 0.91 (t, J = 7.3 Hz, 3H) ppm. MS: M / e 333 (M+1) + .

[0303] Compound B28: 3-((4-amino-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hex-1-ol [ka] Step A: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-((1-((t-butyldimethylsilyl)oxy)hex-3-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 7-bromo-2-((1-((t-butyldimethylsilyl)oxy)hex-3-yl)oxy)-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (500 mg, 0.671 mmol) in THF (10 mL) was added n-BuLi (0.9 mL, 1.44 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, tert-butyl 4-formylpiperidine-1-formate (215 mg, 1.01 mmol) was added. The reaction mixture was stirred at −78 °C for 3.5 h. Upon completion, the reaction mixture was quenched with aqueous NH Cl (20 mL) and extracted with DCM (3 × 30 mL). The combined organic layers were dried over Na SO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (50%) to give the title compound (310 mg, 53%). MS: M / e 879 (M+1) + .

[0304] Step B: 3-((4-amino-7-(hydroxy(piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hex-1-ol [ka] Under N2, tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-((1-((t-butyldimethylsilyl)oxy)hex-3-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate (290 mg, 0.329 mmol) was dissolved in TFA (8 mL) and HO (0.8 mL). The reaction mixture was stirred at 40 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (10 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust pH to 2-3. The aqueous phase was washed with DCM (3 x 50 mL), basified with 2N NaOH to adjust pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 60 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the title compound (110 mg, 92%). MS: M / e 365 (M+1) + .

[0305] Step C: 3-((4-amino-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hex-1-ol [ka] Under N2, 3-((4-amino-7-(hydroxy(piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)hex-1-ol (110 mg, 0.301 mmol) was dissolved in TFA (4 mL) and Et3SiH (4 mL). The reaction mixture was stirred at 90 °C for 12 h. Upon completion, the solvent was removed under vacuum. The residue was diluted with water (10 mL) and DCM (20 mL), and the aqueous phase was acidified with 1 N HCl to adjust pH to 2-3. The aqueous phase was washed with DCM (3 x 50 mL), basified with 2 N LiOH to adjust pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 60 mL). The combined organic layers were dried over Na2SO4 and concentrated under vacuum to give a residue. The residue was purified by preparative HPLC under the following conditions: Column: XBridge Prep C18 OBD column 19 x 150 mm 5 um; Mobile phase A: water (0.1% TFA), Mobile phase B: ACN; Flow rate: 17 mL / min; Gradient: 10% B to 30% B in 12 min; 214 / 254 nm to give the title compound (20 mg, 19%). 1 H NMR (400 MHz, CD3OD) δ 7.42 (s, 1H), 5.30-5.10 (m, 1H), 3.75-3.59 (m, 2H), 3.39 (d, J = 12.4 Hz, 2H), 3.05-2.85 (m, 4H), 2.64 (s, MS: M / e 349 (M+1) + .

[0306] Compound B29: 7-(cyclohexylmethyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(cyclohexyl)methanol [ka] To a solution of N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (500 mg, 0.959 mmol) in THF (10 mL) was added n-BuLi (1.8 mL, 2.88 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, cyclohexylformaldehyde (161 mg, 1.438 mmol) was added. The reaction mixture was stirred at −78 °C for 2.5 h. Upon completion, the reaction mixture was quenched with aqueous NHCl (30 mL) and extracted with DCM (3 × 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (40%) to give the title compound (560 mg, 92%). MS: M / e 634 (M+1) + .

[0307] Step B: (4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(cyclohexyl)methanol [ka] Under N2, (4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(cyclohexyl)methanol (560 mg, 0.883 mmol) was dissolved in TFA (8 mL) and HO (0.8 mL). The reaction mixture was stirred at 35 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was extracted with DCM (3 x 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the residue. The residue was purified by column chromatography on silica gel eluting with methanol (NH3) in methylene chloride (20%) to give the title compound (190 mg, 65%). MS: M / e 334 (M+1). + .

[0308] Step C: 7-(cyclohexylmethyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Under N2, (4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(cyclohexyl)methanol (190 mg, 0.569 mmol) was dissolved in TFA (5 mL) and Et3SiH (5 mL). The reaction mixture was stirred at 90 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with aqueous NaHCO3 (20 mL) and DCM (20 mL), and the aqueous phase was extracted with DCM (3 x 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (66%) in petroleum ether to give the title compound (20 mg, 11%). 1H NMR (400 MHz, CD3OD) δ 7.41 (s, 1H), 5.15-5.05 (m, 1H), 2.77 (d, J = 6.8 Hz, 2H), 1.88-1.56 (m, 9H), 1.55-1.40 (m, 2H), 1.37 (d, J = MS: M / e 318 (M+1) + .

[0309] Compound B30: 7-(((1s,3S)-3-aminocyclobutyl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: ((1R,3s)-3-((S)-(4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)cyclobutyl) tert-butylcarbamate [ka] At −78° C. under a N2 atmosphere, n-BuLi (1.6 M, 0.55 mL, 0.88 mmol) was added to a solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.57 mmol) in THF (3 mL). The mixture was stirred at −78° C. for 30 minutes. Then, at −78° C., a solution of ((1s,3s)-3-formylcyclobutyl) tert-butylcarbamate (204 mg, 1.02 mmol) in THF (2 mL) was added. The reaction was warmed to room temperature and stirred for 30 minutes. The reaction was quenched with saturated aqueous NH4Cl at room temperature and extracted with EA (10 mL × 2). The combined organic phase was washed with brine (10 mL x 2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography to give the title compound (240 mg, yield: 58%). MS: M / e 721 (M+1). + .

[0310] Step B: (S)-(4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)((1s,3R)-3-aminocyclobutyl)methanol [ka] ((1R,3s)-3-((S)-(4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)cyclobutyl) tert-butylcarbamate (240 mg, 0.33 mmol) in TFA / HO (9:1, 5 mL) was stirred at room temperature for 20 h. The reaction was concentrated under reduced pressure. 10 mL HO was added. The mixture was stirred at room temperature for 10 min and then filtered. The filtrate was extracted with DCM (5 mL x 2) to remove impurities. The aqueous layer was basified to pH > 10 with aqueous NaOH (4 M) and extracted with DCM / IPA (5:1, 5 mL x 3). The combined extracts were washed with brine (5 mL x 3), dried over Na2SO4, and concentrated to give the title product (55 mg, yield: 51%). MS: M / e 321 (M+1). + .

[0311] Step C: 7-(((1s,3S)-3-aminocyclobutyl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of (S)-(4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)((1S,3R)-3-aminocyclobutyl)methanol (55 mg, 0.17 mmol), TFA (5 mL), and EtSiH (5 mL) was stirred at 60 °C for 16 h. The reaction was concentrated under reduced pressure. The residue was dissolved in HO (2.5 mL) and extracted with DCM (2 mL × 3). The organic phase was discarded. The inorganic phase was basified with aqueous NaOH (4 M) to pH > 10. The mixture was extracted with DCM / iPrOH (5:1, 2 mL × 5). The combined organic phase was washed with brine (5 mL × 2), dried over NaSO, and concentrated. The residue was purified by preparative TLC (DCM / MeOH(NH3) = 10:1) to give the title compound (8 mg, yield: 15%). 1H NMR (400 MHz, CD3OD) δ 7.28 (s, 1H), 5.20 - 5.01 (m, 1H), 3.51 - 3.35 (m, 1H), 2.96 (d, J = 6.0 Hz, 2H), 2.58 - 2.32 (m, 3H), 1.83 - 1.55 (m, 4H), 1.54 - 1.39 (m, 2H), 1.36 (d, J = 6.0 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 305 (M+1) + .

[0312] Compound B31: (S)-7-((4-(methylamino)cyclohexyl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (4-(methylamino)cyclohexyl)methanol [ka] To a mixture of 4-((t-butoxycarbonyl)amino)cyclohexane-1-formic acid (5 g, 20.57 mmol) in THF (10 mL) was added LAH (2.35 g, 61.73 mmol) in a batch at 0 °C. After stirring at room temperature for 1 h, the mixture was warmed to 60 °C and stirred overnight. The mixture was quenched with NaOH solution (10 mL) and extracted with DCM (50 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated to give the target compound (2.20 g, 74.77%) as a colorless oil. MS: M / e 144 (M+1) + .

[0313] Step B: (4-(methylol)cyclohexyl)(methyl) tert-butylcarbamate [ka] A mixture of (4-(methylamino)cyclohexyl)methanol (2 g, 13.99 mmol), di-tert-butyl dicarbonate (3.66 g, 16.78 mmol), and DIPEA (3.61 g, 27.97 mmol) in DCM (30 mL) was stirred at room temperature for 2 h. The mixture was quenched with water (10 mL) and extracted with DCM (30 mL x 3). The combined organic layers were washed with water and brine, dried over Na2SO4, and concentrated to give a colorless oil, (4-(methylol)cyclohexyl)(methyl)tert-butylcarbamate (3.26 g, 95.92%). MS: M / e 244 (M+1). + .

[0314] Step C: (4-Formylcyclohexyl)(methyl) tert-butylcarbamate [ka] A mixture of (4-(methylol)cyclohexyl)(methyl) tert-butylcarbamate (3 g, 12.35 mmol) and DMP (6.28 g, 14.82 mmol) in DCM (30 mL) was stirred at room temperature for 2 hours. The mixture was filtered, diluted with PE, filtered, and concentrated to give the desired compound (2.32 g, 77.98%) as a yellow oil. MS: M / e 242 (M+1) + .

[0315] Step D: (4-((4-(bis(3,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)cyclohexyl)(methyl) tert-butylcarbamate [ka] To a solution of (S)-N,N-bis(3,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.3839 mmol) in THF (5 mL) was added n-butyllithium (0.29 mL, 0.4607 mmol) at -78 °C and stirred for 1 h. Then, a solution of (4-formylcyclohexyl)(methyl) tert-butylcarbamate (139 mg, 0.5758 mmol) in THF (1 mL) was added dropwise at -78 °C. After the addition, the mixture was warmed to room temperature and stirred for 3 h. The mixture was quenched with saturated ammonium chloride solution (5 mL) and extracted with DCM (20 mL x 3). The combined organic layers were washed with brine, dried over NaSO, concentrated, and purified by column chromatography (DCM / MeOH = 20:1 to 5:1) to give the target compound (198 mg, 67.60%) as a yellow oil. MS: M / e 763 (M+1). + .

[0316] Step E: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(4-(methylamino)cyclohexyl)methanol [ka] A solution of (4-((4-(bis(3,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)cyclohexyl)(methyl) tert-butylcarbamate (198 mg, 0.2595 mmol) in TFA (2 mL) was stirred at room temperature overnight. The mixture was concentrated and purified by preparative TLC to give a white solid, (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(4-(methylamino)cyclohexyl)methanol (70 mg, 74.52%). MS: M / e 363 (M+1). + .

[0317] Step F: (S)-7-((4-(methylamino)cyclohexyl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] A mixture of (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(4-(methylamino)cyclohexyl)methanol (70 mg, 0.1934 mmol) and triethylsilane (1 mL) in TFA (2 mL) was stirred at 90° C. overnight. The mixture was concentrated and purified by preparative HPLC to give the desired compound (35 mg, 52.31%). 1 H NMR (400 MHz, DMSO-d6) δ 8.35 (br.s, 2H), 8.08 ( s,1H ), 8.01 (s, 1H), 7.32 (s, 1H), 4.97 (dd, J = 12.5, 6.5 Hz, 1H), 2.89 (s, 1H), 2.70 (d, J = 6.2 Hz, 2H), 2.53 (d, J = 5.5 Hz, 2H), 2.00 (d, J = 10.4 Hz, 2H), 1.71 (m, 4H), 1.58 - 1.50 (m, 1H), 1.42 - 1.32 (m, 2H), 1.28 (d, J = 6.1 Hz, 3H), 1.26 - 1.13 (m, 3H), 1.13 - 0.98 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 347 (M+1) + .

[0318] Compound B32: (S)-7-((1-methylpiperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0319] [ka] To a mixture of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (65 mg, 0.2 mmol), formaldehyde (30%, 0.5 mL) in MeOH (2 mL) was added NaBHCN (40 mg, 0.63 mmol) at room temperature, and the mixture was stirred for 16 hours. The mixture was concentrated, diluted with EA (10 mL), washed with brine (10 mL x 3), dried over NaSO, and concentrated under reduced pressure. The residue was purified by preparative TLC to give the title compound (18 mg, yield: 27%). 1 H NMR (400 MHz, CD3OD) δ 7.32 (s, 1H), 5.18 - 5.01 (m, 1H), 3.02 (d, J = 12.0 Hz, 2H), 2.85 (d, J = 6.8 Hz, 2H), 2.40 (s, 3H), 2.24 (t, J = 12.0 Hz, 2H), 1.98 - 1.82 (m, 1H), 1.82 - 1.70 (m, 3H), 1.65 - 1.55 (m, 1H), 1.54 - 1.38 (m, 4H), 1.36 (d, J = 6.0 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 333 (M+1) + .

[0320] Compound B33: 7-(((1R,5S,6s)-3-azabicyclo[3.1.0]hex-6-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0321] [ka] Step A: (1R,5S,6r)-6-((S)-(4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-3-azabicyclo[3.1.0]hexane-3-tert-butyl formate [ka] At −78°C under a N atmosphere, n-BuLi (1.6 M, 0.55 mL, 0.88 mmol) was added to a solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.57 mmol) in THF (3 mL). The mixture was stirred at −78°C for 30 minutes. Then, at −78°C, a solution of tert-butyl (1R,5S,6r)-6-formyl-3-azabicyclo[3.1.0]hexane-3-formate (218 mg, 1.03 mmol) in THF (2 mL) was added. The reaction was warmed to room temperature and stirred for 30 minutes. The reaction was quenched with saturated aqueous NH4Cl at room temperature and extracted with EA (10 mL × 2). The combined organic phase was washed with brine (10 mL x 2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography to give the title compound (270 mg, yield: 65%). MS: M / e 733 (M+1) + .

[0322] Step B: (S)-(4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)((1R,5S,6r)-3-azabicyclo[3.1.0]hex-6-yl)methanol.

[0323] [ka] tert-Butyl (1R,5S,6r)-6-((S)-(4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-3-azabicyclo[3.1.0]hexane-3-formate (270 mg, 0.37 mmol) in TFA / HO (9:1, 5 mL) was stirred at room temperature for 20 h. The reaction was concentrated under reduced pressure. 10 mL HO was added. The mixture was stirred at room temperature for 10 min and then filtered. The filtrate was extracted with DCM (5 mL x 2) to remove impurities. The aqueous layer was basified to pH > 10 with aqueous NaOH (4 M) and extracted with DCM / IPA (5:1, 5 mL x 3). The combined extracts were washed with brine (5 mL x 3), dried over Na2SO4, and concentrated to give the title product (35 mg, yield: 26%). MS: M / e 333 (M+1). + .

[0324] Step C: 7-(((1R,5S,6s)-3-Azabicyclo[3.1.0]hex-6-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0325] [ka] A mixture of (S)-(4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)((1R,5S,6r)-3-azabicyclo[3.1.0]hex-6-yl)methanol (35 mg, 0.1 mmol), TFA (5 mL), and EtSiH (5 mL) was stirred at 60 °C for 16 h. The reaction was concentrated under reduced pressure. The residue was dissolved in HO (2.5 mL) and extracted with DCM (2 mL × 3). The organic phase was discarded. The inorganic phase was basified with aqueous NaOH (4 M) to pH > 10. The mixture was extracted with DCM / iPrOH (5:1, 2 mL × 5). The combined organic phase was washed with brine (5 mL × 2), dried over NaSO, and concentrated. The residue was purified by preparative TLC (DCM / MeOH(NH3) = 10:1) to give the title compound (12 mg, yield: 36%). 1 H NMR (400 MHz, CD3OD) δ 7.36 (s, 1H), 5.19 - 5.01 (m, 1H), 3.22 (d, J = 11.6 Hz, 2H), 3.13 (d, J = 11.6 Hz, 2H), 2.85 (d, J = 6.8 Hz, 2H), 1.86 - 1.66 (m, 3H), 1.65 - 1.54 (m, 1H), 1.54 - 1.38 (m, 2H), 1.35 (d, J = 6.0 Hz, 3H), 1.18 - 1.05 (m, 1H), 0.96 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 317 (M+1) + .

[0326] Step B34: 2-((4-amino-7-(piperidin-4-ylmethyl)imidazo[2,1f][1,2,4]triazin-2-yl)oxy)pent-1-ol [ka] Step A: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-((1-((t-butyldimethylsilyl)oxy)pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 7-bromo-2-((1-((t-butyldimethylsilyl)oxy)pent-2-yl)oxy)-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (980 mg, 1.34 mmol) in THF (20 mL) was added n-BuLi (2.5 mL, 4.0 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, tert-butyl 4-formylpiperidine-1-formate (428 mg, 2.01 mmol) was added. The reaction mixture was stirred at −78 °C for 2.5 h. Upon completion, the reaction mixture was quenched with aqueous NH Cl (30 mL) and extracted with DCM (3 × 50 mL). The combined organic layers were dried over Na SO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (60%) to give the title compound (1 g, 86%). MS: M / e 865 (M+1) + .

[0327] Step B: 2-((4-amino-7-(hydroxy(piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)pent-1-ol [ka] Under N2, tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-((1-((t-butyldimethylsilyl)oxy)pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate (1 g, 1.156 mmol) was dissolved in TFA (9 mL) and HO (1 mL). The reaction mixture was stirred at 40 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust pH to 2-3. The aqueous phase was washed with DCM (3 x 50 mL), basified with 2N NaOH to adjust pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the title compound (350 mg, 86%). MS: M / e 351 (M+1) + .

[0328] Step C: 2-((4-amino-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)pent-1-ol [ka] Under N2, 2-((4-amino-7-(hydroxy(piperidin-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-2-yl)oxy)pent-1-ol (350 mg, 1.0 mmol) was dissolved in TFA (5 mL) and Et3SiH (5 mL). The reaction mixture was stirred at 90 °C for 12 h. Upon completion, the solvent was removed under vacuum. The residue was diluted with water (10 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust the pH to 2-3. The aqueous phase was washed with DCM (3 x 50 mL), basified with 2N NaOH to adjust the pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 60 mL). The combined organic layers were dried over Na2SO4 and concentrated under vacuum to give a residue. The residue was purified by preparative TLC (DCM / CH3OH (NH3) = 10 / 1) to give the title compound (10 mg).1 H NMR (400 MHz, CD3OD) δ 7.43 (s, 1H), 5.15-5.08 (m, 1H), 3.75-3.71 (m, 2H), 3.38 (d, J = 12.0 Hz, 2H), 3.00-2.85 (m, 4H), 2.22-2.09 (m, 1H), 1.98-1.85 (m, 2H), 1.78-1.65 (m, 2H), 1.55-1.38 (m, 4H), 0.97 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 335 (M+1) + .

[0329] Compound B35: (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylidenemethyl)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0330] [ka] Step A: (S)-4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methylene)piperidine-1-tert-butyl formate.

[0331] [ka] A mixture of (S)-7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.33 mmol), tert-butyl 4-((4,4,5,5-tetramethyl-1,3,2-dioxoboran-2-yl)methylene)piperidine-1-formate (215 mg, 0.67 mmol), Pd(PPh) (38 mg, 0.03 mmol), KCO (93 mg, 0.67 mmol), and HO (0.5 mL) in dioxane (2 mL) was stirred at 100 °C for 16 h. The mixture was diluted with EA (10 mL), washed with brine (10 mL × 3), dried over NaSO, and concentrated. The residue was purified by preparative TLC to give the title compound (100 mg, yield: 42%). MS: M / e 717 (M+1) + .

[0332] Step B: (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylidenemethyl)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0333] [ka] (S)-tert-Butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methylene)piperidine-1-formate (100 mg, 0.14 mmol) in TFA / HO (9:1, 5 mL) was stirred at room temperature for 16 h. The reaction was concentrated under reduced pressure. 5 mL HO was added. The mixture was stirred at room temperature for 2 h and then filtered. The filtrate was basified with aqueous NaOH (4 M) to pH > 10 and extracted with DCM / IPA (5:1, 5 mL x 5). The combined extracts were washed with brine (10 mL x 3), dried over NaSO, and concentrated. The crude product was purified by preparative TLC (DCM / MeOH(NH3) = 10:1) to give the title product (12 mg, yield: 27%). 1H NMR (400 MHz, CD3OD) δ 7.55 (s, 1H), 6.48 (s, 1H), 5.23 - 5.04 (m, 1H), 3.11 (t, J = 6.0 Hz, 2H), 3.06 (t, J = 6.0 Hz, 2H), 2.72 (t, J = 5.6 Hz, 2H), 2.58 (t, J = 5.6 Hz, 2H), 1.85 - 1.67 (m, 1H), 1.67 - 1.54 (m, 1H), 1.54 - 1.38 (m, 2H), 1.35 (d, J = 6.0 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 317 (M+1) + .

[0334] Step B36: 2-(pent-2-yloxy)-7-((tetrahydro-2H-pyran-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(tetrahydro-2H-pyran-4-yl)methanol [ka] To a solution of N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (500 mg, 0.959 mmol) in THF (10 mL) was added n-BuLi (1.8 mL, 2.88 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, tetrahydro-2H-pyran-4-carbaldehyde (164 mg, 1.439 mmol) was added. The reaction mixture was stirred at −78 °C for 2.5 h. Upon completion, the reaction mixture was quenched with aqueous NHCl (30 mL) and extracted with DCM (3 × 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (60%) to give the title compound (400 mg, 66%). MS: M / e 636 (M+1) + .

[0335] Step B: (4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(tetrahydro-2H-pyran-4-yl)methanol [ka] Under N2, (4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(tetrahydro-2H-pyran-4-yl)methanol (400 mg, 0.629 mmol) was dissolved in TFA (8 mL) and HO (0.8 mL). The reaction mixture was stirred at 35 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was extracted with DCM (3 x 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the residue. The residue was purified by column chromatography on silica gel eluting with methanol (NH3) in methylene chloride (10%) to give the title compound (180 mg, 85%). MS: M / e 335 (M+1). + .

[0336] Step C: 2-(pent-2-yloxy)-7-((tetrahydro-2H-pyran-4-yl)methyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Under N2, (4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(tetrahydro-2H-pyran-4-yl)methanol (180 mg, 0.537) was dissolved in TFA (5 mL) and Et3SiH (5 mL). The reaction mixture was stirred at 90 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with aqueous NaHCO3 (20 mL) and DCM (20 mL), and the aqueous phase was extracted with DCM (3 × 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the residue. The residue was purified by preparative TLC (PE / EtOAc = 2 / 1) to give the title compound (70 mg, 41%). 1 H NMR (400 MHz, DMSO-d6) δ 8.17-7.89 (m, 2H), 7.30 (s, 1H), 5.04-4.98 (m, 1H), 3.81 (d, J = 9.2 Hz, 2H), 3.23 (t, J = 11.6 Hz, 2H), 2.73 (d, J = 6.8 Hz, 2H), 1.94 (s, 1H), 1.76-1.61 (m, 1H), 1.59-1.44 (m, 3H), 1.42-1.31 (m, 2H), 1.31-1.16 (m, 5H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 320 (M+1) + .

[0337] Compound B37: (S)-2-(pent-2-yloxy)-N7-(piperidin-4-yl)imidazo[2,1-f][1,2,4]triazine-4,7-diamine [ka] Step A: (S)-tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)amino)piperidine-1-formate [ka] To a solution of (S)-7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.5 mmol) in toluene (10 mL) was added tert-butyl 4-aminopiperidine-1-formate (200 mg, 1 mmol), Pd(dba) (23 mg, 0.025 mmol), t-BuONa (96 mg, 1 mmol), and BINAP (600 mg, 1 mmol). The reaction mixture was protected under a N atmosphere and stirred at 100 °C overnight. HO was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (160 mg, 44.4%). MS: m / e: 720 (M+1). + .

[0338] Step B: (S)-2-(pent-2-yloxy)-N7-(piperidin-4-yl)imidazo[2,1-f][1,2,4]triazine-4,7-diamine [ka] To a mixture of (S)-tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)amino)piperidine-1-formate (160 mg, 0.22 mmol) in TFA (8 mL) was added HO (2 mL), and the resulting mixture was stirred at room temperature for 2 days. The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give the desired compound (17 mg, 34.8%). 1H NMR (400 MHz, DMSO-d6) δ 8.72 (s, 1H), 8.49 (s, 1H), 7.88 (s, 2H), 6.90 (s, 1H), 5.45 (s, 1H), 5.05 (dd, J = 12.3, 5.9 Hz, 1H), 3.48 (s, 2H), 2.95 (m, 2H), 2.06 (d, J = 13.4 Hz, 2H), 1.70 (m, 2H), 1.63 - 1.48 (m, 2H), 1.37 (dt, J = 15.6, 7.7 Hz, 2H), 1.25 (d, J = 6.1 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 320 (M+1) + .

[0339] Compound B38: (S)-7-((1-(2-aminomethyl)piperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (S)-(2-(4-((4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)ethyl)tert-butylcarbamate.

[0340] [ka] To a mixture of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (50 mg, 0.16 mmol), (2-oxoethyl) tert-butylcarbamate (50 mg, 0.31 mmol) in MeOH (2 mL) was added NaBHCN (20 mg, 0.31 mmol) at room temperature, and the mixture was stirred for 16 hours. The mixture was concentrated, diluted with DCM (10 mL), washed with brine (10 mL x 3), dried over NaSO, and concentrated under reduced pressure. The residue was purified by preparative TLC (DCM / MeOH(NH) = 10:1) to give the title compound (45 mg, yield: 63%). MS: M / e 462 (M+1). + .

[0341] Step B: (S)-7-((1-(2-aminomethyl)piperidin-4-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a solution of (S)-2-(4-((4-amino-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)ethyl) tert-butylcarbamate (45 mg, 0.1 mmol) in DCM (5 mL) was added TFA (2 mL), and the solution was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure. The resulting residue was treated with 5 mL of NaHCO solution. The resulting mixture was extracted with DCM / IPA (5:1, 5 mL x 3). The combined extracts were washed with brine (5 mL x 2), dried over NaSO, and concentrated. The crude product was purified by preparative TLC (DCM / MeOH(NH) = 7:1) to give the title product (8 mg, yield: 22%). 1H NMR (400 MHz, CD3OD) δ 7.32 (s, 1H), 5.18 - 5.03 (m, 1H), 3.28 - 2.97 (m, 4H), 3.00 - 2.76 (m, 4H), 2.63 - 2.13 (m, 2H), 2.04 - 1.88 (m, 1H), 1.88 - 1.68 (m, 3H), 1.66 - 1.40 (m, 5H), 1.36 (d, J = 6.0 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 362 (M+1) + .

[0342] Compound B39: (S)-7-(azacyclobut-3-ylmethyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 3-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)azetidine-1-formate.

[0343] [ka] At −78° C. under a N2 atmosphere, n-BuLi (1.6 M, 1.1 mL, 1.72 mmol) was added to a solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.57 mmol) in THF (3 mL). The mixture was stirred at −78° C. for 30 minutes. Then, at −78° C., a solution of tert-butyl 3-formylpiperidine-1-formate (320 mg, 1.72 mmol) in THF (3 mL) was added. The reaction was warmed to room temperature and stirred for 30 minutes. The reaction was quenched with saturated aqueous NH4Cl at room temperature and extracted with EA (10 mL × 2). The combined organic phase was washed with brine (10 mL x 3), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography to give the title compound (420 mg, yield: >90%). MS: M / e 707 (M+1) + .

[0344] Step B: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(azacyclobut-3-yl)methanol.

[0345] [ka] tert-Butyl 3-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)azetidine-1-formate (420 mg, 0.57 mmol) in TFA / HO (9:1, 5 mL) was stirred at 40 °C for 20 h. The reaction was concentrated under reduced pressure. 10 mL HO was added. The mixture was stirred at room temperature for 10 min and then filtered. The filtrate was extracted with DCM (5 mL x 2) to remove impurities. The aqueous layer was basified to pH > 10 with aqueous NaOH (4 M) and extracted with DCM / IPA (5:1, 5 mL x 3). The combined extracts were washed with brine (10 mL x 2), dried over Na2SO4, and concentrated to give the title product (160 mg, yield: 88%). MS: M / e 307 (M+1). + .

[0346] Step C: (S)-7-(Azacyclobut-3-ylmethyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine.

[0347] [ka] A mixture of (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(azacyclobut-3-yl)methanol (160 mg, 0.52 mmol), TFA (5 mL), and EtSiH (5 mL) was stirred at 70 °C for 16 h. Another 5 mL of TFA and EtSiH (5 mL) were added, and the resulting mixture was stirred at 70 °C for 2 d. The reaction mixture was concentrated under reduced pressure. The residue was treated with HO (10 mL) and basified with aqueous NaOH (4 M) to pH > 10. The mixture was extracted with DCM / iPrOH (5:1, 10 mL × 3). The combined organic phase was washed with brine (10 mL × 2), dried over NaSO, and concentrated. The residue was purified by preparative TLC (DCM / MeOH(NH3) = 10:1) to give the title compound (12 mg, yield: 8%).1 H NMR (400 MHz, CD3OD) δ 7.37 (s, 1H), 5.20 - 5.04 (m, 1H), 4.15 (t, J = 9.6 Hz, 2H), 4.02 - 3.90 (m, 2H), 3.48 - 3.35 (m, 1H), 3.22 (d, J MS: M / e 291 (M+1) + .

[0348] Compound B40: (S)-7-((3-aminobicyclo[1.1.1]pent-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (3-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)bicyclo[1.1.1]pent-1-yl) tert-butylcarbamate [ka] To a solution of (S)-7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (450 mg, 0.75 mmol) in THF (10 mL) was added n-BuLi (1.6 M, 0.94 mL, 1.5 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of (3-formylbicyclo[1.1.1]pent-1-yl) tert-butylcarbamate (317 mg, 1.5 mmol) in THF (3 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 3 h and then allowed to warm to room temperature. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (130 mg, yellow oil, 23.6% yield). MS: M / e 733 (M+1) + .

[0349] Step B: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(3-aminobicyclo[1.1.1]pent-1-yl)methanol [ka] To a mixture of the product of Step A (130 mg, crude) in TFA (4.5 mL) was added HO (1 mL), and the resulting mixture was stirred at 40 °C for 12 hours. The mixture was cooled to room temperature and concentrated to dryness. HO (15 mL) was added to the residue, which was then extracted with DCM (15 mL × 2). The aqueous phase was basified to pH = 12-13 with 2 N NaOH, extracted with a mixture of DCM / iPrOH = 4:1 (20 mL × 2), dried over NaSO, filtered, and concentrated. The residue (30 mg) was used directly without further purification. MS: M / e 333 (M+1) + .

[0350] Step C: (S)-7-((3-aminobicyclo[1.1.1]pent-1-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step B (30 mg, crude) in TFA (3 mL) was added EtSiH (3 mL), and the resulting mixture was stirred at 70 °C for 12 hours. The mixture was cooled to room temperature and concentrated to dryness. HO (15 mL) was added to the residue, which was then extracted with DCM (15 mL × 2). The aqueous phase was basified to pH = 12-13 with 2 N NaOH, extracted with a 4:1 mixture of DCM / iPrOH (20 mL × 2), dried over NaSO, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (13.5 mg, 24%, in two steps). 1H NMR (400 MHz, DMSO-d6)δ 8.13 (s, 1H), 8.04 (s, 1H), 7.33 (s, 1H), 5.02 (dd, J = 12.2, 6.1 Hz, 1H), 3.10 (s, 2H), 1.69 (d, J = 11.8 MS: M / e 317(M+1) + .

[0351] Compound B41: 2-((5-methylisoxazol-3-yl)methoxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: 7-Bromo-N,N-bis(2,4-dimethoxybenzyl)-2-((5-methylisoxazol-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a solution of (5-methylisoxazol-3-yl)methanol (113 mg, 1 mmol) in THF (10 mL) was added NaH (60%, 80 mg, 2 mmol) at 0° C. The reaction mixture was stirred at room temperature for 20 minutes. 7-Bromo-2-chloro-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.5 mmol) was added to the mixture. The reaction mixture was stirred at room temperature for 20 minutes. Aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (200 mg, 64.1%). MS: m / e: 624.7 (M+1) + .

[0352] Step B: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-((5-methylisoxazol-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-((5-methylisoxazol-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine (200 mg, 0.32 mmol) in THF (8 mL) was added a solution of n-BuLi (1.6 M, 0.3 mL, 0.48 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formyl-2-methylpiperidine-1-formate (82 mg, 0.38 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (100 mg, 41.3%). MS: M / e 760 (M+1) + .

[0353] Step C: (4-amino-2-((5-methylisoxazol-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(piperidin-4-yl)methanol [ka] To a mixture of the product of Step B (100 mg, 0.131 mmol) in TFA (8 mL) was added HO (2 mL), and the resulting mixture was stirred at room temperature for 2 days. The mixture was concentrated to dryness. HO was added to the residue and filtered. The filtrate was washed with DCM, and the pH was adjusted to 12-13 with 2M NaOH solution. The solution was extracted with DCM (20 mL x 3). The organic phase was washed with brine, dried over NaSO, filtered, and concentrated to give the target compound (30 mg), which was used directly in the next step. MS: M / e 360 ​​(M+1) + .

[0354] Step D: 2-((5-methylisoxazol-3-yl)methoxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step C (30 mg, crude) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85 °C for 2 h. The mixture was cooled to room temperature and concentrated to dryness. The residue was purified by preparative HPLC to give the desired compound (5 mg, 11.1%, over two steps). 1 H NMR (400 MHz, DMSO-d6) δ 8.49 (s, 1H), 8.27 (s, 1H), 8.19 (s, 1H), 7.36 (s, 1H), 6.33 (s, 1H), 5.33 (s, 2H), 3.23 (d, J = 11.7 Hz, MS: M / e 333 (M+1) + .

[0355] Compound B42: 2-(((S)-pent-2-yl)oxy)-7-(pyrrolidin-2-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)pyrrolidine-1-formate [ka] To a solution of (S)-7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (600 mg, 1 mmol) in THF (8 mL) was added a solution of n-BuLi (1.6 M, 1.25 mL, 2 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 2-formylpyrrolidine-1-formate (298 mg, 1.5 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (600 mg, 83.4%). MS: M / e 721 (M+1) + .

[0356] Step B: tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(((methylthio)thiocarbonyl)oxy)methyl)pyrrolidine-1-formate [ka] At 0° C., to a solution of tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)pyrrolidine-1-formate (200 mg, 0.28 mmol), carbon disulfide (32 mg, 0.42 mmol), and imidazole (20 mg, 0.3 mmol) in THF (8 mL) was added NaH (60%, 23 mg, 0.56 mmol), and the mixture was stirred for 30 minutes. Methyl iodide (80 mg, 0.56 mmol) was added to the mixture, and the mixture was stirred at 0° C. for 1.5 hours and at room temperature for 3.5 hours. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL X 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (160 mg, 70.7%). MS: M / e 811 (M+1). + .

[0357] Step C: tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)pyrrolidine-1-formate [ka] To a mixture of tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(((methylthio)thiocarbonyl)oxy)methyl)pyrrolidine-1-formate (90 mg, 0.111 mmol) in toluene (10 mL) was added tri-n-butyltin hydride (65 mg, 0.22 mmol) and AIBN (18 mg, 0.11 mmol). The resulting mixture was protected under a nitrogen atmosphere and stirred at 100 °C overnight. The mixture was then concentrated to dryness. The residue was added to water, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the target compound (60 mg, 77.9%). MS: M / e 705 (M+1) + .

[0358] Step D: 2-(((S)-pent-2-yl)oxy)-7-(pyrrolidin-2-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step C (60 mg, 0.085 mmol) in TFA (8 mL) was added HO (2 mL), and the mixture was stirred at room temperature for 2 days. The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give the desired compound (9 mg, 34.6%). 1H NMR (400 MHz, DMSO-d6) δ 8.74 (s, 1H), 8.21 (s, 1H), 8.10 (s, 1H), 7.44 (s, 1H), 5.02 (dd, J = 12.0, 6.0 Hz, 1H), 3.85 (s, 1H), 3.28 - 3.18 (m, 3H), 3.16 (d, J = 6.6 Hz, 1H), 2.08 (d, J = 6.7 Hz, 1H), 1.97 (d, J = 5.4 Hz, 1H), 1.89 (d, J = 7.1 Hz, 1H), 1.73 - 1.61 (m, 2H), 1.54 (d, J = 6.3 Hz, MS: M / e 305 (M+1) + .

[0359] Compound B43: (S)-7-((2-azaspiro[3.5]non-7-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 7-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-2-azaspiro[3.5]nonane-2-formate [ka] To a solution of (S)-7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (330 mg, 0.55 mmol) in THF (10 mL) was added a solution of n-BuLi (1.6 M, 0.69 mL, 1.1 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 7-formyl-2-azaspiro[3.5]nonane-2-formate (209 mg, 0.82 mmol) in THF (3 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 3 h and then allowed to warm to room temperature. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (200 mg, yellow oil, 47% yield). MS: M / e 775 (M+1) + .

[0360] Step B: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(2-azaspiro[3.5]non-7-yl)methanol [ka] To a mixture of the product of Step A (200 mg, crude) in TFA (4.5 mL) was added HO (1 mL), and the resulting mixture was stirred at 40 °C for 12 hours. The mixture was cooled to room temperature and concentrated to dryness. HO (15 mL) was added to the residue, which was then extracted with DCM (15 mL × 2). The aqueous phase was basified to a pH of 12-13 with 2N NaOH, extracted with DCM / iPrOH = 4:1 (20 mL × 2), dried over NaSO, filtered, and concentrated. The residue (65 mg) was used directly without further purification. MS: M / e 375 (M+1) + .

[0361] Step C: (S)-7-((2-azaspiro[3.5]non-7-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step B (65 mg, crude) in TFA (4 mL) was added EtSiH (4 mL), and the residue was stirred at 70 °C for 12 h. The mixture was cooled to room temperature and concentrated to dryness. HO (15 mL) was added to the residue, which was then extracted with DCM (15 mL × 2). The aqueous phase was basified to pH 12-13 with 2N NaOH, extracted with DCM / iPrOH = 4:1 (20 mL × 2), dried over NaSO, filtered, and concentrated. The residue was purified by preparative HPLC to give the desired compound (8.3 mg, 10%, in two steps). 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.05 (s, 1H), 7.96 (s, 1H), 7.27 (s, 1H), 4.96 (m, 1H), 3.58 (s, 2H), 3.50 (s, 3H), 2.65 (d, J = 6.8 Hz, 2H), 1.95 (d, J = 12.7 Hz, 2H), 1.66 (d, J = 6.2 Hz, 2H), 1.55 (d, J = 9.3 Hz, 3H), 1.35 (d, J = 12.8 Hz, 4H), 1.27 (d, J = 6.0 Hz, 3H), 0.99 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H) ppm. MS: M / e 359 (M+1) + .

[0362] Compound B44: 2-((5-methylthiazol-2-yl)methoxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: 7-Bromo-N,N-di(2,4-dimethoxybenzyl)-2-((5-methylthiazol-2-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a solution of (5-methylthiazol-2-yl)methanol (129 mg, 1 mmol) in THF (10 mL) was added NaH (60%, 80 mg, 2 mmol) at 0° C. The reaction mixture was stirred at room temperature for 20 minutes. 7-Bromo-2-chloro-N,N-bis(2,4-dimethoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (300 mg, 0.5 mmol) was added to the mixture. The reaction mixture was stirred at 70° C. overnight. Aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (240 mg, 75%). MS: m / e: 642 (M+1) + .

[0363] Step B: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-((5-methylthiazol-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-((5-methylthiazol-2-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine (240 mg, 0.38 mmol) in THF (8 mL) was added a solution of n-BuLi (1.6 M, 0.35 mL, 0.56 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formyl-2-methylpiperidine-1-formate (95 mg, 0.45 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (110 mg, 37.8%). MS: M / e 777 (M+1) + .

[0364] Step C: (4-amino-2-((5-methylthiazol-2-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(piperidin-4-yl)methanol [ka] To a mixture of the product of Step B (110 mg, 0.141 mmol) in TFA (8 mL) was added HO (2 mL), and the resulting mixture was stirred at room temperature for 2 days. The mixture was concentrated to dryness. HO was added to the residue and filtered. The filtrate was washed with DCM, and the pH was adjusted to 12-13 with 2M NaOH solution. The solution was extracted with DCM (20 mL x 3). The organic phase was washed with brine, dried over NaSO, filtered, and concentrated to give the target compound (30 mg), which was used directly in the next step. MS: M / e 376 (M+1) + .

[0365] Step D: 2-((5-methylthiazol-2-yl)methoxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step C (30 mg, crude) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 80 °C for 2 h. The mixture was cooled to room temperature and concentrated to dryness. The residue was purified by preparative HPLC to give the desired compound (5 mg, 9.8%, over two steps). 1 H NMR (400 MHz, DMSO-d6) ) δ 8.34 (s, 1H), 8.28 (s, 1H), 7.50 (s, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.23 (s, 1H), 5.52 (s, 2H), 3.21 (d, J = MS: M / e 360 (M+1) + .

[0366] Compound B45: 2-((1-phenylpent-2-yl)oxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: 1-Phenylpent-2-ol [ka] To a solution of 2-phenylacetaldehyde (1.2 g, 10 mmol) in THF (10 mL) was added ethylmagnesium bromide (2M, 7 mL, 14 mmol) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. Water was added to the mixture, which was then extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (520 mg, 31.7%). MS: m / e: 165 (M+1) + .

[0367] Step B: 7-Bromo-N,N-di(4-methoxybenzyl)-2-((1-phenylpent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] At 0°C, NaH (60%, 80 mg, 2 mmol) was added to a solution of 1-phenylpent-2-ol (169 mg, 1 mmol) in THF (10 mL). The reaction mixture was stirred at room temperature for 20 minutes. 7-Bromo-2-chloro-N,N-di(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (243 mg, 0.5 mmol) was added to the mixture. The reaction mixture was stirred at 70°C overnight. Aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (220 mg, 81.9%). MS: m / e: 616 (M+1) + .

[0368] Step C: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-((1-phenylpent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 7-bromo-N,N-bis(4-methoxybenzyl)-2-((1-phenylpent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine (220 mg, 0.36 mmol) in THF (8 mL) was added a solution of n-BuLi (1.6 M, 0.45 mL, 0.72 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formyl-2-methylpiperidine-1-formate (115 mg, 0.54 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (140 mg, 51.8%). MS: M / e 752 (M+1) + .

[0369] Step D: 2-((1-phenylpent-2-yl)oxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step C (140 mg, 0.186 mmol) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85 °C for 4 h. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (5 mL), and the reaction mixture was then heated at 80 °C overnight. The mixture was concentrated, and the residue was purified by preparative HPLC to give the desired compound (4 mg, 15%, in two steps). 1H NMR (400 MHz, DMSO-d6) δ 8.09 (s, 1H), 8.02 (s, 1H), 7.33 - 7.25 (m, 5H), 7.20 (d, J = 3.2 Hz, 1H), 5.11 (s, 1H), 3.06 (d, J = 12.3 Hz, 3H), 2.89 - 2.83 (m, 1H), 2.75 (d, J = 6.3 Hz, 2H), 2.57 (s, 2H), 1.90 (s, 1H), 1.68 - 1.53 (m, 4H), 1.46 - 1.31 (m, 2H), 1.24 (s, 2H), 0.86 (t, J = 7.0 Hz, 3H) ppm. MS: M / e 395 (M+1) + .

[0370] Compound B46: 7-(piperidin-4-ylmethyl)-2-((tetrahydrofuran-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: 7-Bromo-N,N-di(4-methoxybenzyl)-2-((tetrahydrofuran-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] At 0°C, NaH (60%, 160 mg, 4 mmol) was added to a solution of (tetrahydrofuran-3-yl)methanol (204 mg, 2 mmol) in THF (10 mL). The reaction mixture was stirred at room temperature for 20 minutes. 7-Bromo-2-chloro-N,N-di(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (487 mg, 1 mmol) was added to the mixture. The reaction mixture was stirred at 70°C overnight. Aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (500 mg, 90%). MS: m / e: 554 (M+1) + .

[0371] Step B: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-((tetrahydrofuran-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 7-bromo-N,N-bis(4-methoxybenzyl)-2-((tetrahydrofuran-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine (220 mg, 0.39 mmol) in THF (8 mL) was added a solution of n-BuLi (1.6 M, 0.45 mL, 0.72 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formyl-2-methylpiperidine-1-formate (115 mg, 0.54 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (130 mg, 47.6%). MS: M / e 689 (M+1) + .

[0372] Step C: 7-(piperidin-4-ylmethyl)-2-((tetrahydrofuran-3-yl)methoxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step B (130 mg, 0.33 mmol) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85° C. for 4 hours. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (5 mL), and the reaction mixture was heated at 80° C. overnight. The mixture was concentrated, and the residue was purified by preparative HPLC to give the desired compound (18 mg, 16.3%). 1H NMR (400 MHz, DMSO-d6) δ 8.13 (s, 1H), 8.03 (s, 1H), 7.30 (s, 1H), 4.19 (d, J = 6.8 Hz, 1H), 4.15 - 4.07 (m, 1H), 3.77 (dd, J = 16.7, 8.5 Hz, 2H), 3.65 (d, J = 7.6 Hz, 1H), 3.55 - 3.48 (m, 1H), 2.96 (d, J = 12.1 Hz, 2H), 2.71 (d, J = 6.6 Hz, 2H), 2.69 - 2.63 (m, 1H), 2.45 (s, 2H), 2.00 (s, MS: M / e 333 (M+1) + .

[0373] Compound B47: 2-(hept-4-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(hept-4-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of 2-(hept-4-yloxy)-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (160 mg, 0.327 mmol) in THF (8 mL) was slowly added dropwise a solution of n-BuLi (1.6 M, 0.31 mL, 0.5 mmol) while maintaining the temperature between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formylpiperidine-1-formate (98 mg, 0.46 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (120 mg, 52.4%). MS: M / e 703 (M+1) + .

[0374] Step B: 2-(hept-4-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step A (120 mg, 0.17 mmol) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85° C. for 4 hours. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (5 mL), and the reaction mixture was stirred at 80° C. overnight. The mixture was concentrated in vacuo, and the residue was purified by preparative HPLC to give the desired compound (6 mg, 10.2%). 1H NMR (400 MHz, DMSO-d6) δ 8.07 (s, 1H), 7.97 (s, 1H), 7.31 (s, 1H), 5.02 - 4.90 (m, 1H), 3.12 (d, J = 12.3 Hz, 2H), 2.74 (d, J = 6.7 MS: M / e 347 (M+1) + .

[0375] Step B48: 2-(pent-3-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(pent-3-yloxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of N,N-bis(4-methoxybenzyl)-2-(pent-3-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (110 mg, 0.23 mmol) in THF (8 mL) was added a solution of n-BuLi (1.6 M, 0.3 mL, 0.48 mmol) dropwise, while maintaining the temperature between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formylpiperidine-1-formate (60 mg, 0.3 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (70 mg, 45.2%). MS: M / e 675 (M+1) + .

[0376] Step B: 2-(pent-3-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step A (70 mg, 0.103 mmol) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85 °C for 4 h. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (5 mL), and the reaction mixture was stirred at 80 °C overnight. The mixture was concentrated, and the residue was purified by preparative HPLC to give the desired compound (7 mg, 21.2%). 1H NMR (400 MHz, DMSO-d6) δ 8.06 (s, 1H), 7.96 (s, 1H), 7.29 (s, 1H), 4.82 - 4.73 (m, 1H), 3.00 (d, J = 12.0 Hz, 2H), 2.71 (d, J = 6.7 Hz, MS: M / e 319 (M+1) + .

[0377] Compound B49: (S)-2-(hex-3-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: (S)-2-(hex-3-yloxy)-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a solution of (S)-hex-3-ol (102 mg, 1 mmol) in THF (10 mL) was added NaH (60%, 80 mg, 2 mmol) at 0° C. The reaction mixture was stirred at room temperature for 20 minutes. 2-Chloro-N,N-di(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (204 mg, 0.5 mmol) was added to the reaction mixture. The reaction mixture was stirred at 70° C. overnight. Aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by column chromatography to give the title product (190 mg, 80%). MS: m / e: 476 (M+1) + .

[0378] Step B: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(((S)-hex-3-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of (S)-2-(hex-3-yloxy)-N,N-bis(4-methoxybenzyl)imidazo[2,1-f][1,2,4]triazin-4-amine (190 mg, 0.4 mmol) in THF (8 mL) was slowly added dropwise a solution of n-BuLi (1.6 M, 0.44 mL, 0.72 mmol) while maintaining the temperature between -75 and -65 °C. After 1 h, a suspension of tert-butyl 4-formylpiperidine-1-formate (122 mg, 0.6 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (90 mg, 32.7%). MS: M / e 689 (M+1) + .

[0379] Step C: (S)-2-(hex-3-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step B (90 mg, 0.130 mmol) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85 °C for 4 h. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (5 mL), and the reaction mixture was stirred at 80 °C overnight. The mixture was concentrated in vacuo, and the residue was purified by preparative HPLC to give the desired compound (9 mg, 20.8%). 1H NMR (400 MHz, DMSO-d6) δ 8.06 (br.s, 1H), 7.96 (s, 1H), 7.29 (s, 1H), 4.91 - 4.81 (m, 1H), 3.00 (d, J = 11.8 Hz, 2H), 2.71 (d, J = 6.7 Hz, 2H), 2.54 (s, 2H), 1.83 (s, 1H), 1.72 - 1.51 (m, 6H), 1.42-1.33 (m, 2H), 1.25 - 1.07 (m, 2H), 0.90 (t, J = 7.3 Hz, 6H) ppm. MS: M / e 333 (M+1) + .

[0380] Compound B50: (S)-7-((7-azaspiro[3.5]non-2-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 2-methylene-7-azaspiro[3.5]nonane-7-formate [ka] To a solution of PhPCHBr (5.98 g, 16.74 mmol) in THF (30 mL) was added NaHMDS (8.4 mL, 16.8 mmol) at -78 °C under N2. After stirring at -78 °C for 10 min, the reaction was warmed to 25 °C and stirred for 2 h. At 0 °C, tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-formate (2 g, 8.37 mmol) in THF (10 mL) was added dropwise. The reaction mixture was stirred at 70 °C for 5 h. Upon completion, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (25%) in petroleum ether to give the title compound (1.2 g, 61%). 1 H NMR (400 MHz, DMSO-d6) δ 4.84 (s, 2H), 3.26 (s, 4H), 2.41 (s, 4H), 1.53-1.43 (m, 4H), 1.41 (s, 9H) ppm. Step B: tert-butyl 2-(methylol)-7-azaspiro[3.5]nonane-7-formate [ka] Under N2, 9-BBN (15 mL, 7.5 mmol) was added to a solution of tert-butyl 2-methylene-7-azaspiro[3.5]nonane-7-formate (1.2 g, 5.06 mmol) in THF (20 mL). After stirring at 70 °C for 6 h, the reaction was cooled to 0 °C and NaOH (3N, 8 mL) and HO (8 mL) were added. The reaction mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with ice-water (20 mL) and extracted with DCM (3 x 50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (70%) in petroleum ether to give the title compound (1 g, 78%). 1H NMR (400 MHz, DMSO-d6) δ 4.44 (t, J = 5.2 Hz, 1H), 3.35 (s, 2H), 3.24 (s, 2H), 3.15 (s, 2H), 2.36-2.24 (m, 1H), 1.76 (t, J = 10.4 Hz, 2H), 1.50-1.40 (m, 4H), 1.41-1.30 (m, 11H) ppm. Step C: tert-butyl 2-formyl-7-azaspiro[3.5]nonane-7-formate [ka] To a solution of tert-butyl 2-(methylol)-7-azaspiro[3.5]nonane-7-formate (1 g, 3.92 mmol) in DCM (20 mL) was added DMP (2 g, 4.72 mmol) at 0 °C under N. Stirring was continued at 25 °C for 3 h. Upon completion, the reaction mixture was quenched with aqueous NaSO (30 mL) and extracted with DCM (3 x 50 mL). The combined organic layers were washed with aqueous NaHCO (50 mL), dried over NaSO, and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (50%) in petroleum ether to give the title compound (660 mg, 67%). 1 H NMR (400 MHz, DMSO-d6) δ 9.67 (s, 1H), 3.25 (s, 2H), 3.17 (s, 3H), 1.98-1.85 (m, 4H), 1.56-1.46 (m, 2H), 1.38 (s, 9H), 1.36-1.29 (m, 2H) ppm. Step D: tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-7-azaspiro[3.5]nonane-7-formate [ka] To a solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (500 mg, 0.959 mmol) in THF (10 mL) was added n-BuLi (1.2 mL, 1.920 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, tert-butyl 2-formyl-7-azaspiro[3.5]nonane-7-formate (340 mg, 1.344 mmol) in THF (5 mL) was added. The reaction mixture was stirred at −78 °C for 2.5 h. Upon completion, the reaction mixture was quenched with aqueous NHCl (30 mL) and extracted with DCM (3 × 50 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (40%) to give the title compound (560 mg, 75%). MS: M / e 775 (M+1) + .

[0381] Step E: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(7-azaspiro[3.5]non-2-yl)methanol [ka] Under N2, tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-7-azaspiro[3.5]nonane-7-formate (560 mg, 0.722 mmol) was dissolved in TFA (9 mL) and HO (1 mL). The reaction mixture was stirred at 40 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust the pH to 1-2. The aqueous phase was washed with DCM (3 x 20 mL), basified with 2N NaOH to adjust the pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the crude compound (280 mg, crude). MS: M / e 375 (M+1) + .

[0382] Step F: (S)-7-((7-azaspiro[3.5]non-2-yl)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Under N2, (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(7-azaspiro[3.5]non-2-yl)methanol (280 mg, crude) was dissolved in TFA (6 mL) and Et3SiH (6 mL). The reaction mixture was stirred at 90 °C for 12 h. Upon completion, the solvent was removed under vacuum. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust the pH to 1-2. The aqueous phase was washed with DCM (3 x 20 mL), basified with 2N NaOH to adjust the pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 60 mL). The combined organic layers were dried over Na2SO4 and concentrated under vacuum to give a residue. The residue was purified by preparative TLC (DCM / MeOH (NH3) = 15 / 1) to give the title compound (80 mg, 31%, in two steps). 1 H NMR (400 MHz, CD3OD) δ 7.30 (s, 1H), 5.10 (d, J = 6.0 Hz, 1H), 3.17-3.08 (m, 2H), 3.05 (d, J = 5.2 Hz, 2H), 2.98 (d, J = 7.6 Hz, 2H), 2.88-2.68 (m, 1H), 2.08 (t, J = 10.4 Hz, 2H), 1.86 (d, J = 5.2 Hz, 2H), 1.88-1.70 (m, 3H), 1.71-1.54 (m, 3H), 1.53-1.40 (m, 2H), 1.36 (d, J = 6.0 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H) ppm.MS: M / e 359 (M+1) + .

[0383] Compound B51: 2-(((S)-pent-2-yl)oxy)-7-(piperidin-2-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate [ka] To a solution of (S)-7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (600 mg, 1 mmol) in THF (8 mL) was added n-BuLi (1.6 M, 1.25 mL, 2 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 2-formylpiperidine-1-formate (319 mg, 1.5 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (590 mg, 80.3%). MS: M / e 735 (M+1) + .

[0384] Step B: tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(((methylthio)thiocarbonyl)oxy)methyl)piperidine-1-formate [ka] To a mixture of tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazolyl[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)piperidine-1-formate (130 mg, 0.18 mmol), carbon disulfide (70 mg, 0.9 mmol), and imidazole (20 mg, 0.3 mmol) in THF (8 mL) was added NaH (60%, 23 mg, 0.56 mmol) at 0° C., and the mixture was stirred for 30 minutes. Methyl iodide (126 mg, 0.9 mmol) was added to the mixture, and the mixture was stirred at 0° C. for 1.5 hours and at room temperature for 3.5 hours. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL X 3), washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC to give the desired compound (50 mg, 33.7%). MS: M / e 825 (M+1) + .

[0385] Step C: tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidine-1-formate [ka] To a mixture of tert-butyl 2-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(((methylthio)thiocarbonyl)oxy)methyl)piperidine-1-formate (50 mg, 0.06 mmol) in toluene (10 mL) was added tri-n-butyltin hydride (65 mg, 0.22 mmol) and AIBN (18 mg, 0.11 mmol). The resulting reaction mixture was protected under a N atmosphere and stirred at 100 °C overnight. The mixture was concentrated to dryness. To the residue was added HO, extracted with EtOAc (20 mL × 3), washed with brine, dried over NaSO, filtered, and concentrated. The residue was purified by preparative TLC to give the target compound (20 mg, 45.9%). MS: M / e 719 (M+1) + .

[0386] Step D: 2-(((S)-pent-2-yl)oxy)-7-(piperidin-2-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step C (20 mg, 0.027 mmol) in TFA (8 mL) was added HO (2 mL), and the resulting mixture was stirred at room temperature for 2 days. The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give the desired compound (1 mg, 11.2%). 1 H NMR (400 MHz, CD3OD) δ 7.45 (s, 1H), 5.34 (s, 1H), 5.15 (s, 1H), 3.23 (d, J = 5.6 Hz, 2H), 2.18 (d, J = 6.6 Hz, 1H), 2.02 (s, 2H), 1.88 (d, J = 13.6 Hz, 2H), 1.57 (d, J = 12.1 Hz, 4H), 1.37- 1.26 (M, 3H), 0.96 (t, J = 6.6 Hz, 3H), 0.90 (s, 3H) ppm.MS: M / e 319 (M+1)+ .

[0387] Compound B52 and Compound B53: (S)-7-((3,3-dimethylpiperidin-4-ylidene)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine and 7-((3,3-dimethylpiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazolyl[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-(methylol)-3,3-dimethylpiperidine-1-formate [ka] Under N2, 9-BBN (26 mL, 13.0 mmol) was added to a solution of tert-butyl 3,3-dimethyl-4-methylenepiperidine-1-formate (2 g, 8.88 mmol) in THF (20 mL). After stirring at 70 °C for 8 h, the reaction was cooled to 0 °C, and NaOH (3N, 15 mL) and HO (15 mL) were added. The reaction mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with ice-water (50 mL) and extracted with DCM (3 x 80 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (80%) in petroleum ether to give the title compound (1.7 g, 79%). 1 H NMR (400 MHz, DMSO-d6) δ 4.37 (t, J = 5.2 Hz, 1H), 3.96 (s, 1H), 3.64-3.37 (m, 2H), 3.06 (d, J = 5.6 Hz, 1H), 2.79-2.54 (m, 2H), 1.67 (d, J = 13.2 Hz, 1H), 1.38 (s, 9H), 1.32-1.07 (m, 2H), 0.90 (s, 3H), 0.70 (s, 3H) ppm. Step B: tert-butyl 4-formyl-3,3-dimethylpiperidine-1-formate [ka] To a solution of tert-butyl 4-(methylol)-3,3-dimethylpiperidine-1-formate (1.7 g, 6.99 mmol) in DCM (30 mL) was added DMP (3.6 g, 8.49 mmol) at 0 °C under N. The reaction was stirred at 25 °C for 3 h. Upon completion, the reaction mixture was quenched with aqueous NaSO (50 mL) and extracted with DCM (3 x 50 mL). The combined organic layers were washed with aqueous NaHCO (50 mL), brine (2 x 30 mL), dried over NaSO, and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (40%) in petroleum ether to give the title compound (840 mg, 50%). 1 H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 4.02 (s, 1H), 3.61-3.39 (m, 1H), 2.85-2.57 (m, 2H), 2.31 (t, J = 7.6 Hz, 1H), 1.59-1.49 (m, 2H), 1.39 (s, 9H), 1.11 (s, 3H), 0.83 (s, 3H) ppm. Step C: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-3,3-dimethylpiperidine-1-formate [ka] To a solution of (S)-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (500 mg, 0.959 mmol) in THF (10 mL) was added n-BuLi (0.9 mL, 1.44 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, tert-butyl 4-formyl-3,3-dimethylpiperidine-1-formate (340 mg, 1.41 mmol) in THF (4 mL) was added. The reaction mixture was stirred at −78 °C for 2.5 h. Upon completion, the reaction mixture was quenched with aqueous NHCl (50 mL) and extracted with DCM (3 × 50 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (40%) to give the title compound (600 mg, 82%). MS: M / e 763 (M+1) + .

[0388] Step D: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(3,3-dimethylpiperidin-4-yl)methanol [ka] Under N2, tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-3,3-dimethylpiperidine-1-formate (600 mg, 0.786 mmol) was dissolved in TFA (9 mL) and HO (1 mL). The reaction mixture was stirred at 40 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust the pH to 1-2. The aqueous phase was washed with DCM (3 x 30 mL), basified with 2N NaOH to adjust the pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 120 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the crude compound (240 mg, crude). MS: M / e 363 (M+1) + .

[0389] Step E: (S)-7-((3,3-dimethylpiperidin-4-methylene)methyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazine 4-amine and 7-((3,3-dimethylpiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazine 4-amine [ka] Under N2, (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(3,3-dimethylpiperidin-4-yl)methanol (240 mg, crude) was dissolved in TFA (5 mL) and Et3SiH (5 mL). The reaction mixture was stirred at 90 °C for 12 h. Upon completion, the solvent was removed under vacuum. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust the pH to 1-2. The aqueous phase was washed with DCM (3 x 20 mL), basified with 2N NaOH to adjust the pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 120 mL). The combined organic layers were dried over Na2SO4 and concentrated under vacuum to give a residue. The residue was purified by preparative TLC (DCM / MeOH (NH3) = 40 / 1 to 20 / 1) to give the products Compound B52 (3 mg) and Compound B53 (25 mg, 9%, in two steps).

[0390] Compound B52: 1 H NMR (400 MHz, CD3OD) δ 7.55 (s, 1H), 6.62 (s, 1H), 5.17-5.05 (m, 1H), 3.16 (t, J = 5.6 Hz, 2H), 3.02 (s, 2H), 2.88 (t, J = 5.6 Hz, 2H), 1.84-1.66 (m, 1H), 1.67-1.52 (m, 1H), 1.53-1.39 (m, 2H), 1.36 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H) ppm.MS: M / e 345 (M+1) + .

[0391] Compound B53: 1H NMR (400 MHz, CD3OD) δ 7.35 (s, 1H), 5.16-5.01 (m, 1H), 3.29-3.15 (m, 2H), 3.13-3.04 (m, 1H), 2.89-2.74 (m, 2H), 2.64-2.51 (m, 1H), 1.99-1.85 (m, 1H), 1.82-1.69 (m, 1H), 1.69-1.56 (m, 3H), 1.55-1.41 (m, 2H), 1.37 (d, J = 6.0 Hz, 3H), 1.22 (s, 3H), 1.14 (s, 3H), 1.02-0.91 (m, 3H).MS: M / e 347 (M+1) + .

[0392] Compound B54: 7-((1-(2-(methylamino)propyl)piperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazine 4-amine [ka] Step A: (1-(methoxy(methyl)amino)-1-oxoprop-2-yl)(methyl) tert-butylcarbamate [ka] To a solution of N-(t-butoxycarbonyl)-N-methylalanine (1 g, 4.93 mmol) in DMF (10 mL) under N2, HATU (2 g, 5.26 mmol) and DIEA (1.7 mL, 9.62 mmol) were added. After stirring for 10 min, the reaction was cooled to 0 °C, and N,O-dimethylhydroxylamine hydrochloride (526 mg, 5.42 mmol) was added. The reaction mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with ice-water (30 mL) and extracted with DCM (3 x 60 mL). The combined organic layers were washed with brine (3 x 20 mL), dried over Na2SO4, and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (30%) in petroleum ether to give the title compound (1.1 g, 91%). 1 H NMR (400 MHz, DMSO-d6) δ 5.05-4.67 (m, 1H), 3.67 (s, 3H), 3.10 (s, 3H), 2.74 (s, 3H), 1.39 (d, J = 7.6 Hz, 9H), 1.21 (dd, J = 11.6, 7.2 Hz, 3H) ppm. Step B: (1-oxoprop-2-yl) tert-butylcarbamate [ka] To a solution of (1-(methoxy(methyl)amino)-1-oxoprop-2-yl)(methyl) tert-butylcarbamate (1 g, 4.07 mmol) in THF (20 mL) at 0 °C under N was added LAH (620 mg, 16.32 mmol). After stirring at 0 °C for 0.5 h, the reaction was stirred at 25 °C for an additional 2 h. Upon completion, the reaction mixture was quenched with water (0.7 mL), 15% NaOH (0.7 mL), and water (2.1 mL) at 0 °C, and NaSO was added. The mixture was filtered, and the combined filtrate was concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate (30%) in petroleum ether to give the title compound (580 mg, 76%).1 H NMR (400 MHz, DMSO-d6) δ 9.53-9.38 (m, 1H), 4.05-3.85 (m, 1H), 2.85 (s, 3H), 1.37 (s, 9H), 1.20 (t, J = 7.6 Hz, 3H) ppm. Step C: (1-(4-((4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)prop-2-yl)(methyl) tert-butylcarbamate [ka] To a solution of (S)-2-(pent-2-yloxy)-7-(piperidin-4-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-amine (50 mg, 0.157 mmol) and (1-oxoprop-2-yl)tert-butylcarbamate (44 mg, 0.235 mmol) in MeOH (3 mL) was added NaBHCN (22 mg, 0.349 mmol) at 0 °C under N. The reaction mixture was stirred at 25 °C for 24 h. Upon completion, the solvent was concentrated in vacuo to give a residue. The residue was purified by preparative TLC (DCM / MeOH (NH) = 18 / 1) to give the title compound (30 mg, 39%). MS: M / e 490 (M+1). + .

[0393] Step D: 7-((1-(2-(methylamino)propyl)piperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a solution of (1-(4-((4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)methyl)piperidin-1-yl)prop-2-yl)(methyl) tert-butylcarbamate (30 mg, 0.061 mmol) in DCM (3 mL) at 0° C. under N2, TFA (2 mL) was added. The reaction mixture was stirred at 25° C. for 1 h. Upon completion, the solvent was concentrated in vacuo to give a residue. The residue was diluted with DCM / MeOH = 1 / 1 and basified with 2N NaOH. The residue was purified by preparative TLC (DCM / MeOH (NH3) = 18 / 1) to give the title compound (15 mg, 63%). 1 H NMR (400 MHz, CD3OD) δ 7.30 (s, 1H), 5.14-5.05 (m, 1H), 3.36 (s, 1H), 3.04 (s, 1H), 2.84 (d, J = 6.8 Hz, 3H), 2.69 (s, 3H), 2.50 (s, 2H), 2.29 (s, 1H), 2.05 (s, 1H), 1.91-1.65 (m, 4H), 1.64-1.53 ​​(m, 1H), 1.50-1.39 (m, 4H), 1.36 (d, J = 6.0 Hz, 3H), 1.25 (d, J = 6.4 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H) ppm.MS: M / e 390 (M+1) + .

[0394] Compound B55 and Compound B56: 7-((8-azabicyclo[3.2.1]oct-3-ylidene)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine and 7-((8-azabicyclo[3.2.1]oct-3-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 3-(methylol)-8-azabicyclo[3.2.1]octane-8-formate [ka] At 0 °C under the protection of a N2 atmosphere, BH3-THF (1 M, 2.5 mmol, 5 mL) was added to a solution of tert-butyl 3-methylene-8-azabicyclo[3.2.1]octane-8-formate (448 mg, 2 mmol) in THF (5 mL). The reaction was stirred at room temperature overnight. Aqueous NaOH (3 M, 3.3 mL) and H2O2 (30%, 3.3 mL) were then added to the mixture, and the reaction was continued with stirring overnight. H2O was added to the mixture, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. Purification by preparative TLC gave the title product (348 mg) as an oil. MS: m / e 242 (M+1) + .

[0395] Step B: tert-butyl 3-formyl-8-azabicyclo[3.2.1]octane-8-formate [ka] To a solution of tert-butyl 3-(methylol)-8-azabicyclo[3.2.1]octane-8-formate (348 mg, 1.54 mmol) in DCM (10 mL) was added Dess-Martin periodinane (979 mg, 2.31 mmol). The reaction was stirred at room temperature for 4 hours. HO was added to the mixture and extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. Purification by preparative TLC afforded the title product (200 mg, 57.7%). MS: m / e 240 (M+1) + .

[0396] Step C: tert-butyl 3-((4-(bis(4-methoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-8-azabicyclo[3.2.1]octane-8-formate [ka] To a solution of (S)-N,N-bis(4-methoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (290 mg, 0.6 mmol) in THF (4 mL) was added a solution of n-BuLi (1.6 M, 0.56 mL, 0.9 mmol) dropwise, maintaining the temperature between -75 and -65 °C. After 1 h, a suspension of tert-butyl 3-formyl-8-azabicyclo[3.2.1]octane-8-formate (200 mg, 0.89 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (60 mg, crude yellow oil). MS: M / e 701 (M+1) + .

[0397] Step D: 7-((8-Azabicyclo[3.2.1]oct-3-ylidene)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine and 7-((8-Azabicyclo[3.2.1]oct-3-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step C (60 mg, crude) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85° C. for 4 hours. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (5 mL), and the reaction was heated at 80° C. overnight. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC to give compound B55 (0.6 mg) and compound B56 (0.9 mg).

[0398] Compound B55: 1H NMR (400 MHz, CD3OD) δ 7.46 (s, 1H), 6.60 (s, 1H), 4.53 (s, 1H), 4.06 (s, 2H), 2.87 (t, J = 14.7 Hz, 2H), 2.52 (d, J = 14.5 Hz, 1H), 2.09 (s, 1H), 1.96 (d, J = 19.5 Hz, 2H), 1.67 (s, 2H), 1.51 (s, 2H), 1.37 (s, 2H), 1.26 (d, J = 6 Hz, 3H), 0.87 (s, 3H) ppm.MS: M / e 343 (M+1) + .

[0399] Compound B56: 1 H NMR (400 MHz, CD3OD) δ 7.30 (s, 1H), 4.53 (s, 1H), 3.91 (s, 2H), 3.07 (d, J = 8.6 Hz, 2H), 2.29 (d, J = 16.2 Hz, 2H), 2.09 (s, 4H), 1.94 (s, 1H), 1.69 (d, J = 15.5 Hz, 2H), 1.51 (s, 2H), 1.36 (s, 2H), 1.27 (d, J = 6 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H) ppm.MS: M / e 345 (M+1) + .

[0400] Compound B57: 7-((3,3-difluoropiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 3,3-difluoro-4-(methylol)piperidine-1-formate [ka] At 0 °C under the protection of a N2 atmosphere, BH3-THF (1 M, 2.5 mmol, 1.5 mL) was added to a solution of tert-butyl 3,3-difluoro-4-methylenepiperidine-1-formate (223 mg, 1 mmol) in THF (5 mL). The reaction was stirred at room temperature overnight. Aqueous NaOH (3 M, 1.7 mL) and H2O2 (30%, 1.7 mL) were then added to the mixture, and the reaction was continued with stirring overnight. H2O was added to the mixture, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. Purification by preparative TLC gave the title product (100 mg) as an oil. MS: m / e 252 (M+1) + .

[0401] Step B: tert-butyl 3,3-difluoro-4-formylpiperidine-1-formate [ka] To a solution of tert-butyl 3,3-difluoro-4-(methylol)piperidine-1-formate (100 mg, 0.41 mmol) in DCM (10 mL) was added Dess-Martin periodinane (265 mg, 0.2 mmol). The reaction was stirred at room temperature for 4 hours. H2O was added to the mixture and extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. Purification by preparative TLC gave the title product (48 mg, 48%). MS: m / e 250 (M+1) + .

[0402] Step C: tert-butyl 4-((4-(bis(4-methoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-3,3-difluoropiperidine-1-formate [ka] To a solution of (S)-N,N-bis(4-methoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (97 mg, 0.2 mmol) in THF (4 mL) was added a solution of n-BuLi (1.6 M, 0.2 mL, 0.3 mmol) dropwise, and the temperature was maintained between -75 and -65 °C. After 1 h, a suspension of tert-butyl 3,3-difluoro-4-formylpiperidine-1-formate (48 mg, 0.2 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred at -70 °C for 2 h and then allowed to warm to room temperature overnight. The reaction was quenched with saturated NH4Cl solution, extracted with EtOAc (20 mL × 3), washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative TLC to give the desired compound (20 mg, 14.1%). MS: M / e 711 (M+1) + .

[0403] Step D: 7-((3,3-difluoropiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] To a mixture of the product of Step C (20 mg, 0.028 mmol) in TFA (4 mL) was added EtSiH (4 mL), and the resulting mixture was stirred at 85 °C for 4 h. The mixture was cooled to room temperature and concentrated to dryness. To the residue was added TFA (5 mL), and the reaction was heated at 80 °C overnight. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC to give the product (1.1 mg, 11.1%). 1H NMR (400 MHz, CD3OD) δ 7.28 (s, 1H), 5.00 (d, J = 5.8 Hz, 1H), 2.76 (s, 2H), 2.58 - 2.40 (m, 2H), 2.09 (t, J = 7.6 Hz, 1H), 1.94 (s, 1H), 1.74 (s, 1H), 1.65 (s, 1H), 1.62 - 1.55 (m, 1H), 1.51 (s, 2H), 1.37 (s, 2H), 1.27 (d, J = 6.2 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H) ppm.MS: M / e 355 (M+1) + .

[0404] Compounds B58 and B59: 7-((1-((R or S)-2-(methylamino)propyl)piperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine and 7-((1-((S or R)-2-(methylamino)propyl)piperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Compound B54, 7-((1-(2-(methylamino)propyl)piperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine (150 mg, 0.386 mmol), was purified by preparative SFC (Chiral PAK AD-H column, 3 cm*25 cm, 5 μm, flow rate 20 mL / min, phase: hexane (2 mM NH3-MeOH):IPA = 90:10, UV: 220 nm, 25 °C) to give compound B58 (55 mg) and compound B59 (53 mg).

[0405] Compound B58: 1H NMR (400 MHz, CD3OD) δ 7.29 (s, 1H), 5.14-5.02 (m, 1H), 2.94 (d, J = 11.2 Hz, 1H), 2.85-2.71 (m, 4H), 2.40 (s, 3H), 2.32-2.14 (m, 2H), 2.10 (t, J = 11.2 Hz, 1H), 1.91-1.70 (m, 3H), 1.70-1.54 (m, 3H), 1.54-1.25 (m, 7H), 1.02 (d, J = 6.4 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H) ppm.MS: M / e 390 (M+1) + .

[0406] Compound B59: 1 H NMR (400 MHz, CD3OD) δ 7.29 (s, 1H), 5.14-5.04 (m, 1H), 2.93 (d, J = 11.2 Hz, 1H), 2.85-2.64 (m, 4H), 2.40 (s, 3H), 2.30-2.12 (m, MS: M / e 390 (M+1) + .

[0407] Compound B60: 7-((3-methylpiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Step A: tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-3-methylpiperidine-1-formate [ka] To a solution of (S)-7-bromo-N,N-bis(2,4-dimethoxybenzyl)-2-(pent-2-yloxy)imidazo[2,1-f][1,2,4]triazin-4-amine (500 mg, 0.833 mmol) in THF (10 mL) was added n-BuLi (1.04 mL, 1.664 mmol) at −78 °C under N. After stirring at −78 °C for 0.5 h, tert-butyl 4-formyl-3-methylpiperidine-1-formate (284 mg, 1.251 mmol) was added. The reaction mixture was stirred at −78 °C for 2.5 h. Upon completion, the reaction mixture was quenched with aqueous NHCl (20 mL) and extracted with DCM (3 × 30 mL). The combined organic layers were dried over NaSO and concentrated in vacuo to give a residue. The residue was purified by column chromatography on silica gel eluting with ethyl acetate in petroleum ether (40%) to give the title compound (400 mg, 64%). MS: M / e 749 (M+1) + .

[0408] Step B: (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(3-methylpiperidin-4-yl)methanol [ka] Under N2, tert-butyl 4-((4-(bis(2,4-dimethoxybenzyl)amino)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(hydroxy)methyl)-3-methylpiperidine-1-formate (400 mg, 0.534 mmol) was dissolved in TFA (9 mL) and HO (1 mL). The reaction mixture was stirred at 40 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust the pH to 1-2. The aqueous phase was washed with DCM (3 x 20 mL), basified with 2N NaOH to adjust the pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 60 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the crude compound (180 mg, crude). MS: M / e 349 (M+1) + .

[0409] Step C: 7-((3-methylpiperidin-4-yl)methyl)-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-4-amine [ka] Under N2, (4-amino-2-(((S)-pent-2-yl)oxy)imidazo[2,1-f][1,2,4]triazin-7-yl)(3-methylpiperidin-4-yl)methanol (180 mg, crude) was dissolved in TFA (5 mL) and Et3SiH (5 mL). The reaction mixture was stirred at 90 °C for 12 h. Upon completion, the solvent was removed in vacuo. The residue was diluted with water (20 mL) and DCM (20 mL), and the aqueous phase was acidified with 1N HCl to adjust the pH to 1-2. The aqueous phase was washed with DCM (3 x 20 mL), basified with 2N NaOH to adjust the pH to 13-14, and extracted with DCM / i-PrOH (5 / 1, 3 x 120 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC to give the title compound (12 mg). 1H NMR (400 MHz, CD3OD) δ 7.58 (s, 1H), 5.13 (d, J = 6.0 Hz, 1H), 3.34 (s, 1H), 3.15 (dd, J = 10.4, 4.4 Hz, 2H), 3.07-2.86 (m, 3H), 2.36 (s, 1H), 2.15 (s, 1H), 1.84-1.68 (s, 3H), 1.67-1.55 (m, 1H), 1.55-1.40 (m, 2H), 1.37 (d, J = 6.4 Hz, 3H), 1.16 (d, J = 7.2 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H) ppm.MS: M / e 333 (M+1) + .

[0410] TLR8 stimulation determined by HEK-Blue Detection This assay is designed to study stimulation of human TLR8 protein in the HEK-Blue hTLR8 tool cell line by monitoring NF-κB activation. The hTLR8 gene and an optimized secreted fetal alkaline phosphatase (SEAP) reporter gene were cotransfected into HEK293 cells to obtain HEK-Blue hTLR8 cells. The SEAP reporter gene was placed under the control of an IFN-β minimal promoter fused with five NF-κB and AP-1 binding sites. Stimulation with TLR8 ligand activates NF-κB and AP-1, thereby inducing SEAP expression. Using HEK-Blue Detection, a cell culture medium that enables real-time detection of SEAP, SEAP levels can be easily determined. HEK-Blue Detection contains all nutrients necessary for cell growth and a specific SEAP color substrate. Hydrolysis of the substrate by SEAP produces a purple / blue color that can be measured spectrophotometrically.

[0411] After growing to 50-80% confluence, HEK-Blue hTLR7 / 8 cells were seeded at a density of 40,000 cells / well in 96-well plates (Costar 3599). Compounds were then added in 10-point serial dilutions ranging from 1 nM to 10 μM in 0.1% DMSO / HEK-Blue Detection. These plates were then incubated for 16 hours at 37°C in 5% CO2. Optical density readings were taken at 620-655 nm on a BMG PHERAstar FSX instrument. The EC50 for each compound was determined by calculating the percentage of maximal activation identified with resiquimod or motolimod.

[0412] The EC50 values ​​of the test compounds of the present invention are as follows:

[0413] Table 1: Compounds used in HEK-Blue hTLR8 cells ("D" indicates EC50 >10 μmol) [Table 1-1] [Table 1-2] [Table 1-3] PBMC (peripheral blood mononuclear cells) measurement Cell preparation, isolation and culture Human whole blood was collected from healthy volunteers using BD Vacutainer® Lithium Heparin Tubes. PBMCs were prepared using SepMate™ (STEMCELL) with Ficoll separation solution (GE Healthcare). Cell viability was monitored by Countstar to be 85% or higher. PBMCs were cultured in RPMI 1640 (Gibco) supplemented with 10% (v / v) FBS (Gibco), 1 x MEM NEAA (Gibco), 1 x GlutaMAX (Gibco), 1 mM sodium pyruvate (Gibco), 50 μM 2-mercaptoethanol (Sigma), and 100 U / ml penicillin-streptomycin (Thermo Fisher Scientific).

[0414] Cell stimulation PBMCs were seeded into 96-well plates (Costar 3894) at a density of 2x10^5 cells / well. TLR7 / 8 compounds were then added in a 10-point serial dilution series, with final concentrations ranging from 1 nM to 10 uM in 0.1% DMSO / RPMI 1640. The plates were then incubated at 37°C in 5% CO2 for 24 hours.

[0415] HTRF (homogeneous time-resolved fluorescence) After the indicated time points, cytokines in the cell culture supernatants were measured using a Human IL6 kit (cisbio) and a Human TNF alpha kit (cisbio) according to the manufacturer's recommendations. The EC50 of each compound was determined by calculating the maximal activation percentage identified with Resiquimod or Motolimod.

[0416] Table 2. PBMC assay of compounds ("D" indicates EC50 >10 μmol) [Table 2] While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications, and other variations thereof will be apparent to those skilled in the art, and all such alternatives, modifications, and variations are intended to fall within the spirit and scope of the invention.

Claims

1. A compound of formula (I), or a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof. [In formula (I), X is N; L 1 Ha- (CR a R b ) m - and where m is a number from 0 to 8, R a and R b each independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, or -OR c and Here, R c is a hydrogen atom, an alkyl group, an alkenyl group, or an alkynyl group, R 1 is -OR 1a , -SR 1a , -NR 1a R 1b or an alkyl group, said alkyl group optionally containing one or two or three substituents R 1d is replaced by R 1a and R 1b are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and each of the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, cycloalkynyl group, heterocyclic group, aryl group, or heteroaryl group is optionally selected from the group consisting of halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with 1e an aryl group optionally substituted with R 1e a heteroaryl group optionally substituted with CH 3 - (OCH 2 CH 2 ) n- (where n is a number from 3 to 10) or -OR 1f and is substituted with one, two or three substituents selected from Here, R 1e is a halogen, a nitro group, a cyano group, a hydroxyl group, an amino group (-NH 2 ), an alkylamino group, a dialkylamino group, a -C optionally substituted with halogen 1-6 an alkyl group, a carboxyl group, an alkoxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group, or a dialkylaminocarbonyl group; Here, R 1f is an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group, each of which is optionally 1-4 substituted with an alkyl group or a halogen; R 1d is independently hydrogen, oxo, -CN, -NO 2 , hydroxyl group, amino group (-NH 2 ), an alkylamino group, a dialkylamino group, a halogen, a haloalkyl group, an alkyl group, a haloalkoxy group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group; R 2 and R 3 are independently hydrogen; R 4 is hydrogen, an alkyl group, an alkenyl group, or an alkynyl group, each of which independently and optionally has one or two or three substituents R 4d is replaced by R 4d is independently hydrogen, oxo, -CN, -NO 2 , halogen, hydroxyl group, NH 2-, an alkylamino group, a dialkylamino group, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, the alkoxy group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group, or the heteroaryl group may each optionally be a halogen atom, a hydroxyl group, NH 2 -, alkylamino, dialkylamino or alkoxy; Ring A is a cycloalkyl group or a heterocyclic ring; R 5 is a halogen, oxo, a hydroxyl group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, or -C(=O)OR 5a where R 5a is hydrogen, an alkyl group or a haloalkyl group; p is a number 0, 1, 2 or 3; L 2 is a direct bond, -(CR f R g ) t -, -O-, -S-, -S(O)-, -SO 2 -, -C(O)-, -C(O)O-, -OC(O)-, or -NR d -, where R d Ha-C 1-6 alkyl group, where t is a number from 1 to 8, and -(CR f R g ) t - 1 or 2 CR f R g The moiety is unsubstituted or O, S, SO, SO 2 , C(O) and NR f and is substituted with one or more moieties selected from R f and R g each, if present, is independently a hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group; R 6 is hydrogen, -NR 6a R 6b , an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group or the heteroaryl group each independently and optionally has one or two or three substituents R 6c is replaced by R 6a and R 6b are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group, or the heteroaryl group may each optionally be a halogen, a hydroxyl group, NH 2 -, alkylamino, dialkylamino or alkoxy; R 6c are independently hydrogen, halogen, a cyano group, -NO 2 , -OR 6d , -SR 6d , -NR 6d R 6e , -COR 6d , -SO 2 R 6d , -C(=O)OR 6d , -C(=O)NR 6d R 6e , -C(=NR 6d ) N.R. 6e R 6f , -N(R 6d ) C(=O)R 6e , -N(R 6d ) C(=O)OR 6e , -N(R 6d )C(O)NR 6e R 6f , -N(R 6d ) S(O)NR 6e R 6f , -N(R 6d) S (O) 2 N.R. 6e R 6f , -NR 6d SO 2 R 6e , an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group or the heteroaryl group each independently and optionally has one or two or three substituents R 6g is replaced by R 6d , R 6e and R 6f are independently hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group or a heteroaryl group, and the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, the heterocyclic group, the aryl group or the heteroaryl group each optionally has one or two or three substituents R 6g is replaced by R 6g are independently selected from hydrogen, halogen, cyano, -NO 2 , -OR 6h , -SR 6h , -NR 6h R 6i , -COR 6h , -SO 2 R 6h , -C(=O)OR 6h , -C(=O)NR 6h R 6i , -C(=NR 6h ) N.R. 6i R 6j , -N(R 6h ) C(=O)R 6i , -N(R 6h ) C(=O)OR 6i , -N(R 6h )C(O)NR 6i R 6j , -N(R 6h ) S(O)NR 6i R 6j , -N(R 6h ) S (O) 2 N.R. 6i R 6h , -NR 6h SO 2 R 6i , an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group; R 6h , R 6i and R 6j are independently hydrogen, an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group, and the alkyl group, the alkoxy group, the alkenyl group, the alkynyl group, the cycloalkyl group, the cycloalkenyl group, the cycloalkynyl group, a heterocyclic group, an aryl group, or a heteroaryl group are each independently and optionally selected from halogen, -C 1-4 Alkyl group, -C 1-4 Alkoxy group, hydroxyl group, nitro group, -NH 2 , an alkylamino group, a dialkylamino group, or a cyano group.

2. 2. The compound of claim 1, wherein m is a number from 1 to 5, or a number from 1 to 3, or a number of 1.

3. L 1 Ha-CR a R b The compound according to claim 1, wherein [Here, R a and R b each independently represents hydrogen, -C 1-8 An alkyl group (preferably -C 1-4 is an alkyl group, more preferably a methyl group) or —OH; L 1 Ha-CH 2 -, -CH(OH)- or -CH(CH 3 )-.

4. R 1 Yes - OR 1a Or -NR 1a R 1b 2. The compound of claim 1, [Here, R 1a and R 1b is defined as in formula (I).

5. R 1 Yes - OR 1a Or -NR 1a R 1b 2. The compound of claim 1, [Here, R 1a , R 1b are independently hydrogen, -C 1-8 Alkyl group or -C 2-8 alkenyl group, 1-8 Alkyl group or -C 2-8 Each alkenyl group optionally includes R 1e a heterocyclic group optionally substituted with 1e an aryl group optionally substituted with CH 3 - (OCH 2 CH 2 ) n - (wherein n is a number from 3 to 10, preferably 4-8, more preferably 5-7) or -OR 1f and is substituted with one, two or three substituents selected from Here, R 1e is halogen, -C optionally substituted with halogen 1-6 an alkyl group, a carboxyl group, an alkoxycarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group, or a dialkylaminocarbonyl group; Here, R 1f Ha-C 1-8 an alkyl group, an aryl group, or a heteroaryl group, each of which is optionally -C 1-4 It is substituted with an alkyl group or a halogen.

6. R 1 Yes - OR 1a 2. The compound of claim 1, [Here, R 1ais optionally a halogen, R 1e -C optionally substituted with 1-8 Alkyl group, R 1e a cycloalkyl group optionally substituted with R 1e a heterocyclic group optionally substituted with 1e an aryl group optionally substituted with R 1e a heteroaryl group optionally substituted with CH 3 - (OCH 2 CH 2 ) n - (where n is a number from 3 to 10) or -OR 1f -C substituted with one, two or three substituents selected from 1-8 is an alkyl group, Here, R 1e and R 1f is defined as in formula (I).

7. R 1 Yes - OR 1a 2. The compound of claim 1, [Here, R 1a is a branched alkyl group, preferably -C 4-8 alkyl groups in which the branched chain substituent is alpha to the oxygen atom, including, but not limited to, but-2-yl, pent-2-yl, pent-3-yl, hept-2-yl, hept-3-yl, hept-4-yl, oct-2-yl, oct-3-yl, oct-4-yl, or oct-5-yl.

8. R 5 is a halogen, oxo, hydroxyl group, C 1-8 Alkyl groups, halogenated C 1-8 Alkyl group, C 1-8 Alkoxy group, halogenated C 1-8 Alkoxy group or -C(=O)OR 5a 2. The compound of claim 1, [Here, R 5a is hydrogen, C 1-8 Alkyl group or halogenated C 1-8 is an alkyl group, and p is a number 0, 1, or 2.

9. 2. The compound of claim 1, wherein p is a number equal to 0 or 1.

10. The compound of claim 1 , wherein ring A is a heterocyclic or cycloalkyl ring.

11. Ring A is azetidin-3-yl, azepan-4-yl; piperidin-2-yl, piperidin-3-yl, piperidin-4-yl; pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl; piperazin-1-yl; 7-azaspiro[3.5]non-2-yl, 2-azaspiro[3.3]hept-6-yl, 7-azaspiro[3.5]non-2-yl, 2-azaspiro[3.5]non-7-yl; 2. The compound of claim 1, which is 3-azabicyclo[3.1.0]hex-6-yl, 2-azabicyclo[2.2.1]hept-5-yl, 8-azabicyclo[3.2.1]oct-3-yl, 2-azabicyclo[4.1.0]hept-5-yl; cyclobutyl, bicyclo[1.1.1]pent-1-yl; bicyclo[1.1.1]pent-1-yl; or 1,2,3,6-tetrahydropyridin-4-yl.

12. R 5 is a methyl group, an ethyl group, an isopropyl group, an oxo group, a fluorine group, a trifluoromethyl group, a hydroxyl group, or an ethoxycarbonyl group, L 2 -R 6 are each independently a methyl group, an ethyl group, an isopropyl group; a 2-(methylamino)ethyl group; a benzyl group; a piperidin-4-ylmethyl group; a (methylamino)methyl group; a 2-(methylamino)ethyl group; a methylol group; a trifluoromethyl group; a pyrrolidin-3-yl, pyrrolidin-2-yl, piperidin-4-yl; a hydroxyl group; an ethoxycarbonyl group; a phenyl group; a methylamino group, or an amino group.

13. The above part are piperidin-4-yl, 1-methylpiperidin-4-yl, 1-(2-(methylamino)ethyl)piperidin-4-yl, 1-(pyrrolidin-3-yl)piperidin-4-yl, 1-(pyrrolidin-2-yl)piperidin-4-yl, 1-(piperidin-4-yl)piperidin-4-yl, 4-methylpiperidin-4-yl, 3-hydroxypiperidin-4-yl, 3-oxopiperidin-4-yl, 3-fluoropiperidin-4-yl, 3,3-difluoropiperidin-4-yl, 3-benzylpiperidin-4-yl, 1-(piperi ... 4-((methylamino)methyl)piperidin-1-yl, 2-ethylpiperidin-4-yl, 2-ethoxycarbonyl piperidin-4-yl, 2-methylol piperidin-4-yl, 1-methyl-2-((methylamino)methyl)piperidin-4-yl, 1-isopropyl-2-((methylamino)methyl)piperidin-4-yl, 2,6-dimethylpiperidin-4-yl, 2,2-dimethylpiperidin-4-yl, 2-(trifluoromethyl)piperidin-4-yl, 2-phenylpiperidin-4-yl, 4-(methylamino)piperidin-1-yl; piperidin-2-yl; pyrrolidin-3-yl; azetidin-3-yl; azepan-4-yl; (R)-3-methylpiperazin-1-yl; (S)-3-methylpiperazin-1-yl; (S)-3-methylpiperazin-1-yl; (R)-3-methylpiperazin-1-yl; 2-hydroxy-7-azaspiro[3.5]non-2-yl; 3-azabicyclo[3.1.0]hex-6-yl; 2-azaspiro[3.3]hept-6-yl; 7-azaspiro[3.5]non-2-yl 2-Azabicyclo[4.1.0]hept-5-yl; 1,2,3,6-tetrahydropyridin-4-yl; 3-aminobicyclo[1.1.1]pent-1-yl; or 3-((methylamino)methyl)bicyclo[1.1.1]pent-1-yl.

14. or a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof.

15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable carrier or excipient.

16. Use of a compound according to any one of claims 1 to 14 or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for modulating TLR8.

17. 15. Use of a compound according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition in a patient.

18. 18. The use according to claim 17, wherein the disease or condition is cancer.

Citation Information

Patent Citations

  • Pyrrolopyrimidine compounds used as tlr7 agonists

    JP2017524037A